View Filing Data

Document And Entity Information	9 Months Ended
Document And Entity Information	Jul. 31, 2013
Document Information [Line Items]
Document Type	S-1
Amendment Flag	false
Document Period End Date	Jul. 31, 2013
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Entity Filer Category	Smaller Reporting Company

BALANCE SHEETS - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
ASSETS
Cash	$ 40	$ 232	$ 1,096,538
Prepaid expenses	55,111	25,798	37,474
Other current assets	33,182	8,182	2,221
Deferred expenses - current	1,323,511	860,293	0
Total Current Assets	1,411,844	894,505	1,614,021
Deferred expenses - long term	289,834	342,007	1,380,103
Property and equipment (net of accumulated depreciation)	61,442	78,068	0
Intangible assets (net of accumulated amortization)	2,499,791	2,413,755	2,256,852
Deferred financing cost (net of accumulated amortization)	62,034	49,024	65,848
Other assets	38,438	38,438	38,438
TOTAL ASSETS	4,363,383	3,815,797	5,355,262
Other Current Receivable		0	477,788
LIABILITIES AND SHAREHOLDERS' DEFICIENCY
Accounts payable	5,541,431	5,155,797	2,420,260
Accrued expenses	1,242,464	1,367,412	2,976,334
Short term convertible notes and fair value of embedded derivative	2,037,962	2,089,099	5,091,298
Notes payable - former officer	427,606	477,274	408,069
Notes payable - other	0	250,000	0
Total Current Liabilities	9,249,463	9,339,582	10,895,961
Deferred rent	0	4,803	62,441
Long-term convertible note	1,104,680	0	570,802
Common stock warrant liability	736,059	434,136	6,391,071
Total Liabilities	11,090,202	9,778,521	17,920,275
Commitments and Contingencies
Shareholders' Deficiency:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; issued and outstanding 740 at July 31, 2013 and at October 31, 2012. Liquidation preference of $10,277,570	0	0
Common stock - $0.001 par value; authorized 25,000,000 shares, issued and outstanding 4,898,248 at July 31, 2013 and 3,158,433 at October 31, 2012.	4,898	3,158	2,001
Additional paid-in capital	64,083,331	52,119,567	33,248,236
Promissory note receivable	(10,633,584)	(10,484,022)	(10,283,510)
Deficit accumulated during the development stage	(60,181,464)	(47,601,427)	(35,531,740)
Total Shareholders’ Deficiency	(6,726,819)	(5,962,724)	(12,565,013)
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIENCY	$ 4,363,383	$ 3,815,797	$ 5,355,262

BALANCE SHEETS [Parenthetical] - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000	25,000,000
Common stock, shares issued	4,898,248	3,158,433	2,001,377
Common stock, shares outstanding	4,898,248	3,158,433	2,001,377
Series B Preferred Stock [Member]
Preferred stock, shares issued	740	740	740
Preferred stock, shares outstanding	740	740	740
Liquidation preference	$ 10,277,570	$ 9,722,570	$ 9,722,570

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
Revenue	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 1,863,343	$ 1,863,343
Research & development expenses	1,319,936	1,331,415	4,411,793	5,760,158	6,646,094	8,078,901	29,802,834	34,214,629
General & administrative expenses	1,733,677	2,251,725	6,299,670	4,297,110	5,688,677	4,939,935	26,868,510	33,168,179
Total Operating Expenses	3,053,613	3,583,140	10,711,463	10,057,268	12,334,771	13,018,836	56,671,344	67,382,808
Loss from Operations	(3,053,613)	(3,583,140)	(10,711,463)	(10,057,268)	(12,334,771)	(13,018,836)	(54,808,001)	(65,519,465)
Other income (expense):
Interest expense	(142,842)	(1,045,297)	(600,004)	(4,241,805)	(4,536,528)	(4,698,983)	(14,985,865)	(15,585,869)
Other income (expense)	(17,372)	25,375	(15,926)	25,715	12,002	(78,911)	259,709	243,783
(Loss) on note retirement	1,723	(932,421)	349,009	(2,173,491)	(2,187,787)	(461,595)	(992,942)	(643,933)
Gain on change in fair value of common stock warrant liability and embedded derivative liability	1,616,919	2,430,914	(2,326,843)	6,020,434	6,630,610	9,763,113	21,042,296	18,715,454
Net Loss before income tax benefit	(1,595,185)	(3,104,569)	(13,305,227)	(10,426,415)	(12,416,474)	(8,495,212)	(49,484,803)	(62,790,030)
Income tax benefit	0	0	725,190	346,787	346,787	379,472	1,927,260	2,652,450
Net Loss	(1,595,185)	(3,104,569)	(12,580,037)	(10,079,628)	(12,069,687)	(8,115,740)	(47,557,543)	(60,137,580)
Dividends attributable to preferred shares	185,000	185,000	555,000	555,000	740,000	1,538,686	2,322,570	2,877,570
Net Loss applicable to common stock	$ (1,780,185)	$ (3,289,569)	$ (13,135,037)	$ (10,634,628)	$ (12,809,687)	$ (9,654,426)	$ (49,880,113)	$ (63,015,150)
Net Loss per common share, basic and diluted (in dollars per share)	$ (0.37)	$ (1.19)	$ (3.13)	$ (4.45)	$ (5.00)	$ (5.41)
Weighted average number of common shares outstanding, basic and diluted (in shares)	4,775,772	2,774,814	4,190,062	2,387,443	2,564,819	1,783,348

STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Promissory Note And Interest Receivable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2002	$ 78,557		$ 125		$ 245,368	$ (166,936)
Balance (in shares) at Dec. 31, 2002			124,781
Options granted to consultants and professionals	8,484				8,484
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004		$ (15,969)			15,969
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)		(232)
Conversion of debenture to Common Stock	15,969	$ 15,969
Debt Conversion, Converted Instrument, Shares Issued		232
Net Loss	(909,745)					(909,745)
Balance at Dec. 31, 2003	(806,735)		$ 125		269,821	(1,076,681)
Balance (in shares) at Dec. 31, 2003			124,781
Options granted to consultants and professionals	5,315				5,315
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004		$ (43,884)			43,884
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004 (in shares)		(638)
Stock dividend on preferred stock		$ 43,884				(43,884)
Stock dividend on preferred stock (in shares)		638
Net Loss	(538,076)					(538,076)
Balance at Oct. 31, 2004	(1,339,496)		$ 125		319,020	(1,658,641)
Balance (in shares) at Oct. 31, 2004			124,781
Options granted to consultants and professionals	64,924				64,924
Retroactive restatement to reflect re-capitalization on Nov. 12, 2004	(88,824)				(88,824)
Common Stock issued to Placement Agent on re-capitalization			$ 6		(6)
Common Stock issued to Placement Agent on re-capitalization (in shares)			6,020
Effect of re-capitalization			$ 6		(6)
Effect of re-capitalization (in shares)			6,020
Conversion of debenture to Common Stock	613,158		$ 17		613,141
Issuance of Common Stock for cash, net of shares to Placement Agent	4,353,000		$ 140		4,352,860
Issuance of Common Stock for cash, net of shares to Placement Agent (in shares)			139,605
Issuance of common stock to consultants	166,777		$ 5		166,772
Debt Conversion, Converted Instrument, Shares Issued			17,091
Issuance of common stock in connection with the registration statement	117,498		$ 3		117,495
Issuance of common stock in connection with the registration statement (in shares)			3,275
Issuance costs	(329,673)				(329,673)
Issuance of common stock to consultants (in shares)			4,695
Net Loss	(1,805,789)					(1,805,789)
Balance at Oct. 31, 2005	1,751,575		$ 302		5,215,703	(3,464,430)
Balance (in shares) at Oct. 31, 2005			301,487
Options granted to consultants and professionals	172,831				172,831
Conversion of debenture to Common Stock	300,000		$ 14		299,986
Issuance of common stock to consultants	139,672		$ 4		139,668
Debt Conversion, Converted Instrument, Shares Issued			14,135
Options granted to employees and directors	71,667				71,667
Issuance of Common Stock to employees and directors	54,858		$ 2		54,856
Issuance of common stock to consultants (in shares)			4,449
Issuance of Common Stock to employees and directors (in shares)			1,835
Net Loss	(6,197,744)					(6,197,744)
Balance at Oct. 31, 2006	(3,707,141)		$ 322		5,954,710	(9,662,173)
Balance (in shares) at Oct. 31, 2006			321,906
Stock issued	9,380,902		$ 474		9,380,428
Stock Issued (in shares)			473,826
Options granted to consultants and professionals	268,577				268,577
Conversion of debenture to Common Stock	1,000,000		$ 56		999,944
Issuance of common stock to consultants	221,778		$ 9		221,769
Debt Conversion, Converted Instrument, Shares Issued			55,793
Options granted to employees and directors	222,501				222,501
Offering Expenses	(2,243,535)				(2,243,535)
Warrants issued on conjunction with issuance of common stock	1,505,550				1,505,550
Issuance of Common Stock to employees and directors	73,800		$ 3		73,797
Issuance of common stock to consultants (in shares)			8,800
Issuance of Common Stock to employees and directors (in shares)			3,331
Net Loss	(2,454,453)					(2,454,453)
Balance at Oct. 31, 2007	4,267,979		$ 864		16,383,741	(12,116,626)
Balance (in shares) at Oct. 31, 2007			863,656
Options granted to consultants and professionals	(42,306)				(42,306)
Issuance of common stock to consultants	14,616		$ 1		14,615
Options granted to employees and directors	257,854				257,854
Offering Expenses	(78,013)				(78,013)
Warrants issued on conjunction with issuance of common stock	39,198				39,198
Common Stock Penalty Shares (in shares)			1,694
Issuance of Common Stock to employees and directors	86,001		$ 8		85,993
Issuance of common stock to consultants (in shares)			1,230
Issuance of Common Stock to employees and directors (in shares)			7,966
Common Stock Penalty Shares	31,778		$ 2		31,776	0
Net Loss	(5,416,418)					(5,416,418)
Balance at Oct. 31, 2008	(839,311)		$ 875		16,692,858	(17,533,044)
Balance (in shares) at Oct. 31, 2008			874,546
Options granted to consultants and professionals	12,596				12,596
Issuance of common stock to consultants	51,979		$ 21		51,958
Options granted to employees and directors	467,304		0		467,304
Issuance of Common Stock to employees and directors	18,180		3		18,177
Common stock issued upon exercise of warrants	0		$ 26		(26)
Warrants classified as a liability	(12,785,695)				(12,785,695)
Issuance of common Stock Warrants	(3,587,625)				(3,587,625)
Issuance of common stock to consultants (in shares)			20,768
Issuance of Common Stock to employees and directors (in shares)			3,382
Common stock issued upon exercise of warrants (in shares)			26,400
Net Loss	929,244					929,244
Balance at Oct. 31, 2009	(15,733,328)		$ 925		869,547	(16,603,800)
Balance (in shares) at Oct. 31, 2009			925,096
Stock issued	6,828,293	$ 0			6,828,293
Stock Issued (in shares)		789
Options granted to employees and directors	455,166				455,166
Issuance of Common Stock to employees and directors	115,500		$ 6		115,494
Common stock issued upon exercise of warrants	8,050,077		498	$ (10,659,710)	18,709,289
Common stock issued upon conversion of Bridge Notes	3,322,091		$ 123		3,321,968
Common stock issued upon conversion of Bridge Notes (in shares)			123,312
Common stock issued to University of Pennsylvania	70,000		$ 3		69,997
Common stock issued to University of Pennsylvania (in shares)			3,111
Common stock issued to former employees	0		$ 1		(1)
Adjustments to Additional Paid in Capital, Warrant Issued	(7,693,230)				(7,693,230)
Common stock issued to former employees (in shares)			1,157
Common stock issued to Numoda	595,000		$ 28		594,972
Common stock issued to Numoda (in shares)			28,000
Issuance of Common Stock to employees and directors (in shares)			6,000
Common stock issued upon exercise of warrants (in shares)			498,120
Net Loss	(10,812,200)					(10,812,200)
Balance at Oct. 31, 2010	(14,802,631)	$ 0	$ 1,584	(10,659,710)	23,271,495	(27,416,000)
Balance (in shares) at Oct. 31, 2010		789	1,584,796
Stock issued	1,676,554	$ 0			1,676,554
Stock Issued (in shares)		177
Options granted to consultants and professionals	28,197				28,197
Issuance of common stock to consultants	50,000		$ 3		49,997
Options granted to employees and directors	717,029				717,029
Common stock issued upon exercise of warrants	3,415,997		184	(2,389,500)	5,805,313
Issuance of common Stock Warrants	(1,228,838)				(1,228,838)
Common stock issued upon conversion of Bridge Notes	1,818,717		$ 76		1,818,641
Common stock issued upon conversion of Bridge Notes (in shares)			76,106
Common stock issued to former employees	81,531		$ 6		81,525
Preferred Stock redeemed	(90,003)	$ 0		3,051,000	(3,141,003)
Preferred Stock redeemed (in shares)		(226)
Common Stock Issued Upon Exchange of Warrants	1,533,965		47		1,533,918
Common stock issued upon conversion of May 2011 Notes	2,263,183		$ 101		2,263,082
Common stock issued to former employees (in shares)			6,017
Reclassification Of Warrant Liability	36,982				36,982
Reclassification of Embedded Derivative Liability to Beneficial Conversion Feature	132,488				132,488
Interest On Optimums Notes Receivable	202,856				202,856
Interest on Optimus Notes	(285,300)			(285,300)
Common stock issued upon exercise of warrants (in shares)			183,889
Common stock issued upon exchange of warrants (in shares)			46,725
Stock Issued During Period Shares Conversion Of May 2011 Notes (in shares)			101,177
Common stock issued upon exercise of warrants (in shares)			2,667
Net Loss	(8,115,740)					(8,115,740)
Balance at Oct. 31, 2011	(12,565,013)		$ 2,001	(10,283,510)	33,248,236	(35,531,740)
Balance (in shares) at Oct. 31, 2011		740	2,001,377
Issuance of common stock to consultants	39,857		$ 3		39,854
Options granted to employees and directors	1,146,843				1,146,843
Common stock issued upon exercise of warrants	411,765		22		411,742
Common Stock Issued Upon Exchange of Warrants	223,596		13		223,583
Issuance of shares upon conversion of convertible promissory notes	5,288,549		243		5,288,306
Fair value of equity warrants issued in connection with Rodman May 2012 Financing	279,807				279,807
Common stock issued upon conversion of JMJ Notes	666,041		$ 67		665,974
Common stock issued upon conversion of JMJ Notes (in shares)			66,607
Common stock issued to directors as earned stock compensation	32,558		$ 8		32,550
Issuance of shares to employees under ESPP Plan	18,301		$ 2		18,299
Issuance of shares to employees under ESPP Plan (in shares)			1,656
Issuance of shares to investors as part of the May 2012 Debt for Equity Exchange	6,049,397		$ 422		6,048,995
Common stock issued to Numoda	1,380,000		$ 120		1,379,880
Common stock issued to Numoda (in shares)			120,000
Issuance of shares under JMJ Settlement Agreement	1,070,000		$ 65		1,069,935
Issuance of shares under JMJ Settlement Agreement (in shares)			64,615
Exchange of Platinum Bridge Note	260,705				260,705
Issuance of shares to Socius	1,804,559		$ 192		1,804,368
Stock Issued During Period Shares New Issues To Socius (in shares)			192,466
Issuance of common stock to consultants (in shares)			3,321
Common stock issued upon exercise of warrants (in shares)			21,961
Common stock issued upon exchange of warrants (in shares)			12,777
Issuance of shares upon conversion of convertible promissory notes (in shares)			243,433
Common stock issued to directors as earned stock compensation (in shares)			7,997
Issuance of shares to investors as part of the May 2012 Debt for Equity Exchange (in shares)			422,209
Interest on Optimus Notes Receivable	0			(200,512)	200,512
Net Loss	(12,069,687)					(12,069,687)
Balance at Oct. 31, 2012	(5,962,724)		$ 3,160	$ (10,484,022)	$ 52,120,186	$ (47,601,427)
Balance (in shares) at Oct. 31, 2012		740	3,158,419
Adjustments to Additional Paid in Capital, Warrant Issued	800,000
Net Loss	(12,580,037)
Balance at Jul. 31, 2013	$ (6,726,819)

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
OPERATING ACTIVITIES
Net Loss	$ (12,580,037)	$ (10,079,628)	$ (12,069,687)	$ (8,115,740)	$ (47,557,543)	$ (60,137,580)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash charges to consultants and employees for options and stock	3,103,122	877,251	1,146,843	795,226	4,980,046	8,083,168
Amortization of deferred financing costs	28,909	0	78,824	0	338,824	367,733
Amortization of discount on convertible promissory notes	18,392	1,331,368	1,553,984	482,507	2,710,377	2,728,769
Impairment of intangible assets	0	0	0	0	26,087	26,087
Non-cash interest expense	528,023	2,885,053	2,844,456	4,106,212	11,494,012	12,022,035
(Gain) Loss on change in fair value of derivative liabilities	2,326,843	(6,020,434)	(6,630,610)	(9,763,113)	(21,042,296)	(18,715,454)
Warrant expense	30,887	0	150	557,935	764,360	795,247
Settlement expense	364,335	0	265,000	0	265,000	629,335
Employee Stock Purchase Plan	21,029	9,727	18,301	0	18,301	39,330
Value of penalty shares issued	0	0	0	0	149,276	149,276
Depreciation expense	13,626	9,184	13,776	28,406	209,448	223,074
Amortization expense of intangibles	117,920	109,859	148,002	132,288	742,642	860,562
Write off of intangible assets	0	0		33,211	33,211	33,211
Interest income	0	0	0	267	267	267
Loss (Gain) on note retirement	(349,009)	2,173,491	2,187,787	461,595	992,942	643,933
Changes in operating assets and liabilities :
Decrease (increase) in prepaid expenses	(42,243)	(2,452)	11,676	1,037	(25,797)	(68,040)
decrease in grant receivable			0	244,479	0
(Increase) in other current assets	(25,000)	(30,961)	(5,961)	(2,221)	(8,182)	(33,182)
(Increase) in other assets	0	0		(38,438)	(132,271)	(132,271)
(Increase) decrease in deferred expenses	(411,045)	365,925	177,803	(1,146,783)	(694,572)	(1,105,617)
Increase (decrease) in accounts payable and accrued expenses	1,914,577	4,445,333	5,719,172	3,123,302	12,504,260	14,418,838
(Decrease) in deferred rent	(4,803)	(43,228)	(57,637)	62,441	4,803	0
Increase in interest payable	24,840	24,759	29,779	94,547	(7,298)	17,542
Net cash used in operating activities	(4,919,634)	(3,944,753)	(4,568,344)	(8,942,842)	(34,234,103)	(39,153,737)
INVESTING ACTIVITIES
Cash paid on acquisition of Great Expectations	0	0		0	(44,940)	(44,940)
Proceeds from sale of equipment	3,000	0				3,000
Purchase of property and equipment	0	(91,844)	(91,844)	0	(241,937)	(241,937)
Cost of intangible assets	(203,955)	(258,940)	(304,905)	(296,358)	(3,220,645)	(3,424,600)
Net cash used in investing activities	(200,955)	(350,784)	(396,749)	(296,358)	(3,507,522)	(3,708,477)
FINANCING ACTIVITIES
Proceeds from convertible notes	2,110,500	500,000	3,282,463	8,351,423	17,859,400	19,969,900
Repayment of convertible notes	0	(87,941)	(52,941)	(169,739)	(1,649,030)	(1,649,030)
Payment of deferred offering expenses	(21,919)	(58,500)	(62,000)	(52,000)	(114,000)	(135,919)
Cash paid for deferred financing costs	0	0	0	(25,000)	(584,493)	(584,493)
Proceeds from notes payable	0	2,388,963	250,000	0	250,000	250,000
Proceeds from former officer loan	11,200	0	74,500	295,000	1,444,485	1,455,685
Repayment of former officer loan	(85,700)	0	(35,000)	(600,000)	(1,130,000)	(1,215,700)
Deferred investment funds	0	50,000	0		0	0
Net proceeds from issuance of Preferred Stock	0	0	0	1,342,672	8,610,499	8,610,499
Payment on cancellation of warrants	0	0	0	0	(600,000)	(600,000)
Proceeds from exercise of warrants	94,444	411,765	411,765	1,085,001	1,666,766	1,761,210
Net proceeds of issuance of common stock	3,011,872	0		0	11,988,230	15,000,102
Net cash provided by financing activities	5,120,397	3,204,287	3,868,787	10,227,357	37,741,857	42,862,254
Net increase (decrease) in cash	(192)	(1,091,250)	(1,096,306)	988,157	232	40
Cash at beginning of period	232	1,096,538	1,096,538	108,381	0	0
Cash at end of period	$ 40	$ 5,288	$ 232	$ 1,096,538	$ 232	$ 40

Supplemental Disclosures of Cash Flow Information - USD ($)	9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
Cash paid for Interest	$ 188	$ 53,027	$ 53,027	$ 148,392	$ 788,017	$ 788,205
Cash paid for Taxes	0	2,080				16,453
Supplemental Schedule of Non-cash Investing and Financing Activities
Equipment acquired under notes payable	0	0	0	0	45,580	45,580
Common stock issued to Founders	0	0	0	0	40	40
Notes payable and accrued interest converted to preferred stock	0	0	0	0	15,969	15,969
Stock dividend on preferred stock	0	0	0	0	43,884	43,884
Accounts Payable from vendors settled in Common Stock			3,249,990	0	3,249,990
Accounts Payable from consultants settled with Common Stock	12,307	62,275	62,275	0	114,253	126,560
Notes payable and embedded derivative liabilities converted to common stock	1,962,599	4,636,255	9,324,971	4,149,114	15,160,221	10,604,969
Intangible assets acquired with notes payable	0	0	0	0	360,000	360,000
Intangible assets acquired with common stock	0	0	0	0	70,000	70,000
Debt discount in connection with recording the original value of the embedded derivative liability		306,568	306,568	3,505,605	6,473,385	6,473,385
Allocation of the original secured convertible debentures to warrants	0	0	0	0	214,950	214,950
Allocation of the warrants on convertible notes as debt discount		279,807	571,207	778,052	3,001,806	2,710,406
Cancellation of note receivable in connection with preferred stock redemption	0	0	0	(3,051,000)	(3,051,000)	(3,051,000)
Note receivable in connection with exercise of warrants	0	0	0	2,389,500	9,998,210	9,998,210
Common stock issued in exchange for warrants	0	134,796	134,796	0	134,796	134,796
Warrants Issued in connection with issuance of common stock	0	0	517,797	0	2,023,347	1,505,550
Warrants Issued in connection with issuance of preferred stock	$ 0	$ 0	$ 0	$ 0	$ 3,587,625	$ 3,587,625

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Nature Of Operations and Basis Of Presentation [Abstract]

Nature Of Operations and Basis Of Presentation [Text Block]

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis Inc. (the “Company”) is a clinical development stage biotechnology company with the intent to develop safe and effective immunotherapies for cancer and infectious diseases. These immunotherapies are based on a platform technology under exclusive license from the University of Pennsylvania (“Penn”) that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm strains use a fragment of the protein listeriolysin (“LLO”), fused to a tumor associated antigen (“TAA”), or other antigen of interest. The Company refers to these as Lm-LLO immunotherapies. The Company believes these Lm-LLO agents redirect the potent immune response to Lm that is inherent in humans, to the TAA or antigen of interest. Lm-LLO based immunotherapies stimulate the immune system to induce antigen-specific anti-tumor immune responses involving both innate and adaptive arms of the immune system. In addition, this technology facilitates the immune response by altering the microenvironment of tumors to make them more susceptible to immune attack.

The Company’s lead construct, ADXS-HPV, is being evaluated in four ongoing clinical trials for human papilloma virus (“HPV”)-associated diseases as follows: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (with the Gynecologic Oncology Group (“GOG”), largely underwritten by the National Cancer Institute (“NCI”); head and neck cancer (with the Cancer Research, United Kingdom (“CRUK”), (U.K) and anal cancer (Brown University, Oncology Group (“BrUOG”), U.S.). In addition, the Company has developed immunotherapies for prostate cancer and HER2 overexpressing cancers (such as breast, gastric and other cancers in humans and osteosarcoma in canines). Over fifteen distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Since inception in 2002, the Company has focused its development efforts on understanding its technology and establishing a drug development pipeline that incorporates this technology into therapeutic immunotherapies, currently those targeting HPV-associated diseases (cervical cancer, head and neck cancer and anal cancer), prostate cancer, and HER2 overexpressing cancers. Although no immunotherapies have been commercialized to date, research and development and investment continues to be placed behind the pipeline and the advancement of this technology. Pipeline development and the further exploration of the technology for advancement entail risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting its clinical development program.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets. These losses are expected to continue for an extended period of time. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Subsequent to July 31, 2013, the Company raised an aggregate of approximately $800,000 in additional capital through the sale of equity securities and convertible promissory notes.

If the Company fails to raise a significant amount of capital, the Company may need to significantly curtail or cease operations in the near future. Any sale of common stock below $3.16 per share (as may be further adjusted) with respect to certain of the Company’s outstanding debt instruments, or $15.11 per share (as may be further adjusted) with respect to certain of its outstanding warrants, will trigger significant dilution due to the anti-dilution protection provisions contained therein.

The Company recognizes it will need to raise additional capital over and above the amount raised subsequent to July 31, 2013 in order to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily represent realizable or settlement values. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis of Presentation

The accompanying unaudited interim financial statements include all adjustments (consisting only of those of a normal recurring nature) necessary for a fair statement of the results of the interim period. The October 31, 2012 balance sheet is derived from the audited balance sheet included in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2012 (the “Form 10-K”). These interim financial statements should be read in conjunction with the Company’s financial statements and notes for the fiscal year ended October 31, 2012 included in the Form 10-K. The Company believes these financial statements reflect all adjustments and reclassifications that are necessary for a fair presentation of its financial position and results of operations for the periods presented.

Estimates

The preparation of financial statements in accordance with U.S. Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Reverse Stock Split

At the Annual Meeting of Stockholders held on June 14, 2013, the Company’s stockholders approved the filing of a Certificate of Amendment to effect a reverse stock split of its issued and outstanding common stock, and the filing of a Certificate of Amendment to decrease the total number of its authorized shares of common stock. On July 11, 2013, the Company’s Board of Directors authorized a reverse stock split at a ratio of 1-for-125 and approved the implementation of the authorized share capital decrease after the effectiveness of the reverse stock split. Accordingly, the Company amended its Amended and Restated Certificate of Incorporation by the filing of two Certificates of Amendment with the Delaware Secretary of State as follows: (a) on July 11, 2013, to effect a 1-for-125 reverse stock split of its outstanding common stock, par value $0.001 per share, to take effect on July 12, 2013 at 4:30 p.m. EDT, and (b) on July 12, 2013, to decrease the total number of authorized shares of common stock on a post-reverse stock split basis, so that the total number of shares that the Company has the authority to issue is 30,000,000 shares, of which 25,000,000 shares are common stock and 5,000,000 shares are “blank check” preferred stock. The reverse stock split was effective at approximately 4:30 p.m. EDT on July 12, 2013, and the share capital decrease took effect thereafter upon filing with the Delaware Secretary of State. All references in this Report to number of shares, price per share and weighted average number of shares of common stock outstanding prior to this reverse stock split have been adjusted to reflect the reverse stock split on a retroactive basis, unless otherwise noted.

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Advaxis Inc. (the “Company”) is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Its platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations.

Since the Company’s inception in 2002, it has focused its initial development efforts upon immunotherapies targeting cervical cancer, its predecessor condition, cervical intraepithelial neoplasia, head and neck cancer, breast cancer, prostate cancer, and other cancers and infectious diseases. Although no products have been commercialized to date, research and development and investment continue to be placed behind the pipeline and the advancement of this technology. Pipeline development entails risk and expense. It is anticipated that ongoing operational costs for the Company will continue to increase significantly due to several ongoing clinical trials in this fiscal year.

Basis of Presentation

The preparation of financial statements in accordance with Generally Accepted Accounting Principles (GAAP) involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from estimates.

The Company’s products are being developed and have not generated significant revenues. As a result, the Company has suffered recurring losses and its liabilities exceed its assets which raises substantial doubt about its ability to continue as a going concern. These losses are expected to continue for an extended period of time. The Company intends to continue raising funds through the sale of both debt and equity in order to continue funding ongoing clinical trials activity.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. There is a working capital deficiency, a shareholders’ deficiency and recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amount and classification of recorded assets and liabilities should the Company be unable to continue operations. Management’s plans are to continue to raise additional funds through the sales of debt or equity securities. Subsequent to October 31, 2012, the Company successfully raised an aggregate of approximately $950,000 in additional capital through the sale of debt and equity securities.

The Company recognizes it will need to raise additional capital over and above the amount raised subsequent to October 31, 2012 in order to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

Accordingly, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) the contract price is fixed or determinable, and (iv) collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple research grants. For the three and nine months ended July 31, 2013 and 2012, the Company did not receive any revenue from such grants.

For revenue contracts that contain multiple elements, revenue arrangements with multiple deliverables are divided into separate units of accounting if the delivered item has value to the customer on a standalone basis and there is objective and reliable evidence of the fair value of the undelivered item.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of July 31, 2013 and October 31, 2012, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common stockholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.


	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Stock-based compensation for directors is reflected in general and administrative expenses in the statements of operations. Stock-based compensation for employees and consultants could be reflected in research and development expenses or general and administrative expenses in the statements of operations depending on the nature of the services provided by the employees or consultants.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used the Black Scholes valuation model which approximated the binomial lattice options pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument could be required within 12 months of the balance sheet date.

Hybrid Financial Instruments

For certain hybrid financial instruments, the Company elected to apply the fair value option to account for these instruments. The Company made an irrevocable election to measure such hybrid financial instruments at fair value in their entirety, with changes in fair value recognized in earnings at each balance sheet date. The election may be made on an instrument by instrument basis.

Debt Discount and Amortization of Debt Discount

Debt discount represents the fair value of embedded conversion options of various convertible debt instruments and attached convertible equity instruments issued in connection with debt instruments. The debt discount is amortized over the earlier of (i) the term of the debt or (ii) conversion of the debt, using the straight-line method which approximates the interest method. The amortization of debt discount is included as a component of other expenses in the accompanying statements of operations.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment.” This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In February 2013, the FASB issued ASU No. 2013-02, “Reporting of Amounts Reclassified Out of Other Comprehensive Income.” ASU 2013-02 finalized the reporting for reclassifications out of accumulated other comprehensive income, which was previously deferred, as discussed below. The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. However, they do require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. An entity is also required to present on the face of the financials where net income is reported or in the footnotes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income, but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. Other amounts need only be cross-referenced to other disclosures required that provide additional detail of these amounts. The amendments in this update are effective for reporting periods beginning after December 15, 2012. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2013, the FASB issued ASU No. 2013-05, “Foreign Currency Matters (Topic 830): Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity.” This ASU addresses the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business within a foreign entity. The guidance outlines the events when cumulative translation adjustments should be released into net income and is intended by the FASB to eliminate some disparity in current accounting practice. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In March 2013, the FASB issued ASU 2013-07, “Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting.” The amendments require an entity to prepare its financial statements using the liquidation basis of accounting when liquidation is imminent. Liquidation is imminent when the likelihood is remote that the entity will return from liquidation and either (a) a plan for liquidation is approved by the person or persons with the authority to make such a plan effective and the likelihood is remote that the execution of the plan will be blocked by other parties or (b) a plan for liquidation is being imposed by other forces (for example, involuntary bankruptcy). If a plan for liquidation was specified in the entity’s governing documents from the entity’s inception (for example, limited-life entities), the entity should apply the liquidation basis of accounting only if the approved plan for liquidation differs from the plan for liquidation that was specified at the entity’s inception. The amendments require financial statements prepared using the liquidation basis of accounting to present relevant information about an entity’s expected resources in liquidation by measuring and presenting assets at the amount of the expected cash proceeds from liquidation. The entity should include in its presentation of assets any items it had not previously recognized under U.S. GAAP but that it expects to either sell in liquidation or use in settling liabilities (for example, trademarks). The amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

In July 2013, the FASB issued ASU 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” Under this new guidance, companies must present this unrecognized tax benefit in the financial statements as a reduction to deferred tax assets created by net operating losses or other tax credits from prior periods that occur in the same taxing jurisdiction. If the unrecognized tax benefit exceeds such credits it should be presented in the financial statements as a liability. This update is effective for annual and interim reporting periods for fiscal years beginning after December 15, 2013. The adoption of this standard did not have a material impact on the Company’s financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying consolidated financial statements.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and is subject to audit by tax authorities beginning with the year ended October 31, 2009.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Revenue from license fees and grants is recognized when the following criteria are met; persuasive evidence of an arrangement exists, services have been rendered, the contract price is fixed or determinable, and collection is reasonably assured. In licensing arrangements, delivery does not occur for revenue recognition purposes until the license term begins. Nonrefundable upfront fees received in exchange for products delivered or services performed that do not represent the culmination of a separate earnings process will be deferred and recognized over the term of the agreement using the straight line method or another method if it better represents the timing and pattern of performance. Since its inception, all of the Company’s revenues have been from multiple research grants. For the years ended October 31, 2012 and 2011, the Company did not receive any revenue from such grants.

Cash

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of October 31, 2012 and 2011, the Company did not have any cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Property and Equipment

Property and equipment consists of laboratory equipment and is stated at cost. Depreciation and amortization is provided for on the straight-line basis over the estimated useful lives of the respective asset ranging from3 to 5 years. Expenditures for maintenance and repairs that do not materially extend the useful lives of the respective assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations.

Intangible Assets

Intangible assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line basis over their remaining useful lives which are estimated to be twenty years from the effective dates of the University of Pennsylvania (Penn) License Agreements, beginning in July 1, 2002. These legal and filing costs are invoiced to the Company through Penn and its patent attorneys.

Management has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash flows. Net assets are recorded on the balance sheet for patents and licenses related to ADXS-HPV, ADXS-PSA and ADXS-HER2 and other products that are in development. However, if a competitor were to gain FDA approval for a treatment before us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to these assets. In addition, if an application is rejected or fails to be issued the Company would record an impairment of its estimated book value.

Deferred financing costs

The Company has recorded deferred financing costs as a result of fees incurred by the Company in conjunction with its debt financing activities. These costs are amortized using the straight-line method over the shorter of (a) the term of the related debt or (b) the expected conversion date of the debt into equity instruments, which approximates the effective interest method. The amortization of deferred financing costs is included as a component of other expenses in the accompanying statements of operations. At October 31, 2012 and 2011, accumulated amortization totaled $89,976 and $11,152, respectively.

Net Loss Per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the periods. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential common stock outstanding during the period. Therefore, in the case of a net loss the impact of the potential common stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income the impact of the potential common stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. For 2012 and 2011, approximately 440,000 warrants and 345,200 warrants, respectively (excluding approximately 205,000 warrants, held by an affiliate of Optimus) include anti-dilutive provisions to adjust the number and price of the warrants based on certain types of equity transactions.

	As of October 31,
	2012		2011
Warrants		802,580		1,102,734
Stock Options		358,459		218,539
Convertible Debt (using the if-converted method)		271,354		493,283
Total		1,432,393		1,814,556

Research and Development Expenses

Research and development costs are expensed as incurred and include but are not limited to clinical trial and related manufacturing costs, payroll and personnel expenses, lab expenses, facilities and related overhead costs.

Stock Based Compensation

Fair Value of financial instruments

The carrying amounts of financial instruments, including cash, receivables, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Derivative Financial instruments

Debt discount and amortization of debt discount

Recent Accounting Pronouncements

In May 2011, FASB issued ASU No. 2011-04, Fair Value Measurements (ASC Topic 820). This ASU provides additional guidance on fair value disclosures. This guidance contains certain updates to the measurement guidance as well as enhanced disclosure requirements. The most significant change in disclosures is an expansion of the information required for “Level 3” measurements including enhanced disclosure for: (1) the valuation processes used by the reporting entity; and (2) the sensitivity of the fair value measurement to changes in unobservable inputs and the interrelationships between those unobservable inputs, if any. This guidance is effective for interim and annual periods beginning on or after December 15, 2011, with early adoption prohibited. Other than requiring additional disclosures on the Company’s “Level 3” disclosures, the adoption of this new guidance did not have a material impact on the Company’s consolidated results of operations and financial position.

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment.” This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s financial position and results of operations.

Income Taxes

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and are subject to audit by tax authorities beginning with the year ended October 31, 2009.

Reclassification

Certain accounts in the prior year financial statements have been reclassified, for comparative purposes, in order to conform with the presentation in the current year financial statements. These reclassifications have no effect on the previously reported net loss.

SHARE-BASED COMPENSATION EXPENSE

12 Months Ended

Oct. 31, 2012

Share-based Compensation [Abstract]

Share Based Compensation [Text Block]

3. SHARE-BASED COMPENSATION EXPENSE

The Company adopted ASC 718 and used the modified prospective transition method, which requires the application of the accounting standard as of November 1, 2005, the first day of the Company’s fiscal year 2006. In accordance with the modified prospective transition method, the Company’s Financial Statements for prior periods were not restated to reflect, and do not include the impact of ASC 718. The Company began recognizing expense in an amount equal to the fair value of share-based payments (stock option awards) on their date of grant, over the requisite service period of the awards (usually the vesting period). Under the modified prospective method, compensation expense for the Company is recognized for all share based payments granted and vested on or after November 1, 2005 and all awards granted to employees prior to November 1, 2005 that were unvested on that date but vested in the period over the requisite service periods in the Company’s Statement of Operations. Prior to the adoption of the fair value method, the Company accounted for stock-based compensation to employees under the intrinsic value method of accounting set forth in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. Therefore, compensation expense related to employee stock options was not reflected in operating expenses in any period prior to the fiscal year of 2006 and prior period results have not been restated. Since the date of inception to October 31, 2005 had the Company adopted the fair value based method of accounting for stock-based employee compensation under the provisions of ASC 718, Stock Compensation expense would have totaled $328,176 and the effect on the Company’s net loss would have been as follows for the period March 1, 2002 (date of inception) to October 31, 2012:

	March 1, 2002 (date of inception) to October 31, 2012
Net Loss as reported	$	(47,557,543)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176)
Adjusted Net Loss	$	(47,796,502)

PROPERTY AND EQUIPMENT

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

3. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:


	July 31, 2013 (Unaudited)			October 31, 2012
Laboratory equipment	$	284,516		$	287,516
Accumulated depreciation		(223,074	)		(209,448	)
Net Property and Equipment	$	61,442		$	78,068

Depreciation expense for the three and nine months ended July 31, 2013 and 2012 and the period from March 1, 2002 (inception) to July 31, 2013 was $4,442, $13,626, $4,592, $9,184, and $223,074, respectively.

4. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	October 31, 2012		October 31, 2011
Laboratory Equipment	$	287,518	$	195,672
Accumulated Depreciation		(209,450)		(195,672)
Net Property and Equipment	$	78,068	$	—

Depreciation expense for the years ended October 31, 2012 and 2011 and the period from March 1, 2002 (inception) to October 31, 2012 was $13,776, $28,406 and $209,450, respectively.

INTANGIBLE ASSETS

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

4. INTANGIBLE ASSETS

Under the Penn license agreements, the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from the Company’s patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:


	July 31, 2013 (Unaudited)			October 31, 2012
License	$	651,992		$	651,992
Patents		2,626,365			2,422,409
Total intangibles		3,278,357			3,074,401
Accumulated amortization		(778,566	)		(660,646	)
Intangible Assets	$	2,499,791		$	2,413,755

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. No patent applications with future value were abandoned or expired and charged to expense in the three and nine months ended July 31, 2013 or 2012. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $40,109, $117,920 and $37,435, $109,858 for the three and nine months ended July 31, 2013 and 2012 and $860,562 for the period from March 1, 2002 (inception) to July 31, 2013, respectively.

Estimated amortization expense for the next five years is as follows:


Year ended October 31,
2013, remainder	$	35,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

5. INTANGIBLE ASSETS

Under the Penn license agreements we are billed actual patent expenses as they are passed through from Penn and or billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	October 31, 2012		October 31, 2011
License	$	651,992	$	651,992
Patents		2,422,409		2,117,505
Total intangibles		3,074,401		2,769,497
Accumulated Amortization		(660,646)		(512,645)
Intangible Assets	$	2,413,755	$	2,256,852

The expirations of the existing patents range from 2014 to 2023 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. During the fiscal year ended October 31, 2011, the Company wrote off approximately $33,000 in capitalized patent costs related to four patent applications that had expired or were abandoned. No patent applications with future value were abandoned or expired and charged to expense in the current year. Amortization expense for licensed technology and capitalized patent cost is included in general and administrative expenses and aggregated $148,002, $132,288 and $742,642 for the years ended October 31, 2012 and 2011 and for the period from March 1, 2002 (inception) to October 31, 2012, respectively.

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013		140,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

ACCRUED EXPENSES:

12 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

6. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	October 31, 2012		October 31, 2011
Salaries and other compensation	$	774,001	$	531,040
Clinical Trial		56,468		2,358,248
Vendors		77,512		—
Consultants		32,200		32,200
Financing costs		174,970		—
Legal		214,902		46,346
Interest Payable		28,859		—
Other		8,500		8,500
	$	1,367,412	$	2,976,334

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

5. SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE


	July 31, 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing	$	—	$	58,824
December 2011 Note Financing		—		131,928
May 2012 Note Financing		83,333		588,313
Bridge Notes		62,882		185,758
JMJ Financial		995,166		73,590
Hanover Holdings Note		—		362,791
Magna		—		333,086
Chris French		—		25,950
Asher		507,830		150,687
Yvonne Paterson		—		103,804
James Patton		—		78,909
Redwood Management LLC		388,751		—
Total Convertible Notes		2,037,962		2,093,640
Unamortized discount – Original Issue Discount (OID)		—		(4,541	)
Current Portion of Convertible Notes	$	2,037,962	$	2,089,099

Convertible Notes payable consist of the following:

October 2011 Note Financing

The notes issued by the Company in the offering completed in October 2011, which it refers to as the October 2011 Notes, matured on October 31, 2012. At October 31, 2012, there was one remaining October 2011 Note with an outstanding principal balance of $58,824.

During the nine months ended July 31, 2013, pursuant to the terms of an Assignment Agreement, the Company delivered a convertible note, which we refer to as the Second Magna Exchange Note, to Magna Group, LLC, an affiliate of Hanover, which it refers to as Magna, in an aggregate principal amount of $58,824, convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

During the nine months ended July 31, 2013, the Company converted the $58,824 in principal into 18,224 shares of common stock at conversion prices ranging from $3.16 to $3.25, recording non-cash expense of approximately $70,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, there were no outstanding October 2011 Notes.

December 2011 Note Financing

At October 31, 2012, there was one remaining note that was issued by the Company in the offering completed in December 2011, which it refers to as the December 2011 Note, with an outstanding principal balance of $158,824, having an unamortized debt discount of $26,896.

During the nine months ended July 31, 2013, pursuant to the terms of an Assignment Agreement, the Company delivered a convertible note to Magna in an aggregate principal amount of $170,589 (including the above $158,824 and a junior subordinated convertible promissory note in the amount of $11,765), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity.

Accretion of the discount was $26,896 for the three months ended January 31, 2013, resulting in the December 2011 Note being recorded at its principal value of $158,824, on the balance sheet, prior to its assignment. During the nine months ended July 31, 2013, the Company converted the $170,589 in principal into 48,888 shares of its common stock at a conversion price of $3.49, recording non-cash expense of approximately $104,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, there were no outstanding December 2011 Notes.

May 2012 Note Financings

Effective May 14, 2012, the Company entered into a Note Purchase Agreement, which it refers to as the May 2012 Notes, in which investors acquired $953,333 of convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash, representing an original issue discount of 25%. The May 2012 Notes are convertible into shares of common stock at $18.75 per share. Additionally, investors received warrants, which the Company refers to as the May 2012 Warrants, to purchase such number of shares of common stock equal to 50% of the number of shares of our common stock that would be issuable upon conversion of their May 2012 Notes at an exercise price of $18.75 per share. The May 2012 Notes matured on May 18, 2013. The Company may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances. As of July 31, 2013 the conversion price of the May 2012 Notes was $3.16 due to the anti-dilution provisions contained therein and the exercise price of the May 2012 Warrants was $10.625 as a result of the price reset provisions contained therein.

The Company elected to apply the fair-value option to account for the May 2012 Notes and has recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the May 2012 Notes which amounted to $266,332 for the period from the date of issuance or May, 14, 2012 through July 31, 2013 were recognized as a non-cash expense in the changes in fair value account on the statement of operations. Accretion of the discount, related to the original fair value of the associated warrants, was recognized through interest expense, amounting to $291,400 for the period from the date of issuance or May 14, 2012 through July 31, 2013.

In addition, as a result of the reset provisions discussed above, the May 2012 Warrants, which have been recorded at a fair value of $291,400 on May 14, 2012, are being reflected as a warrant liability as of the date of issuance. At October 31, 2012, the warrant liability amounted to $112,487. As of July 31, 2013, the warrant liability amounted to $18,426, which resulted in a non-cash income of $65,294 for the three months ended July 31, 2013 and non-cash expense of $7,717 for the nine months ended July 31, 2013, being recorded in the changes in fair value account on the statement of operations.

During the nine months ended July 31, 2013, the Company converted $870,000 in principal into 275,240 shares of its common stock at a conversion price of $3.16, recording non-cash expense of approximately $25,200 to the loss on retirement account, on the statements of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, approximately $83,000 in principal remained outstanding on one May 2012 Note. As of July 31, 2013, this May 2012 Note, which matured on May 18, 2012, was recorded on the balance sheet, as a current liability, at its remaining principal value of $83,333.

On August 8, 2013, the remaining May 2012 Note holder converted $83,333 in principal into 26,371 shares of common stock at a conversion rate of $3.16.

Currently, there are no remaining May 2012 Notes. (See Note 14: Subsequent Events for more information on these conversions after the balance sheet date).

Junior Subordinated Convertible Promissory Notes

The Company refers to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in the Company’s Bridge Notes, each investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of warrant. As of October 31, 2012, substantially all of the Bridge Warrants had an exercise price of $18.75 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the maturity date. The warrants may be exercised on a cashless basis under certain circumstances.

As of October 31, 2012, the Company had approximately $186,000 in principal outstanding on its junior subordinated convertible promissory notes with maturity dates ranging to May 12, 2012.

During the three and nine months ended July 31, 2013, pursuant to the terms of various Assignment Agreements, the Company delivered convertible notes to Magna in aggregate principal amounts of $170,589 (including $11,765 of junior subordinated convertible promissory notes plus the above December 2011 Note in the principal amount of $158,824) and $111,111 (consisting of one junior subordinated convertible promissory note), convertible into shares of common stock, which bears interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity. The Company converted the exchange note, which it refers to as the Third Magna Exchange Note, in the principal amount of $111,111 into 34,241 shares of its common stock at a conversion price of $3.25 per share, recording non-cash expense of approximately $106,000 to the loss on retirement account, on the statement of operations, for the difference between the amount of the principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, approximately $63,000 in principal remained outstanding on the junior unsubordinated convertible promissory notes, with maturity dates ranging to October 22, 2011. These notes are currently in default and are recorded as current liabilities on the balance sheet at July 31, 2013.

JMJ Financial

On August 27, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued JMJ Financial a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which it refers to as the JMJ August 2012 Note. As of October 31, 2012, the JMJ August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares, the JMJ August 2012 Note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the JMJ August 2012 Note was $73,590.

During the nine months ended July 31, 2013, the Company converted the JMJ August 2012 Note totaling $100,000 into 24,744 shares of its common stock. The Company recorded non-cash income of approximately $96,000 upon conversion. This non-cash income was recorded to the gain on retirement account, on the statement of operations, representing the difference between the fair value of the JMJ August 2012 Note, as reported on the balance sheet, and the fair value of the shares issued as a result of the conversion.

On December 28, 2012, in a private placement pursuant to a note purchase agreement, the Company issued JMJ Financial a one month convertible promissory note, which it refers to as the JMJ December 2012 Note, in the aggregate principal amount of $100,000 for a purchase price of $100,000. If repaid before January 31, 2013, the principal amount of the JMJ December 2012 Note would be $125,000. If the JMJ December 2012 Note was to be rolled into a future financing, the principal amount would be $115,000.

On April 26, 2013, in a private placement, the Company issued JMJ Financial a convertible promissory note (“JMJ April 2013 Note”). The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10% original issue discount). As of April 26, 2013, the Company had only borrowed $425,000 from JMJ Financial under this convertible promissory note. JMJ Financial paid $300,000 in cash and exchanged the JMJ December 2012 Note with an aggregate principal amount of $125,000 as consideration for the note. The exchange was analyzed and management concluded that the exchange qualifies for modification accounting. On June 27, 2013, the Company borrowed an additional $100,000 under the convertible promissory note. JMJ Financial has no obligation to lend the Company the remaining $195,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note. The Company may not prepay any portion of the note without JMJ Financial’s consent.

The convertible promissory note matures April 26, 2014 and, in addition to the 10% original issue discount, provides for payment of a one-time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s common stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares of common stock as of such date. The Company agreed to reserve at least 160,000 shares of its common stock for conversion of the note. The note also provides for penalties and rescission rights if the Company does not deliver shares of its common stock upon conversion within the required timeframes.

The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18% or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multiplied by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.

The Company also granted JMJ Financial the right, at its election, to participate in the next public offering of its securities by exchanging, in whole or in part, the funded portion of this note for a subscription to such public offering in an amount equal to 125% of the sum of the funded portion of the principal amount of being exchanged plus all accrued and unpaid interest, liquidated damages, fees, and other amounts due on such exchanged principal amount. However, the note was subsequently amended in September 2013 to remove this right. See Note 14 — Subsequent Events. If the Company completes a public offering of $10,000,000 or more, JMJ Financial has the right, at its election, to require repayment of the note, in whole or in part, in amount equal to 125% of the sum of the funded principal amount being repaid plus all accrued and unpaid interest liquidated damages, fees, and other amounts due on such principal amount. In September 2013, this note was amended to lower this threshold to $5,000,000. See Note 14 — Subsequent Events.

At July 31, 2013, the outstanding JMJ April 2013 Note was recorded on the balance sheet at its fair value of $995,166.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Hanover Holdings I, LLC, which the Company refers to as Hanover, a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which the Company refers to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note the Company refers to as the Hanover PIPE Notes.

On December 6, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which the Company refers to as the Hanover December 2012 Note. The Hanover December 2012 Note bears interest at a rate of 12% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover December 2012 Note. The Hanover December 2012 Note is convertible into shares of the Company’s common stock at a conversion price of $3.75 per share. On December 5, Hanover exchanged the Initial Hanover PIPE Notes for convertible notes in the form of the Hanover December 2012 Note in all material respects (other than date of issuance, exchange date, the maturity date of May 19, 2013 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Initial Hanover PIPE Note and the maturity date of June 19, 2013 solely with respect to the exchanged Hanover PIPE Note issued in exchange for the Second Hanover PIPE Note) that also are convertible into shares of its common stock at a conversion price of $3.75 per share, which the Company refers to as the Exchanged Hanover PIPE Notes. In addition, on December 6, 2012, the Company issued Hanover a convertible promissory note in the aggregate principal amount of $100,000, which the Company refers to as the Hanover December 2012 Note. Each of the Hanover December 2012 Note and the Exchanged Hanover PIPE Notes are subject to limitations on conversion if after giving effect to such conversion Hanover would beneficially own more than 4.99% of the Company’s common stock.

Due to the fixed conversion price of $3.75, the Company reversed fair value adjustments taken in the period ended October 31, 2012 resulting in the Hanover PIPE Notes being recorded on the balance sheet at principal value. Then, the Company recorded beneficial conversion features in the aggregate principal amount of $122,092 as a discount to these notes. Accretion of the discounts amounted to $10,055 and $122,092 for the three and nine months ended July 31, 2013, respectively.

During the nine months ended July 31, 2013, the note-holder converted principal of $365,000 into 97,333 shares of the Company’s common stock at a conversion rate of $3.75 per share. During the nine months ended July 31 2013, the Company recognized interest expense of approximately $72,000 in order to accrete the unamortized debt discount back to the notes’ principal through the dates of conversion.

As of July 31, 2013, there were no remaining Hanover Notes.

Magna Note

As of October 31, 2012, the Magna Exchange Note was recorded at a fair value of $333,086 on the balance sheet.

During the nine months ended July 31, 2013, Magna converted the remaining approximately $300,000 in principal into 80,992 shares of the Company’s common stock at prices ranging from $3.21 to $4.14, resulting in non-cash expense for the period of approximately $44,000 resulting from the difference between the amount of principal converted and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, the Magna Exchange Note had been converted in full.

Chris French

During the nine months ended July 31, 2013, the Company converted principal of $25,000 of a note issued to Chris French plus accrued interest of approximately $633, into 4,527 shares of its common stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 2,263 shares, which expires on October 26, 2015 and revalued the warrant liability, at July 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of approximately $21,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, this note no longer remained outstanding.

Asher

On September 11, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Asher Enterprises, Inc, which it refers to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matured on June 13, 2013, nine months from its issuance date. The Asher Note was able to be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provided that at no time would Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Asher Note which amounted to $47,187, for the period from the date of issuance were recorded as non-cash expense for the period ended October 31, 2012. During the nine months ended July 31, 2013, Asher converted principal of $103,500 and accrued interest into approximately 16,439 shares of the Company’s common stock at a conversion rate of approximately $6.50/share.

On November 12, 2012, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $153,500, for a purchase price of $150,000, which it refers to as the Second Asher Note. The Second Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Second Asher Note. The Second Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Second Asher Note matured on August 14, 2013, nine months from its issuance date. The Second Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time would Asher be entitled to convert any portion of the Second Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized gains on the mark-to-market of the Second Asher Note which amounted to $63,980, for the period from the date of issuance were recorded as non-cash income for the period ended July 31, 2013. During the three months ended July 31, 2013, Asher converted principal of $153,500 and accrued interest into approximately 44,161 shares of the Company’s common stock at a conversion prices ranging from $3.43/share to $3.90/share.

On May 1, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $203,500, for a purchase price of $200,000, which it refers to as the Third Asher Note. The Third Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Third Asher Note. The Third Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Third Asher Note matures on February 3, 2014, nine months from its issuance date. The Third Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time would Asher be entitled to convert any portion of the Third Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Third Asher Note which amounted to $131,462 for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Third Asher Note was recorded on the balance sheet at its fair value of $334,962.

On July 12, 2013, in a private placement pursuant to a note purchase agreement, the Company issued Asher a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which it refers to as the Fourth Asher Note. The Fourth Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or accelerations of the principal of the Fourth Asher Note. The Fourth Asher Note is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the common stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Fourth Asher Note matures on April 16, 2014, nine months from its issuance date. The Fourth Asher Note may be converted by Asher, at its option, in whole or in part and included a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Fourth Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock of the Company as of such date.

Unrealized losses on the mark-to-market of the Fourth Asher Note which amounted to $69,368, for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Fourth Asher Note was recorded on the balance sheet at its fair value of $172,868.

Yvonne Paterson

During the nine months ended July 31, 2013, the Company converted principal of $100,000 of a note issued to Yvonne Paterson plus accrued interest of approximately $2,532, into 18,107 shares of its common stock at a conversion price of $5.625 per share. In addition, the Company issued a warrant to acquire 9,054 shares, which expires on October 26, 2015 and revalued the warrant liability, at July 31, 2013, with an exercise price of $5.625, resulting in non-cash expense of approximately $32,000 resulting from the difference between the fair value of the note as shown on the balance sheet plus accrued interest to-date and the fair value of the shares issued as a result of the conversion.

As of July 31, 2013, this note no longer remained outstanding.

James Patton

On August 2, 2012, in a private placement pursuant to a Note Purchase Agreement, the Company issued Dr. James Patton, a member of our board of directors, a convertible promissory note, which it refers to as the Patton Note in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of the Company’s common stock at a per share conversion price equal to $3.16 and is subject to “full ratchet” anti-dilution protection upon certain equity issuances below $3.16 per share (as may be further adjusted). Additionally, Dr. Patton received a warrant, which the Company refers to as the Patton Warrant, to purchase such number of shares of its common stock equal to 50% of such number of shares of common stock issuable upon conversion of the Patton Note at an exercise price of $10.625 per share. The Patton Note matured on August 2, 2013 and was redeemable under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017 and may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

As of July 31, 2013, the Patton Warrants had a fair value of $2,304, resulting in non-cash income of approximately $8,400 and $5,700 for the three and nine months ended July 31, 2013, respectively.

During the three months ended July 31, 2013, the Company converted the principal amount of the Patton Note, of $66,667, into 21,092 shares at a conversion price of $3.16. The Company recorded non-cash income of approximately $94,000 and $3,590 for the three and nine months ended July 31, 2013, respectively.

Accretion of the discount amounted to $3,355, for the three and nine months ended July 31, 2013.

As of July 31, 2013, the Patton Note no longer remained outstanding and the number of shares of common stock to be acquired upon the exercise of the Patton Warrant remained at 1,778.

Redwood Management LLC

On June 21, 2013, the Company entered into a bridge financing arrangement with Redwood Management, LLC (“Redwood”), an accredited investor, for which Aegis Capital Corp. acted as placement agent and received an 8% fee based on the consideration paid to to the Company. Accordingly, on June 21, 2013, the Company entered into a Securities Purchase Agreement with Redwood Management LLC, which it refers to as Redwood, and in a private placement thereunder issued Redwood a convertible promissory note in the aggregate principal amount of $277,777, for a purchase price of $250,000 (or a 10% original issue discount), which it refers to as the Redwood Note. The Redwood Note bears interest at a rate of 5%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Redwood Note. The Redwood Note is convertible into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $6.25, or (ii) 70% of the ten day average value weighted average price (“VWAP”) for the ten trading days immediately preceding the conversion date. The Redwood Note matures on December 30, 2013, six months from its issuance date. The Redwood Note may be converted by Redwood, at its option, in whole or in part. The Redwood Note includes a limitation on conversion, which provides that at no time will Redwood be entitled to convert any portion of the Redwood Note, to the extent that after such conversion, Redwood (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

The Company agreed to reserve at least 2.5 times the number of shares of its common stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwood’s consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.

Unrealized losses on the mark-to-market of the Redwood Note which amounted to $110,972, for the period from the date of issuance were recorded as non-cash expense for the period ended July 31, 2013. As of July 31, 2013, the Redwood Note was recorded on the balance sheet at its fair value of $388,751.

7. CONVERTIBLE NOTES & FV OF EMBEDDED DERIVATIVE

Convertible Notes payable consist of the following:

	October 31, 2012		October 31, 2011
May 2011 Note Financing	$	—	$	3,392,158
October 2011 Note Financing		58,824		1,341,738
December 2011 Note Financing		131,928		—
May 2012 Note Financing		588,313		—
Bridge Notes		185,758		711,701
JMJ Financial		73,590		570,802
Hanover Holdings Note		362,791		—
Magna		333,086		—
Chris French		25,950		—
Asher		150,687		—
Yvonne Paterson		103,804		—
James Patton		78,909		—
Total Convertible Notes		2,093,640		6,016,399
Unamortized discount		(4,541)		(1,300,345)
Derivative Liability		—		946,046
		2,089,099		5,662,100
Current Portion of Convertible Notes		2,089,099		5,091,298
Long-term Convertible Notes less current portion	$	—	$	570,802

May 2011 Note Financing

On May 9, 2011, we entered into a Note Purchase Agreement with certain accredited investors, whereby the investors acquired approximately $7.1 million of our convertible promissory notes, which we refer to as the May 2011 Notes, for an aggregate purchase price of approximately $6.0 million in a private placement.

The May 2011 Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of May 2011 Notes purchased at the closing on May 12, 2011. The May 2011 Notes are convertible into shares of our common stock, at a per share conversion price equal to $18.75. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2011 Note at an exercise price of $18.75 per share.

The May 2011 Notes mature on May 12, 2012. We may redeem the May 2011 Notes, at the option of the Company only, under certain circumstances. The warrants are exercisable at any time on or before May 12, 2014. The warrants may be exercised on a cashless basis under certain circumstances. To the extent an investor does not elect to convert its May 2011 Notes as described above, the principal amount not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The May 2011 Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided, only 85% of the initial principal amount of each May 2011 Note is convertible prior to maturity. The May 2011 Notes and warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the May 2011 Notes or exercise any of the warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate charge of $4,905,842 at the date of issuance.

During the twelve months ended October 31, 2011, the Company converted approximately $1,897,000 in principal into 101,177 shares of the Company’s common stock at a conversion price of $18.75. During the twelve months ended October 31, 2012, the Company converted approximately $1,962,060 in principal into 104,643 shares of the Company’s common stock at a conversion price of $18.75, recording non-cash expense of approximately $ 318,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $3.2 million in remaining outstanding principal on the May 2011 Notes, pursuant to which such holders received an aggregate of approximately 300,800 shares of Common Stock and warrants to purchase an aggregate of approximately 28,800 shares of Common Stock in exchange for surrendering or converting the Existing May 2011 Notes and surrendering warrants to purchase an aggregate of approximately 179,200 shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $1.3 million resulting from this exchange. As of October 31, 2012, there was no remaining principal outstanding under the May 2011 Notes.

Accretion of the discount was $1,788,718 and $3,117,123 for the years ended October 31, 2012 and 2011 respectively.

October 2011 Note Financing

On October 28, 2011, we entered into a Note Purchase Agreement, which we refer to as the October 2011 Notes, with certain accredited investors, including Thomas A. Moore, our Chairman and Chief Executive Officer, and Mark J. Rosenblum, our Chief Financial Officer, (Mr. Rosenblum acquired a note in the principal amount of approximately $59,000 for an aggregate purchase price of $50,000) whereby the investors acquired approximately $2.3 million of our convertible promissory notes, which we refer to as the Notes, for an aggregate purchase price of approximately $2.0 million in a private placement, which we refer to as the October 2011 offering. The Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the October 2011 offering, which took place on October 31, 2011. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $18.75. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $18.75 per share. The Notes purchased in the October 2011 offering were paid for in cash or, with respect to Notes acquired by Mr. Moore, in exchange for the cancellation of $400,000 of outstanding indebtedness owed by us to Mr. Moore.

The Notes mature on October 31, 2012. Subsequent to October 31, 2012, the remaining outstanding note was assigned to Magna (see Footnote 16: Subsequent Events, Other Hanover-Related Transactions). We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before October 31, 2014. The Warrants may be exercised on a cashless basis under certain circumstances.

To the extent an investor does not elect to convert its Notes as described above, the principal amount of the Notes not so converted on or prior to the maturity date shall be payable in cash on the maturity date.

The Notes may be converted by the investors, at the option of such investor, in whole or in part. However, except as otherwise provided in the Notes, only 85% of the initial principal amount of each Note is convertible prior to maturity. The Notes and Warrants include a limitation on conversion or exercise, which provides that at no time will an investor be entitled to convert any portion of the Notes or exercise any of the Warrants, to the extent that after such conversion or exercise, such investor (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of our common stock as of such date.

In connection with the October 2011 offering, we entered into a Registration Rights Agreement, dated as of October 28, 2011 with the investors. Pursuant to such agreement, we agreed with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and filed a registration statement to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants which became effective on November 23, 2011.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate change of $987,439 at the date of issuance.

During the year ended October 31, 2012, the Company converted approximately $1.2 million in principal into 65,466 shares of the Company’s common stock at a conversion price of $18.75, recording non-cash expense of approximately $ 296,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $1.0 million in outstanding principal on the October 2011 Notes, pursuant to which such holders received an aggregate of approximately 96,800 shares of Common Stock and warrants to purchase an aggregate of approximately 10,400 shares of Common Stock in exchange for surrendering or converting the Existing October 2011 Notes and surrendering warrants to purchase an aggregate of approximately 48,000 shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $530,000 resulting from this exchange.

Accretion of the discount was $984,733 and $2,705 for the years ended October 31, 2012 and 2011 respectively. The outstanding principal balance was $54,824 at October 31, 2012.

December 2011 Note Financing

On December 29, 2011, we entered into a Note Purchase Agreement, which we refer to as the December 2011 Notes, with certain accredited investors, whereby the investors acquired approximately $1,232,000 million of our convertible promissory notes for an aggregate purchase price of approximately $1.0 million in a private placement, which we refer to as the December 2011 offering. The December 2011 Notes were issued with an original issue discount of 15%. Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the December 2011 offering. The Notes are convertible into shares of our common stock, at a per share conversion price equal to $18.75. Additionally, each investor received a warrant, which we refer to as the Warrants, to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the Note at an exercise price of $18.75 per share.

The Notes mature on January 9, 2013. We may redeem the Notes under certain circumstances. The Warrants are exercisable at any time on or before January 9, 2015. The Warrants may be exercised on a cashless basis under certain circumstances.

In connection with the December 2011 offering, we entered into a Registration Rights Agreement with the investors. Pursuant to such agreement, we agreed with the investors to provide certain rights to register under the Securities Act of 1933, as amended, the shares of our common stock issuable upon any conversion of the Notes and the exercise of the Warrants, and agreed to file a registration statement to register the offering of the shares of our common stock issuable upon conversion of the Notes and the exercise of the Warrants. The registration statement was filed on January 27, 2012.

Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with each of the May, October and December 2011 offerings and received compensation of cash placement fees equal to amounts ranging from 6% to 7% of the aggregate purchase price paid by investors and Warrants to purchase 26,629 shares of our common stock (approximately 4% of the shares of our common stock issuable upon conversion of all the Notes), which warrants are exercisable at $18.75 per share and shall expire on dates ranging from May 12, 2014 to January 9, 2015.

The Company evaluated the fair value of the embedded conversion option and warrants and recorded an aggregate charge of $586,376 at the date of issuance.

During the year ended October 31, 2012, the Company converted approximately $828,000 in principal into 44,133 shares of the Company’s common stock at a conversion price of $18.75, recording non-cash expense of approximately $ 205,000. In addition, the Company entered into exchange agreements with certain holders of an aggregate of approximately $215,000 in outstanding principal on the December 2011 Notes, pursuant to which such holders received an aggregate of approximately 20,000 shares of Common Stock and warrants to purchase an aggregate of approximately 10,400 shares of Common Stock in exchange for surrendering or converting the Existing December 2011 Notes and surrendering warrants to purchase an aggregate of approximately 23,200 shares of Common Stock originally issued in the Prior Offerings. The Company recorded non-cash expense of approximately $100,000 resulting from this exchange. In October 2012, $31,284 of principal was assigned pursuant to the terms of an assignment agreement with Magna Group, LLC.

Accretion of the discount was $559,480 for the year ended October 31, 2012. The outstanding principal balance, at October 31, 2012 was $158,824. On the balance sheet, the December 2011 Notes were recorded at $131,928 ($158,824 net of debt discount of $28,896). Subsequent to October, 31, 2012, the remaining outstanding note was assigned to Magna (see Footnote 16: Subsequent Events, Other Hanover-Related Transactions.)

May 2012 Note Financings

Effective May 14, 2012, we entered into a Note Purchase Agreement with certain accredited investors, whereby the investors acquired $953,333 of our convertible promissory notes for an aggregate purchase price of approximately $715,000 in cash which represented an original issue discount of 25%. The May 2012 Notes are convertible into shares of our common stock at $18.75 per share. Additionally, each investor received a warrant to purchase such number of shares of our common stock equal to 50% of such number of shares of our common stock issuable upon conversion of the May 2012 Notes at an exercise price of $18.75 per share. The Notes and Warrants also provide that on December 1, 2012, solely to the extent the conversion price of the Notes or the exercise price of the Warrants, as applicable, is less than the “Market Price” (as defined in the Notes or the Warrants, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The May 2012 Notes mature on May 18, 2013. We may redeem the May 2012 Notes under certain circumstances. The May 2012 Warrants are exercisable at any time on or before May 18, 2017. The May 2012 Warrants may be exercised on a cashless basis under certain circumstances and expire on May 18, 2017.

The Company elected to apply the fair-value option to account for the May 2012 notes and have recorded the May 2012 Notes at a fair value of $454,680 upon issuance. Unrealized losses on the mark-to-market of the notes which amounted to $133,634 for the period from the date of issuance or May, 14, 2012 through October 31, 2012 were recognized as a noncash expense.

In addition, as a result of the reset provisions discussed above, the warrants which have been recorded at a fair value of $291,400 on May 14, 2012 are being reflected as a warrant liability as of the date of issuance. As of October 31, 2012, the warrant liability amounted to $112,487 which resulted in a noncash income of approximately $178,913 for the year ended October 31, 2012.

Rodman & Renshaw, LLC acted as the exclusive placement agent in connection with the May 2012 offering and received compensation of a cash placement fee equal to 7% of the aggregate purchase price paid by investors (Rodman raised $400,000 of the total purchase price of $715,000) in the May 2012 offering amounting to $28,000 and warrants to purchase 2,844 shares of our common stock, which warrants are exercisable at $18.75 per share and shall expire on May 18, 2017.

Senior Convertible Promissory Notes

Effective June 18, 2009, the Company entered into a Note Purchase Agreement with certain accredited investors, pursuant to which such investors acquired senior convertible promissory notes of the Company. At July 31, 2011, the Company had one outstanding senior convertible promissory note with $88,824 in principal value and $26,471 in accrued interest remaining. On August 19, 2011, the Company issued 6,149 shares of common stock to this investor in full satisfaction of this senior convertible promissory note. As of October 31, 2011, the Company had no remaining senior convertible promissory notes outstanding.

Junior Subordinated Convertible Promissory Notes

We refer to all Junior Subordinated Convertible Promissory Notes as “Bridge Notes”.

The Bridge Notes are convertible into shares of the Company’s common stock at a fixed exercise price. For every dollar invested in our Bridge Notes, each Investor received warrant coverage ranging from approximately 23% to 75%, subject to adjustments upon the occurrence of certain events as more particularly described below and in the form of Warrant. As of October 31, 2012, substantially all of the Bridge Warrants have an exercise price of $18.75 per share. The Bridge Notes may be prepaid in whole or in part at the option of the Company without penalty at any time prior to the Maturity Date. The warrants may be exercised on a cashless basis under certain circumstances.

During the twelve month period ended October 31, 2011, the Company reached agreement with ten investors, whose notes were to mature on dates ranging from December 31, 2010 to April 30, 2011, in the aggregate principal value of approximately $479,000 (included in the above aggregate principal value of $1,886,851) to exchange their original notes for new notes due on dates ranging from March 31, 2011 to August 2, 2011. In return for exchanging their notes, these investors received additional interest of $25,208 plus approximately 6,528 additional warrants, valued using the BSM model (which approximates the Lattice Model), at approximately $87,000.

During the twelve month period ended October 31, 2011, the Company reached agreement with three investors, whose notes were to mature on dates ranging between August 1 and October 31, 2011,in the aggregate principal value of approximately $318,000 (included in the above aggregate principal value of $1,886,851) to make partial repayments on their notes totaling $99,000 and exchanged the remaining principal on the original notes for new notes (with the same amount of principal) due on dates ranging from March 31, 2012 to May 31, 2012. These three investors also received approximately 5,804 additional warrants, at a fair value totaling approximately $80,000.

The Company accounted for two of these three note exchanges as substantial debt modifications under ASC 470-50: Debt Modifications and Extinguishments. Therefore, the Company recorded the present values of the principal on the new notes along with the fair value of the additional warrants issued and wrote off the remaining principal on the old notes. The Company then recorded a loss on exchange of approximately $22,000 (other income/(expense)) for the difference between (1) the sum of the remaining principal on the old notes and (2) the sum of the present values of the principal on the new notes and the fair value of the additional warrants. For the third investor, the Company recorded approximately $27,000 to equity (included in the above fair value of $80,000), representing the fair value of the additional warrants issued upon exchange of their note.

During the twelve month period ended October 31, 2011, the Company repaid approximately $530,000 in principal and interest. In addition, the Company converted approximately $1.3 million of principal and interest on these outstanding junior subordinated convertible promissory notes into69,221 shares of the Company’s common stock at a conversion price of $18.75 per share.

As of October 31, 2011, the Company had approximately $756,000(in principal to be repaid to investors) in outstanding junior subordinated convertible promissory notes with Original Issue Discount (“OID”) amounts ranging from 10% to 15% and with maturity dates ranging from October 19, 2011 to May 12, 2012. These junior unsubordinated notes were recorded on the balance sheet, at October 31, 2011, at $711,701 (remaining principal of $756,000 net of debt discount of approximately $45,000).

During the year ended October 31, 2012, the Company entered into an exchange agreement with an accredited investor in which the investor exchanged a convertible promissory note in the aggregate principal amount of $300,000 for (i) a convertible promissory note in the aggregate principal amount $352,941 and in substantially the same form as the existing note except with a maturity date of June 30, 2012 and (ii) a warrant to purchase up to 18,823 shares of common stock at an exercise price of $18.75 per share. The warrants expire in February 2015. The Company recorded noncash expense of approximately $247,000 to the loss on note retirement account resulting from this exchange for the year ended October 31, 2012. In October 2012, this note was assigned to Magna (see Magna Note disclosure in this footnote).

During the year ended October 31, 2012, the Company paid approximately $53,000 in principal on its Bridge Notes. In addition, the Company converted approximately $169,000 of principal on these Bridge Notes into 9,013 shares of the Company’s common stock at a conversion price of $18.75 per share. The Company recorded noncash expense of approximately $27,000 to the gain on note retirement account resulting from these conversions.

As of October 31, 2012, the Company had approximately $186,000 in principal outstanding on its junior subordinated convertible promissory notes with maturity dates ranging from October 19, 2011 to May 12, 2012.

JMJ Financial

On October 31, 2011, the Company held two notes from JMJ Financial in the aggregate principal amount of $660,000. These notes bear interest at a rate of 8% per annum. Due to the conversion feature into a variable number of shares, these notes are valued at fair value each reporting period. At October 31, 2011, the fair value of these notes was $570,802. These notes were classified as long-term convertible notes at October 31, 2011 as they had maturity dates in April 2014.

In November and December, 2011, the Company converted $500,000 of the aggregate principal amount of $660,000 into 28,800 shares of common stock. As a result, the Company recorded a noncash income of approximately $36,000 related to the conversion of these notes to equity.

On May 8, 2012, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with JMJ Financial which provides for (i) an additional borrowing by the Company of $500,000 from JMJ Financial on the principal amount outstanding under one of the notes issued by JMJ to the Company in April 2011, (ii) the cancellation of all of the outstanding notes issued by JMJ to the Company in April 2011, (iii) the cancellation of all of the outstanding notes issued by the Company to JMJ in April 2011, other than the portion of such notes for which JMJ has paid cash to the Company, (iv) a mutual release of any claims held by the Company or JMJ relating to an outstanding dispute and (v) the issuance by the Company of 32,000 newly issued shares of the Company’s common stock (the “ Settlement Shares ”) to JMJ as consideration for the cancellation of the notes and the release. As a result of the Settlement Agreement, no further payments will be made by either the Company or JMJ under the notes issued by each party in April 2011. The Company recorded noncash expense of approximately $805,000 for the issuance of the Settlement Shares to JMJ under the Settlement Agreement and recognition of a beneficial conversion feature, resulting from the issuance of shares.

During the year ended October 31, 2012, the Company converted the remaining notes outstanding totaling $660,000 into 37,807 shares of the Company’s common stock. The Company recorded noncash income of approximately $250,000 upon conversion.

On August 27, 2012, in a private placement pursuant to a note purchase agreement, we issued JMJ Financial a one year convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000,. The August 2012 Note is initially convertible at a per share conversion price equal to $18.75. In addition, if the August 2012 Note is converted after November 30, 2012 and the market price of our common stock is less than $20.00 per share on the date of conversion, then the conversion price shall equal 95% of the arithmetic average of the three lowest closing trading prices for the common stock during the 15 trading day period ending on the latest complete trading day prior to the applicable conversion date. Pursuant to the terms of the August 2012 Note, we agreed to register with the SEC up to 26,000 shares of our common stock which may be issuable upon conversion of the August 2012 Note. These shares were registered on August 31, 2012.

On August 27, 2012, we entered into a settlement agreement with JMJ Financial pursuant to which we issued to JMJ Financial 32,615 shares of our common stock for the mutual release of any claims held by our company or JMJ Financial relating to our failure to file the registration statement related to the May 2012 issuance of 32,000 shares of our common stock to JMJ Financial and have the registration statement declared effective by certain prescribed deadlines.

As of October 31, 2012, the August 2012 Note remained outstanding. Due to the conversion feature into a variable number of shares this note is valued at fair value at each reporting period. As of October 31, 2012, the fair value of the note was $73,590. Because this note matures within one year, it has been classified as a current liability on the balance sheet at October 31, 2012.

Hanover Holdings Notes

On September 19, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which we refer to as the Initial Hanover PIPE Note. On October 19, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $132,500, for a purchase price of $132,500, which we refer to as the Second Hanover PIPE Note, which, together with the Initial Hanover PIPE Note we refer to as the Hanover PIPE Notes. The Hanover PIPE Notes bear interest at a rate of 12%, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover PIPE Notes. The Hanover PIPE Notes are convertible into shares of our Common Stock at a conversion price equal to 65% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Hanover PIPE Notes mature eight months from their respective issuance dates. To the extent Hanover does not elect to convert the Hanover PIPE Notes as described above, the principal amount and interest of such Hanover PIPE Notes shall be payable in cash at maturity. The Hanover PIPE Notes may be converted at any time by Hanover, at its option, in whole or in part. The Hanover PIPE Notes include a limitation on conversion, which provides that at no time will Hanover be entitled to convert any portion of the Hanover PIPE Notes, to the extent that after such conversion, Hanover (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

Unrealized losses on the mark-to-market of the notes which amounted to $97,791, for the period from the dates of issuance (September 19 and October 19, 2012) were recorded as non-cash expense.

Magna note

In October 2012, pursuant to the terms of various Assignment Agreements, which we refer to as the Assignment Agreements, Magna Group, LLC, an affiliate of Hanover, which we refer to as Magna, acquired $400,076 in aggregate principal amount of our outstanding convertible notes from certain third parties and entered into agreements to acquire an additional $340,523 in aggregate principal amount of our outstanding convertible notes from other third parties. Pursuant to the terms of such Assignment Agreements, we delivered two convertible notes to Magna in an aggregate principal amount of $740,599, in anticipation of the closing of all of the transactions contemplated by such Assignment Agreements. On October 25, 2012, the convertible note in the aggregate principal amount of $617,723 previously delivered to Magna was exchanged for a new convertible note in the aggregate principal amount of $400,076, convertible into shares of Common Stock, which we refer to as the Magna Exchange Note, to reflect such portion of the convertible notes actually issued as of October 25, 2012 pursuant to the Assignment Agreements, and the remaining convertible note in the aggregate principal amount of $122,876 previously delivered to Magna was returned to us and cancelled. The Magna Exchange Note bears interest at a rate of 6%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Magna Exchange Note. The Magna Exchange Note is convertible into shares of our Common Stock at a conversion price equal to 73% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the lowest complete trading day prior to the applicable conversion date. The Magna Exchange Note matures on October 17, 2013. To the extent Magna does not elect to convert the Magna Exchange Note as described above, the principal amount and interest of the Magna Exchange Note shall be payable in cash at maturity. Upon the closing of the remaining transactions contemplated by such applicable Assignment Agreements, we are obligated to issue additional convertible notes in the form of the Magna Exchange Note with respect to the outstanding $340,523 in aggregate principal amount of convertible notes held by the third party signatories to the other Assignment Agreements, which we anticipate to occur during the fourth quarter of 2012.

The Magna Exchange Note may be converted at any time by Magna, at its option, in whole or in part. The Magna Exchange Note includes a limitation on conversion, which provides that at no time will Magna be entitled to convert any portion of the Magna Exchange Note, to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than4.99% of the outstanding shares of the Common Stock as of such date.

As of October 31, 2012, Magna had converted approximately $0.1 million in principal into 20,176 shares of our common stock at prices ranging from $4.453 - 5.15, which resulted in non-cash expense of approximately $13,500 for the period ended October 31, 2012. Unrealized losses on the mark-to-market of the note which amounted to $33,011, for the period from the date of issuance (October 17, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Asher

On September 11, 2012, in a private placement pursuant to a note purchase agreement, we issued Asher Enterprises, Inc, which we refer to as Asher, a convertible promissory note in the aggregate principal amount of $103,500, for a purchase price of $100,000, which we refer to as the Asher Note. The Asher Note bears interest at a rate of 8%, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Asher Note. The Asher Note is convertible into shares of our Common Stock at a conversion price equal to 61% of the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Asher Note matures on June 13, 2013, nine months from its issuance date. The Asher Note may be converted by Asher, at its option, in whole or in part. The Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the Asher Note, to the extent that after such conversion, Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

Unrealized losses on the mark-to-market of the note which amounted to $47,187, for the period from the date of issuance (September 11, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Chris French

On September 27, 2012, in a private placement pursuant to a note purchase agreement, we issued our employee Christine French a convertible promissory note in the aggregate principal amount of $25,000, for a purchase price of $25,000, which we refer to as the French Note. The French Note bears interest at a rate of 12%, compounded annually. The French Note is convertible into shares of our Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The French Note matures one month from its issuance date. Additionally, Ms. French will receive a warrant, which we refer to as the French Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the French Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The French Warrant may be exercised on a cashless basis under certain circumstances. The French Note and the French Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Ms. French be entitled to convert any portion of the French Note or French Warrant, to the extent that after such conversion or exercise, as applicable, Ms. French (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants to be issued upon future conversion of the note were recorded as a warrant liability, at October 31, 2012, at a fair value of $4,565 at the date of issuance. Unrealized losses on the mark-to-market of the note which amounted to $5,515, for the period from the date of issuance (September 27, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Yvonne Paterson

On September 25, 2012, in a private placement pursuant to a note purchase agreement, we issued our affiliate Dr. Yvonne Paterson a convertible promissory note in the aggregate principal amount of $100,000, for a purchase price of $100,000, which we refer to as the Paterson Note. The Paterson Note bears interest at a rate of 12%, compounded annually. The Paterson Note is convertible into shares of our Common Stock at a conversion price equal to the arithmetic average of the five lowest closing trading prices for the Common Stock during the 10 trading day period ending on the latest complete trading day prior to the applicable conversion date. The Paterson Note matures one month from its issuance date. Additionally, Dr. Paterson will receive a warrant, which we refer to as the Paterson Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the Patterson Note at an exercise price equal to the conversion price then in effect. These warrants have not yet been issued. The Paterson Warrant may be exercised on a cashless basis under certain circumstances. The Paterson Note and the Paterson Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Paterson be entitled to convert any portion of the Paterson Note or Paterson Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Paterson (together with her affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants to be issued upon future conversion of the note were recorded as a warrant liability, at October 31, 2012, at a fair value of $18,258 at the date of issuance. Unrealized losses on the mark-to-market of the note which amounted to $22,062, for the period from the date of issuance (September 27, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

James Patton

On August 2, 2012, in a private placement pursuant to a note purchase agreement, we issued Dr. James Patton, a member of our board of directors, a convertible promissory note, which we refer to as the Patton Note, in the principal amount of $66,667 for a purchase price of $50,000. The Patton Note was issued with an original issue discount of 25%. Dr. Patton paid $0.75 for each $1.00 of principal amount of the Patton Note purchased. The Patton Note is convertible into shares of our Common Stock at a per share conversion price equal to $18.75. Additionally, Dr. Patton received a warrant, which we refer to as the Patton Warrant, to purchase such number of shares of our Common Stock equal to 50% of such number of shares of our Common Stock issuable upon conversion of the Patton Note at an exercise price of $18.75 per share. The Patton Note and Patton Warrant also provide that on December 1, 2012, solely to the extent the conversion price of the Patton Note or the exercise price of the Patton Warrant, as applicable, is less than the Market Price (as defined in the Patton Note or the Patton Warrant, as applicable), such conversion price or exercise price, as applicable, shall be reduced to such Market Price. The Patton Note matures on August 2, 2013. We may redeem the Patton Note under certain circumstances. The Patton Warrant is exercisable at any time on or before August 2, 2017. The Patton Warrant may be exercised on a cashless basis under certain circumstances. The Patton Note and the Patton Warrant each include a limitation on conversion or exercise, as applicable, which provides that at no time will Dr. Patton be entitled to convert any portion of the Patton Note or Patton Warrant, to the extent that after such conversion or exercise, as applicable, Dr. Patton (together with his affiliates) would beneficially own more than 4.99% of the outstanding shares of the Common Stock as of such date.

The warrants issued were recorded as a warrant liability, at the date of issuance, at a fair value of $13,311 at the date of issuance. The company recorded non-cash income from a decline in the fair value of the warrant liability, at October 31, 2012, of $5,200, Unrealized losses on the mark-to-market of the note which amounted to $38,944, for the period from the date of issuance (August 2, 2012) were recorded as non-cash expense for the period ended October 31, 2012.

Accretion of the discount amounted to $3,277, for the period ended October 31, 2012.

NOTES PAYABLE-OFFICER:

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Notes Payable Officer [Abstract]

Notes Payable Officer [Text Block]

6. NOTES PAYABLE-FORMER OFFICER:

Moore Notes

The Company has agreed to sell senior promissory notes, which it refers to as the Moore Notes, to Mr. Moore, a Director of the Company and its former chief executive officer, from time to time, under an agreement which we refer to as the Moore Agreement. The Moore Notes bear interest at the rate of 12% per annum. Currently, under the terms of the amended and restated Moore Notes, the maturity date is the earlier of (i) the date of consummation of an equity financing in an amount of $6.0 million or more or (ii) the occurrence of any event of default as defined in the Moore Notes. As of October 31, 2012, the Company owed Mr. Moore approximately $477,000 in principal and interest under the Moore Notes.

For the nine months ended July 31, 2013, Mr. Moore loaned the Company $11,200 under the Moore Notes. The Company paid Mr. Moore $85,700 principal on the Moore Notes for the nine months ended July 31, 2013. For the three and nine months ended July 31, 2013 as well as the period from inception, the Company recorded interest expense of $7,198, 24,841, $324,862 respectively. As of July 31, 2013 and October 31, 2012, respectively, the Company was not in default under the terms of the Moore Agreement. The Company intends to repay Mr. Moore when funds are sufficiently available. As of July 31, 2013, the Company owed Mr. Moore approximately $428,000 in principal and interest under the Moore Notes.

In August 2013, Mr. Moore resigned as Chairman of the Board of Directors and as Chief Executive Officer and entered into a consulting agreement with the Company, which provided for a $100,000 payment towards the Moore Notes in the event the Company closes a financing greater than $5,000,00 during the initial term of the consulting agreement (which amount may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000). The consulting agreement also provides that if the Company closes any financing equal to or greater than $15,000,000 but does not fully satisfy its cumulative outstanding financial obligations, if any, to Mr. Moore as described above, then the Company must pay the remaining balance of any such outstanding financial obligations on the earlier of: (i) six months from the date of closing; or (ii) upon the completion of an underwritten financing (not currently contemplated). See Note 14 — Subsequent Events.

8. NOTES PAYABLE-OFFICER:

Moore Notes

The Company has agreed to sell senior promissory notes to Mr. Moore, our chief executive officer, from time to time (“the Moore Notes”). These notes bear interest at the rate of 12% per annum. Currently, under the terms of the amended and restated Moore Notes: (i) the maturity date is the earlier of the date of consummation of an equity financing in an amount of $6.0 million or more or the occurrence of any event of default as defined in the Moore Notes. As of October 31, 2011, the Company owed Mr. Moore, our chief executive officer, approximately $408,000 in principal and interest under the Moore Notes.

For the twelve months ended October 31, 2012, Mr. Moore loaned the Company $74,500 under the Moore Notes. The Company paid Mr. Moore $35,000 in principal on the Moore Notes. For the year ended October 31, 2012 and 2011 and the period from inception, the Company recorded interest expense of $29,69520 and $78,077 and $300,022 respectively. As of October 31, 2012 and October 31, 2011, respectively, the Company was not in default under the terms of the Moore Agreement. The Company intends to repay Mr. Moore when funds are sufficiently available. As of October 31, 2012, the Company owed Mr. Moore approximately $477,000 in principal and interest under the Moore Notes.

NOTES PAYABLE-OTHER:

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Other Notes Payable [Abstract]

Other Notes Payable [Text Block]

7. NOTES PAYABLE-OTHER:

JLSI, LLC

On July 21, 2012, the Company received $250,000 from JLSI, LLC in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and which matured on December 31, 2012 (“July 2012 Note”). The Company has recorded approximately $37,000 in interest related to this promissory note, through December 31, 2012.

On March 10, 2013 the Company entered into an Exchange Agreement with JLSI, LLC to exchange the July 2012 Note in the principal amount of $250,000 plus interest of approximately $37,000 for common stock, par value $.001 per share . On December 31, 2012 the parties agreed to prepare the Exchange Agreement with a fixed conversion price of $3.75 per share, the market closing price of the Company’s common stock on December 31, 2012. The Company issued 76,491 shares during the second fiscal quarter of 2013 to settle the note and interest.

As of July 31, 2013, this note no longer remained outstanding.

9. NOTES PAYABLE-OTHER:

On July 21, 2012, the Company received $250,000 from an accredited investor in return for issuing a promissory note in the principal amount of $250,000, which bears interest at 33% per annum, compounded annually and matures on December 31, 2012 (“July 2012 Note”). This note currently still remains outstanding. The Company has recorded approximately $23,000 in interest related to this promissory note, through October 31, 2012. We are currently negotiating conversion of this note into shares of common stock.

LONG-TERM CONVERTIBLE NOTE

9 Months Ended

Jul. 31, 2013

Debt Disclosure [Abstract]

Long-term Debt [Text Block]

8. LONG-TERM CONVERTIBLE NOTE

Tonaquint Note

On December 13, 2012, the Company entered into a securities purchase agreement with Tonaquint, Inc., the Tonaquint Purchase Agreement, whereby the Company issued Tonaquint a convertible promissory note for the initial principal sum of $890,000. The Company refers to this note as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can currently be converted at any time, from time to time, at the option of the holder, in whole or in part, a fixed price of $20.00 per share but is subject to adjustment if and whenever on or after six months from the issue date the Company issues shares of its common stock or other securities convertible into or exchangeable for shares of its common stock below the current conversion price of $20.00.

On the closing date, Tonaquint (i) funded $400,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which is referred to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which is referred to as Mortgage Note 2. Mortgage Note 1 bore interest at a rate of 5% and was due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) eight months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bore interest at a rate of 5% and was due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.

Beginning in June 2013, the Company began making monthly installment payments on the Tonaquint Note as required by the terms of the note, which contemplates 18 installment payments equal to approximately $50,000. These installment payments may be made at the Company’s option in cash or in stock although they must be made in cash if certain conditions are not met. If it chooses to make installment payments in stock, then such stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date (which is adjusted to 70% if the average of the 3 lowest volume weighted average prices during such 20-day period is less than $1.25 per share). Tonaquint has the right to receive additional shares or the Company’s common stock if the market price of the common stock is lower than the price per share on the installment date.

During the three months ended July 31, 2013, the Company issued 27,583 shares of its common stock, in lieu of a cash installment payment, to satisfy $49,444 of principal and approximately $49,000 in accrued interest. This principal payment was converted into shares of common stock at a conversion price of $3.57.

Unrealized losses on the mark-to-market of the Tonaquint Note, which amounted to $264,124, were recorded as a non-cash expense, for the three months ended July 31, 2013. As of July 31, 2013, the Tonaquint Note was recorded on the balance sheet at its fair value of $1,104,680.

On December 13, 2012, the Company also issued Tonaquint a warrant to purchase the number of shares equal to 75% of the principal sum of $890,000 under the Tonaquint Note divided by market price as of the issue date as defined in the warrant agreement. This warrant expires 5-years from the issue date and provides for a variable exercise price per share as defined in the warrant agreement. On March 14, 2013, the Company issued 170,624 shares of its common stock resulting from the partial cashless exercise of the warrant issued to Tonaquint in December 2012. Additionally, on March 13, 2013 and March 19, 2013 Tonaquint made accelerated payments (including interest income) of $202,493 and $202,657 respectively owed to the Company under Mortgage Note 1 and Mortgage Note 2 described above. Accordingly, the Company recorded an increase to cash, interest income and short-term convertible notes received during the second fiscal quarter of 2013. Warrants to purchase up to 86,283 shares of the Company’s common stock issued to Tonaquint remain outstanding.

COMMON STOCK WARRANT LIABILITY

9 Months Ended

Jul. 31, 2013

Warrant Liability [Abstract]

Warrant Liability [Text Block]

9. COMMON STOCK WARRANT LIABILITY

Warrants

As of July 31, 2013, there were outstanding warrants to purchase 899,494 shares of the Company’s common stock with exercise prices ranging from $4.375 to $21.25 per share. Information on the outstanding warrants is as follows:


Type	Exercise Price			Amount		Expiration Date		Type of Financing
Exchange Warrants – Nonexercisable	$	18.75			278,329		October 2014		July 2012 Exchanges
Common Stock Purchase Warrant	$	18.75			28,632		May 2015		May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			11,628		October 2014 - October 2015		Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			17,706		May 2015 - January 2016		December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			13,333		May 2017		May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	15.11 - 21.25			214,416		December 2013 - April 2015		Bridge Notes
Common Stock Purchase Warrant	$	4.375			1,333		December 2015		Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75			376		N/A		Vendor & Other
Common Stock Purchase Warrant	$	10.625 - 18.75			29,883		May 2014 - May 2017		Placement Agent - Convertible Debt Financing
Common Stock Purchase Warrant		5.625 - 10.625			13,095		October 2015 - August 2017		August - September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		357			86,283		December 2014		Tonaquint Promissory Note
		Subtotal:			695,014
Common Stock Purchase Warrant		TBD	⁽¹⁾		204,480		April 2014		Preferred Stock Agreement (4/04/2011)
		Grand Total			899,494

(1)

During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

As of October 31, 2012, there were outstanding warrants to purchase 802,580 shares of the Company’s common stock with exercise prices ranging from $6.625 to $21.25 per share. Information on the outstanding warrants is as follows:


Type	Exercise Price			Amount		Expiration Date		Type of Financing
Exchange Warrants – Nonexercisable	$	18.75			278,329		October 2014		July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	18.75			28,632		May 2015		May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			11,628		October 2014 - October 2015		October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			17,706		January 2015 - January 2016		December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			22,222		May 2017		May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	14.95 - 21.25			198,036		January 2013 - April 2015		Bridge Notes
Common Stock Purchase Warrant	$	18.75			376		N/A		Vendor & Other
Common Stock Purchase Warrant	$	18.75			29,883		May 2014 - May 2017		Placement Agent - Convertible Debt Financing
Common Stock Purchase Warrant		6.625 - 18.75			11,288		October 2015 - August 2017		August - September 2012 Convertible Promissory Notes
		Subtotal:			598,100
Common Stock Purchase Warrant		TBD	⁽¹⁾		204,480		April 2014		Preferred Stock Agreement (4/04/2011)
		Grand Total			802,580

(1)

At both July 31, 2013 and October 31, 2012, the Company had approximately 122,000 and 121,000 of its outstanding warrants, respectively, classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. Its equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

As of July 31 2013, the Company had approximately 777,000 of its total approximately 899,000 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of July 31, 2013 was approximately $0.7 million. At October 31, 2012, the Company had approximately 682,000 of its total approximately 803,000 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2012, was approximately $0.4 million. In fair valuing the warrant liability, at July 31, 2013 and October 31, 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):


	(Unaudited) July 31, 2013			October 31, 2012
Exercise Price:	$	4.375 – 21.25		$	6.625 – 21.25
Stock Price		3.50			5.625
Expected Term:		153 – 1588 days			81 – 1736 days
Expected Volatility		93.73% – 153.00	%		66.51% – 146.78	%
Risk Free Rate:		.08% – .0995	%		0.09 – .056	%

Warrant Liability

As of July 31, 2013, the Company had approximately 777,000 of its total approximately 899,000 warrants classified as liabilities (liability warrants). Of these 777,000 liability warrants, approximately 499,000 warrants are outstanding and 278,000 warrants are exchange warrants — nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 124,000 of the Company’s 804,000 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported in the statement of operations.

As of July 31, 2013 and October 31, 2012, the fair value of the warrant liability was approximately $736,000 and $434,000, respectively. For the three months ended July 31, 2013 and 2012, the Company reported income of approximately $1.8 million and $1.7 million, respectively due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2013 and 2012, the Company reported expense of approximately $1.1 million and income of approximately $4.9 million, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the nine months ended July 31, 2013, an accredited investor exercised 8,889 warrants at an exercise price of $10.625, resulting in net proceeds to the Company of $94,444. During the nine months ended July 31, 2012, investors in the Company exercised 21,961 warrants at a price of $18.75 per share, resulting in total proceeds to the Company of approximately $412,000.

Warrants with Anti-Dilution Provisions

Some of the Company’s warrants (approximately 124,000) contain anti-dilution provisions originally set at $25.00 with a term of five years. As of July 31, 2013, these warrants had an exercise price of approximately $15.11. As of October 31, 2012, these warrants had an exercise price of approximately $18.70. If the Company issues any common stock, except for exempt issuances as defined in the warrant for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “weighted average” formula included in the warrant. For the three months ended July 31, 2013, this anti-dilution provision required the Company to issue approximately 10,000 additional warrant shares; and the exercise price to be lowered to a de minimis amount ($15.11). Any future financial offering or instrument issuance below the current exercise price will cause further anti-dilution and re-pricing provisions in approximately 124,000 of its total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $15.11 and $12.50, weighting the possibility of warrants being exercised at $15.11 between 40% and 50% and warrants being exercised at $12.50 between 60% and 50%.

As of July 31, 2013, there were outstanding warrants to purchase 621,165 shares of the Company’s common stock and exchange warrants — nonexercisable to purchase 278,329 shares of the Company’s common stock with exercise prices ranging from $4.375 to $21.25 per share.

DERIVATIVES

12 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

10. DERIVATIVES

The table below lists the Company’s derivative instruments as of October 31, 2012 and 2011:

Description	Principal		Original Issue Discount		Warrant Liability		Embedded Derivative Liability
Total Valuation at October 31, 2010	$	777,154	$	21,937	$	13,006,194	$	81,028
Issuance of November 2010 Bridge Notes		931,579		96,579		391,076		150,156
Exchange of November 2010 Bridge Notes		17,175		17,175		86,963		9,389
Issuance of January 2011 Bridge Notes		452,941		57,941		173,808		41,024
Note Payoffs		(187,582)
Issuance of Warrants						35,523
Accreted Interest				(73,363)
Exercise of Warrants						(1,382,847)
Change in FV						(3,789,889)		(51,972)
Total Valuation at January 31, 2011		1,991,267		120,269		8,520,828		229,625
Issuance of Q2 2011 Bridge Notes		473,392		43,392		121,238		71,336
Issuance of Long-term Convertible Promissory Notes		626,400						—
Note Payoffs		(159,675)						(5,904)
Issuance of Warrants						2,990,520
Accreted Interest				(74,422)
Exercise of Warrants						(639,960)
Change in FV						4,915,676		763,523
Total Valuation at April 30, 2011	$	2,931,384	$	89,239	$	15,908,302	$	1,058,580
Issuance of Q3 2011 Bridge Notes		11,765		1,765		4,968		5,051
Issuance of May 2011 Notes		7,077,936		1,553,254		—		2,719,345
Note Payoffs		(26,316)						(8,860)
Additional warrants issued to Bridge Note holder						36,376
Exchange of Bridge Notes		8,033		8,033				2,656
Conversion of Bridge Notes		(1,164,947)						(381,209)
Conversion of May 2011 Notes		(671,500)						(166,980)
Exchanges/Exercises of October 2007 Warrants						(1,186,959)
Accreted Interest				(340,050)
Change in FV						(6,826,019)		(2,141,984)
Total Valuation at July 31, 2011	$	8,166,355		1,312,241		7,936,668		1,086,599
Issuance of October 2011 Notes		2,326,471		459,396		—		396,818
Note Payoffs		(155,806)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788)						(10,530)
Conversion of May 2011 Notes		(1,225,561)						(110,494)
Reclassification of Warrant liability to Equity						(186,908)
Exchange of Warrants						816,259
Accreted Interest				(471,290)
Change in FV						(2,174,948)		(416,347)
Total Valuation at October 31, 2011	$	8,976,071		1,300,347		6,391,071		946,046
Issuance of December 2011 Notes		1,232,353		258,178		—		306,568
Conversion of Bridge Notes		(169,000)						—
Conversion of May 2011 Notes		(1,924,060)						(341,342)
Conversion of October 2011 Notes		(1,227,500)						(329,433)
Partial Note Repayments		(52,941)
Conversion of Long-term Convertible Promissory Notes		(540,000)
Exchange of Warrants						59,572
Accreted Interest				(532,559)
Change in FV						(923,052)		159,657
Total Valuation at January 31, 2012	$	6,294,923	$	1,025,966	$	5,527,591	$	741,496
Exchange of Bridge Notes		52,941				—
Conversion of May 2011 Notes		(38,000)						(5,016)
Conversion of December 2011 Notes		(827,500)						(160,677)
Exchange of Warrants						(134,796)
Accreted Interest				(569,419)
Change in FV						(2,302,707)		(438,054)
Total Valuation at April 30, 2012	$	5,482,364	$	456,547	$	3,090,088	$	137,749
Issuance of May 2012 Notes		953,333				291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673)		(200,632)				(115,046)
Debt for Equity Exchange: Bridge Notes		(50,000)				(4,750)
July 2012 Exchange of Warrants						(407,501)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800)
Accreted Interest				(229,392)
Change in FV						(1,703,252)		(20,567)
Total Valuation at July 31, 2012	$	1,739,224		26,523		1,265,985		2,136
Issuance of Patton Note		66,667				13,311
Issuance of French Note		25,000				4,565
Issuance of Paterson Note		100,000				18,258
Issuance of Hanover September Note		132,500
Issuance of Asher Note		103,500
Issuance of Hanover October Note		132,500
Issuance of JMJ Note		100,000
Assignment of Notes to Magna		(384,264)
New Magna Note (result of above assignment)		400,075
Magna Conversions		(100,000)
Accreted Interest				(21,984)
Additional warrants issued due to investors due to anti-dilution provision						150
Change in FV						(868,133)		(2,136)
Total Valuation at October 31, 2012	$	2,315,202		4,541		434,136		—

Warrants

As of October 31, 2012, there were outstanding warrants to purchase 802,580 shares of our common stock with exercise prices ranging from $6.625 to $21.25 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable		18.7		278,329	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant		18.7		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.7		11,628	October 2014 - October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.7		17,706	January 2015 - January 2016	December 2011 Convertible DebtFinancing
Common Stock Purchase Warrant		18.7		22,222	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant		18.69 - 21.25		198,037	January 2013 - April 2015	Bridge Notes
Common Stock Purchase Warrant		18.7		376	N/A	Vendor & Other
Common Stock Purchase Warrant		18.7		29,883	May 2014 - May 2017	Placement Agent – Convertible DebtFinancing
Common Stock Purchase Warrant		6.625 -18.7		11,288	October 2015 - August 2017	August – September 2012 ConvertiblePromissory Notes
		Subtotal:		598,101
Common Stock Purchase Warrant		TBD⁽¹⁾		204,479	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		802,580

(1)

As of October 31, 2011, there were outstanding warrants to purchase 1,102,734 shares of our common stock with exercise prices ranging from $18.75 to $24.40 per share. Information on the outstanding warrants is as follows:

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant		18.75		376,723	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant		18.75		2,296	August 2012	August 2007 Notes
Common Stock Purchase Warrant		18.75		188,745	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.75		62,039	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.75 - 21.25		181,040	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant		18.75		61,396	August 2014	Executive Officer
Common Stock Purchase Warrant		18.75 - 24.40		3,576	February 2012	Vendor & Other
Common Stock Purchase Warrant		18.75		22,438	May 2014 - November 2015	Placement Agent - Convertible DebtFinancing
		Subtotal		898,253
Common Stock Purchase Warrant		TBD⁽¹⁾		204,479	April 2014	Optimus Preferred Stock Agreement(4/04/2011)
		Grand Total		1,102,732

(1)

At October 31, 2012, the Company had approximately 120,800 of its total 802,580 outstanding warrants classified as equity (equity warrants). At October 31, 2011, the Company had approximately 294,400 of its total 1,102,733 outstanding warrants classified as equity (equity warrants). At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the stockholders equity section of the balance sheet. Our equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

At October 31, 2012, the Company had approximately 681,780 of its total 802,580 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2012 was approximately $.4 million At October 31, 2011 the Company had approximately 808,333 of its total 1,102,733 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2011, was approximately $6.39 million. In fair valuing the warrant liability, at October 31, 2012 and October 31, 2011, the Company used the following inputs in its BSM Model:

	10/31/2012		10/31/2011
Exercise Price:		6.625 - 21.257		18.75 - 21.25
Stock Price		5.625		17.625
Expected term:		81 - 1736 days		289 - 1219 days
Volatility %		66.51% - 146.78%		60.23% - 163.40%
Risk Free Rate:		.09% - .72%		.09 - .56%

Warrant Liability/Embedded Derivative Liability

Warrant Liability

As of October 31, 2012, the Company had approximately 681,780 of its total approximately 802,580 total warrants classified as liabilities (liability warrants). Of these 681,780 liability warrants, approximately 403,451 warrants are outstanding and 278,329 warrants are exchange warrants — nonexercisable. The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 104,800 of our 681,780 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e.-the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

As of October 31, 2011, the Company had approximately 808,333 of its total approximately 1,102,733 total warrants classified as liabilities (liability warrants). The Company utilizes the BSM Model to calculate the fair value of these warrants at issuance and at each subsequent reporting date. For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the warrants at the reporting date. Approximately 395,200 of our 808,333 liability warrants are subject to anti-dilution provisions. A certain number of liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the common stock purchase warrant). Any changes in the fair value of the warrant liability (i.e.-the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At October 31, 2012 and 2011, the fair value of the warrant liability was approximately $434,000 and $6,391,000, respectively. For the twelve months ended October 31, 2012 and October 31, 2011, the Company reported income of approximately $6.4 million and $7.8 million, respectively, due to changes in the fair value of the warrant liability.

Exercise of Warrants

During the twelve months ended October 31, 2012, investors in the Company exercised 21,960 warrants at a price of $18.75 per share, resulting in total proceeds to the Company of approximately $412,000. During the twelve months ended October 31, 2011, the Company exercised 57,866 warrants at a price of $18.75 per share, resulting in total proceeds to the Company of $1,085,001.

2011 Warrant Exchange

In addition, in an effort to reduce the number of the warrants outstanding from the October 17, 2007 private placement by the Company, the Company has entered into exchange agreements with certain of the holders of such warrants pursuant to which such holders received shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and/or warrants to purchase shares of Common Stock in amounts that were determined in such negotiations.

During the twelve months ended October 31, 2012, the Company exchanged October 2007 warrants to purchase 38,330 shares of Common Stock for new warrants to purchase 51,107 shares of Common Stock. The new warrants issued pursuant to the exchanges are identical to the October 2007 warrants, except that such warrants do not contain any economic anti-dilution adjustment. The Company recorded noncash expense of approximately $25,000 to the changes in fair value account resulting from this exchange. Subsequently, the Company exchanged these new warrants, in the amount of 51,107 for shares of our common stock in the amount of 12,776. The Company recorded noncash income of approximately $54,000 due to the changes in fair value at the date of exchange and a noncash expense of approximately $89,000 resulting from this exchange of warrants for shares of our common stock during the twelve months ended October 31, 2012.

July 2012 Warrant Exchange

On June 8, 2012, Thomas A. Moore, our Chief Executive Officer, waived our obligation to keep reserved from our authorized and available shares of common stock, such number of shares of our common stock necessary to effect the exercise or conversion, as applicable, in full, of (i) warrants to purchase an aggregate of 88,516 shares of our common stock and (ii) promissory notes convertible into 6,400 shares of our common stock. This waiver expired on August 16, 2012, the date that we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock.

On July 5, 2012, in consideration for the waiver described above, we entered into an exchange agreement with Mr. Moore, with an effective date of June 8, 2012, pursuant to which Mr. Moore surrendered warrants to purchase an aggregate of approximately 88,516 shares of our common stock to us in exchange for receiving warrants to purchase an aggregate of approximately 88,516 shares of our common stock that were not exercisable and for which no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. Mr. Moore also agreed pursuant to the exchange agreement not to convert the promissory notes convertible into 6,400 shares of our common stock until the Company filed on amendment to its certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to its authorized shares of common stock. In addition, the warrants to be issued in the exchange have an extended expiration date of two years following issuance.

In July 2012, we entered into exchange agreements with certain additional holders of an additional 189,812 warrants to purchase shares of our common stock. Similar to Mr. Moore, these holders have surrendered warrants to purchase an aggregate of approximately 189,812 shares of our common stock to us in exchange for receiving warrants to purchase the same aggregate amount of our common stock. These warrant shares were not exercisable and no shares of our common stock were reserved until we filed an amendment to our certificate of incorporation with the Secretary of State of the State of Delaware to effect an increase to our authorized shares of common stock. In addition, warrants to be issued in the exchange have an extended expiration date of two years following issuance.

The Company recorded noncash income of approximately $408,000 as a result of these exchanges.

The Company has included the above exchanged warrants, aggregating to 278,329, in its total warrants of 802,580 as of October 31, 2012. These new warrants are expected to be issued by early 2013.

Expiration of Warrants

During the twelve months ended October 31, 2012, the Company had 126,956 warrants (“October 2007 warrants”), with anti-dilution provisions, and 3,200 warrants, with no such anti-dilution provisions, expire unexercised.

Warrants with anti-dilution provisions

Some of our warrants (approximately 13.1 million) contain anti-dilution provisions originally set at $0.20 with a term of five years. As of October 31, 2012 and 2011 these warrants had an exercise price of approximately $18.75. If the Company issues any Common Stock, except for exempt issuances as defined in the Warrant for consideration less than the exercise price then the exercise price and the amount of warrant shares available would be adjusted to a new price and amount of shares per the “weighted average” formula included in the Warrant. During October 2012, the Company issued shares to an investor from the partial conversion of a convertible promissory note at a conversion price of $4.45. The anti-dilution provision requires the Company to issue approximately 42,400 additional warrant shares; and the exercise price to be lowered a de minimis amount $18.6875. Any future financial offering or instrument issuance below the current exercise price will cause further anti-dilution and re-pricing provisions in approximately 13.1 million of our total outstanding warrants.

For those warrants with exercise price reset features (anti-dilution provisions), the Company computes multiple valuations, each quarter, using an adjusted BSM model, to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company utilized different exercise prices of $18.6875 and $12.50, weighting the possibility of warrants being exercised at $18.687 between 40% and 50% and warrants being exercised at $12.50 between 60% and 50%.

As of October 31, 2012, there were outstanding warrants to purchase 524,251 shares of our common stock and exchange warrants-nonexercisable to purchase 278,329 shares of our common stock with exercise prices ranging from $6.625 to $21.25 per share.

Embedded Derivative Liability

The Company has convertible features (Embedded Derivatives) in its outstanding convertible promissory notes. The Embedded Derivatives are recorded as liabilities at issuance. These Embedded Derivatives are valued using the Black-Scholes Model (BSM Model) and are subject to revaluation at each reporting date. Any change in fair value between reporting periods will be reported on the statement of operations.

At October 31, 2012, the fair value of the Embedded Derivative Liability was $0 as the related notes were paid off, converted or reached maturity. For the twelve months ended October 31, 2012 and October 31, 2011, the Company reported income of approximately $400,000 and approximately $1.9 million, respectively, due to changes in the fair value of the Embedded Derivative Liability partially resulting from debt to equity exchanges during the period.

The fair value of the Warrants and Embedded Derivatives are estimated using an adjusted BSM model. The Company computes multiple valuations, each quarter, using the BSM model for each derivative instrument to account for the various possibilities that could occur due to changes in the inputs to the BSM model as a result of contractually-obligated changes (for example, changes in strike price to account for down-round provisions). The Company effectively weights each calculation based on the likelihood of occurrence to determine the value of the derivative at the reporting date. As of October 31, 2012, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $1.9 million and $0, respectively. As of October 31, 2011, the fair value of the Warrants and Embedded Derivatives was determined to be approximately $6.4 million and $946,000, respectively. We increased income approximately $6.0 million for net changes in the fair value of the common stock warrant liability and embedded derivative liability for the year ended October 31, 2012. We increased income approximately $9.8 million for net changes in the fair value of the common stock warrant liability and embedded derivative liability for year ended October 31, 2011.

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7668309&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41635-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624181-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

STOCK OPTIONS:

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock Options Disclosure [Text Block]

10. STOCK OPTIONS

The Company has one active stock and cash-based incentive plan, the 2011 Omnibus Incentive Plan, which it refers to as the Incentive Plan, pursuant to which the Company has granted stock options to executive officers, directors, employees and consultants. The Incentive Plan was adopted on August 22, 2011 and approved by the stockholders on September 27, 2011. An aggregate of 160,000 shares of the Company’s common stock (subject to adjustment by the Compensation Committee of the Board) are reserved and available for delivery under the Incentive Plan. On August 13, 2012, at the Company’s annual meeting, stockholders ratified and approved an amendment to our Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan to 520,000. As of July 31, 2013, the Company had granted 271,560 options to employees, directors and consultants, at exercise prices ranging from $9.375 to $18.75.All of the company’s outstanding options have intrinsic value of $0.

The Incentive Plan supersedes all of the Company’s previous stock option plans, which include the 2004 Stock Option Plan, the 2005 Stock Option Plan and the 2009 Stock Option plan under which the Company had options to purchase 19,052, 42,952 and 142,735 shares of common stock outstanding. The terms and conditions of the options outstanding under these plans remain unchanged. As of July 31, 2013, the Company had total outstanding options of 467,923.

Total compensation cost for the Company’s stock plans recognized in the statement of operations for the three months ended July 31, 2013 was approximately $320,000, of which approximately $98,000 was included in research and development expenses and approximately $222,000 was included in general and administrative expenses. For the three months ended July 31, 2012, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $290,000 of which approximately $128,000 was included in research and development expenses and approximately $162,000 was included in general and administrative expenses. For the nine months ended July 31, 2013, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $2.6 million of which approximately $1.0 million was included in research and development and approximately $1.6 million was included in general and administrative expenses. For the nine months ended July 31, 2012, total compensation cost for the Company’s stock plans recognized in the statement of operations was approximately $878,000 of which approximately $398,000 was included in research and development and approximately $480,000 was included in general and administrative expenses.

The fair value of options granted for the nine months ended July 31, 2013 and 2012 amounted to $1,657,500 and $2,539,792, respectively.

As of July 31, 2013, there was approximately $1,472,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 1.42 years.

A summary of changes in the stock option plan for nine months ended July 31, 2013 is as follows:

	Number of		Weighted-Average
	Options		Exercise Price
Outstanding at October 31, 2012:		358,459	$	20.00
Granted		134,600	$	9.375
Exercised		—		—
Expired		(25,136)		18.75
Outstanding at July 31, 2013		467,923	$	17.50
Vested and Exercisable at July 31, 2013		290,300	$	17.50

2011 Employee Stock Purchase Plan

The Company’s board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which it refers to as the ESPP, on August 22, 2011, and its stockholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011 and the Company has reserved 40,000 shares of its common stock for issuance under the ESPP.

During the nine months ended July 31, 2013, approximately $22,575 was withheld from employees, on an after-tax basis, in order to purchase approximately 5,290 shares of common stock in February, May and August 2013. During the nine months ended July, 2012, approximately $18,300 was withheld from employees, on an after-tax basis, in order to purchase 1,657 shares of common stock.

11. STOCK OPTIONS:

The Company has one active stock and cash-based incentive plan, the 2011 Omnibus Incentive Plan (the “Plan”), pursuant to which the Company has granted stock options to executive officers, directors, employees and consultants. The Incentive Plan was adopted on August 22, 2011 and approved by the stockholders on September 27, 2011. An aggregate of 160,000 shares of our common stock (subject to adjustment by the compensation committee) are reserved and available for delivery under the 2011 Plan. On August 13, 2012, at our annual meeting, shareholders ratified and approved an amendment to our 2011 Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan to 360,000. At October 31, 2012, the Company had granted 140,320 options to employees and consultants, at an exercise price, of approximately $18.75.

The 2011 Plan supersedes all of the Company’s previous stock option plans, which include the 2004 Stock Option Plan, the 2005 Stock Option Plan and the 2009 Stock Option plan under which the Company had options to purchase 19,052, 43,552 and 155,535 shares of common stock. The terms and conditions of the options outstanding under these plans remain unchanged. As of October 31, 2012, the Company had outstanding options of 358,459.

Total compensation cost for our stock plans recognized in the statement of operations for the year ended October 31, 2012 was approximately $1.09 million, of which approximately $480,000 was included in research and development expenses and approximately $610,000 was included in general and administrative expenses. For the year ended October 31, 2011, total compensation cost for our stock plans recognized in the statement of operations was approximately $651,000 of which approximately $272,000 was included in research and development expenses and approximately $379,000 was included in general and administrative expenses, respectively.

The fair value of options granted for the years ended October 31, 2012 and 2011 amounted to $2,539,792 and $103,125, respectively.

As of October 31, 2012, there was approximately $2,047,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining average vesting period of 2.0 years.

A summary of the grants, cancellations and expirations (none were exercised) of the Company’s outstanding options for the periods starting with October 31, 2010 through October 31, 2012 is as follows:

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2010		211,739		20.00		7.4		415,967
Granted		6,800		15.00		9.2		15,200
Cancelled or Expired		—		—		—		—
Outstanding as of October 31, 2011		218,539		20.00		8.1		367,417
Granted		140,320		18.75		9.0		—
Cancelled or Expired		(400)		12.50		6.75		—
Outstanding as of October 31, 2012		358,459		20.00				—
Vested & Exercisable at October 31, 2012		234,225	$	20.00		5.75	$	—

The fair value of each option granted from the Company’s stock option plans during the years ended October 31, 2012 and 2011 was estimated on the date of grant using the Black-Scholes option-pricing model. Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of the Company’s Common Stock price, (ii) the periods of time over which employees and Board Directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Company’s Common Stock, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options’ expected lives. The Company used their own historical volatility in determining the volatility to be used. Expected lives are based on contractual terms given the early stage of the business and lack of intrinsic value. The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

	Year Ended October 31, 2012		Year Ended October 31, 2011
Expected volatility	143.00	%		150.44	%
Expected Life	10.0 years			10.0 years
Dividend yield	0			0
Risk-free interest rate	2.10	%		3.50	%
Forfeiture Rate	4.4	%		4.4	%

2011 Employee Stock Purchase Plan

Our board of directors adopted the Advaxis, Inc. 2011 Employee Stock Purchase Plan, which we refer to as the ESPP, on August 22, 2011, and our stockholders approved the ESPP on September 27, 2011. The ESPP allows employees to purchase common stock of the Company at an 85% discount to the market price on designated exercise dates. Employees were eligible to participate in the ESPP beginning December 30, 2011. 40,000 shares of our common stock are reserved for issuance under the ESPP.

During the twelve months ended October 31, 2012 approximately $18,300 was withheld from employees, on an after-tax basis, in order to purchase an aggregate of 1,656 shares of our common stock. There was no such activity during the twelve months ended October 31, 2011 as the ESPP was not available.

COMMITMENTS AND CONTINGENCIES

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

11. COMMITMENTS AND CONTINGENCIES

Brio Claim

On March 22, 2013, the Company was notified that a lawsuit against it had been filed by Brio Capital L.P., which it refers to as Brio, in the Supreme Court of the State of New York, County of New York, titled Brio Capital L.P. v. Advaxis Inc., Case No. 651029/2013, which it refers to as the Action. The complaint in the Action alleges, among other things, that the Company breached the terms of certain warrants to purchase shares of its common stock that it originally issued to Brio on October 17, 2007 and on June 18, 2009, each at an initial exercise price of $25.00 per share, and that Brio has suffered damages as a result thereof. Brio’s complaint seeks (i) a preliminary and permanent injunction directing the Company to issue to Brio 21,742 shares of its common stock, along with the necessary corporate resolutions and legal opinions to enable Brio to sell such common stock publicly without restriction; and (ii) damages of at least $500,000 (in an amount to be determined at trial), along with interest, costs and attorneys’ fees related to the Action. On April 15, 2013, in partial settlement of the Brio lawsuit, the Company issued 21,742 shares of common stock, recorded non-cash expense of approximately $232,000 for the nine months ended July 31, 2013 and provided certain corporate resolutions and legal opinions necessary to enable Brio Capital L.P. to sell such common stock publicly without restriction. The Company believes the remaining claims under the Action are entirely without merit, and it intends to vigorously defend itself against the Action.

University of Pennsylvania

On May 10, 2010, the Company entered into a second amendment to the Penn license agreement pursuant to which it acquired exclusive licenses for an additional 27 patent applications related to its proprietary Listeria vaccine technology. As part of this amendment the Company exercised its option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in its common stock (approximately 3,111 shares of its common stock based on a price of $22.50 per share) and agreed to pay historical patent costs incurred by Penn at a cost of approximately $462,000. As of July 31, 2013, the Company owed Penn approximately $460,000 under all licensing agreements.

Numoda

On June 19, 2009 the Company entered into a Master Agreement and on July 8, 2009, it entered into a Project Agreement with Numoda Corporation, which it refers to as Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda is responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Pursuant to the Master Agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 28,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through July 31, 2013, the Company has paid Numoda approximately $7.65 million.

As of July 31, 2013, the Company owed Numoda approximately $1.4 million, which is recorded in Accounts Payable.

Numoda-Socius Stock Issuance

On July 24, 2012, the Circuit Court of the 11^th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which the Company refers to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which the Company refers to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which the Company refers to as the Claim. Socius purchased approximately $1.8 million of the Claim against the Company from Numoda Corporation.

Pursuant to the terms of the Order and the Stipulation, the Company issued and delivered to Socius an aggregate of 197,449 shares of its common stock for the entire Claim in the period from July to November 2012, which were subject to adjustment as described in the Stipulation. During the three and nine months ended July 31, 2013, the Company recorded non-cash income of approximately $0 and $615,000 related to the issuance of stock to Socius in settlement of the Claim.

Separation Agreement

On March 6, 2013, the Company announced the departure of Dr. John Rothman, the Company’s former Executive Vice President of Clinical and Scientific Operations, effective March 1, 2013. On March 20, 2013, the Company entered into a Separation Agreement and General Release with Dr. Rothman, pursuant to which Dr. Rothman released the Company from all claims and agreed to continue to assist the Company as a consultant until February 28, 2014 in exchange for (i) being compensated on an hourly basis for certain project assignments as requested by the Company, (ii) receiving an aggregate of approximately $275,000, paid in installments over the course of the one year consulting period, and (iii) all of the options to purchase shares of the Company’s common stock held by Dr. Rothman being fully vested with the exercise period of such options being extended until March 1, 2015.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10,000 square foot leased facility in Princeton, NJ which approximates $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $38,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset. The Sublease Agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $337,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015.

On March 13, 2013, the Company entered into a modification of the Sublease Agreement whereby all unpaid accrued lease amounts and future lease amounts through June 30, 2013, which the Company estimated to be approximately $450,000, would be satisfied by a payment in total of $200,000, with $100,000 paid on March 13, 2013 and $100,000 payable upon the consummation of a future capital raising transaction by the Company. In addition, lease payments for the period July 1, 2013 through November 30, 2015 will be reduced to a total of $20,000 per month.

Other

Pursuant to a Clinical Research Service Agreement, executed in April 2005, the Company is obligated to pay Pharm — Olam International for service fees related to a Phase I clinical trial. As of July 31, 2013, the Company has no outstanding balance of on this agreement. During the nine months ended July 31, 2013, the Company settled an aged payable balance in the amount of $223,620 for a payment of $75,000, recording non-cash income of approximately $148,000 on this transaction.

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey NOL Transfer Program. In December 2012, the Company received notification that it will receive a net cash amount of approximately $725,000 from the sale of its state NOLs and research and development tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2013.

12. COMMITMENTS AND CONTINGENCIES:

University of Pennsylvania

On May 10, 2010, we entered into a second amendment to the Penn license agreement pursuant to which we acquired exclusive licenses for an additional 27 patent applications related to our proprietary Listeria vaccine technology. As part of this amendment we exercised our option for the rights to seven additional patent dockets, including 23 additional patent applications, at an option exercise fee payable in the form of $35,000 in cash and $70,000 in our common stock (approximately 3,111 shares of our common stock based on a price of $22.50 per share) and agreed to pay historical patent costs incurred by the University of Pennsylvania at a cost of approximately $462,000. As of October 31, 2012, the Company owed the University of Pennsylvania approximately $517,000 under all licensing agreements.

Numoda

On June 19, 2009 we entered into a Master Agreement and on July 8, 2009 we entered into a Project Agreement with Numoda, a leading clinical trial and logistics management company, to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervical cancer and CIN. Numoda will be responsible globally for integrating oversight and logistical functions with the clinical research organizations, contract laboratories, academic laboratories and statistical groups involved. The scope of this agreement covers over three years and is estimated to cost approximately $12.2 million for both trials. Per the agreement, the Company is permitted to pay a portion of outstanding charges to Numoda in the form of the Company’s common stock and during May 2010, the Company issued 28,000 shares of its common stock to an affiliate of Numoda in satisfaction of $350,000 in services rendered by Numoda to the Company under the Master Agreement. The Company has recorded deferred expenses on the balance sheet for this amount and amortizes this amount to expense over the life of the agreement. As the Company is billed by Numoda on a monthly basis, these costs are capitalized to deferred expenses. As the clinical trials progress in terms of patient enrollment and time, the Company reduces the deferred expense balance and recognizes clinical trials expense on the statement of operations. From inception through October 31, 2012, the Company has paid Numoda approximately $7.4 million.

Numoda -Stock Purchase Agreement

On June 13, 2012, we entered into a stock purchase agreement with Numoda Corporation pursuant to which we issued to Numoda 120,000 shares of our common stock, which we refer to as the AR Cancellation Shares, at a purchase price per share of $18.75, in exchange for the immediate cancellation of $2,250,000 of accounts receivables owed by us to Numoda pursuant to the Master Agreement, dated June 19, 2009, between Numoda and us. In connection with such issuance, we registered the AR Cancellation Shares with the Securities and Exchange Commission. The Company recorded noncash income of approximately $869,000 as a result of this stock purchase agreement.

Numoda- Socius Stock Issuance

On July 24, 2012, the Circuit Court of the 11^th Judicial Circuit in and for Miami-Dade County, Florida entered an Order Approving Stipulation for Settlement of Claim, which we refer to as the Order, in the matter titled Socius CG II, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement Claim, which we refer to as the Stipulation, provide for the full and final settlement of Socius’s $2,888,860 claim against the Company ($1.8 million claim from Numoda plus approximately $1 million in transaction related costs) in connection with past due invoices relating to clinical trial services, which we refer to as the Claim. Socius purchased approximately $1.8 million of the Claim against us from Numoda Corporation.

Pursuant to the terms of the Order and the Stipulation, we issued and delivered to Socius an aggregate of 192,467 shares of our common stock for the entire Claim, which are subject to adjustment as described in the Stipulation. The Company recorded noncash income of approximately $618,000 related to the issuance of stock to Socius in settlement of the Claim.

As of October 31, 2012, the Company owed Numoda approximately $858,000, which is recorded in Accounts Payable at the balance sheet date.

Office & Laboratory Lease

In April 2011, the Company entered into a Sublease Agreement and relocated the current offices and laboratory to an approximately 10.000 square foot leased facility in Princeton, NJ. Costs approximate $21,000 per month plus utilities. Utility costs are estimated to be approximately $7,200 per month and are capped at approximately $10,700 per month. The Company made an initial payment of approximately $54,000 prior to entering the new facility. Approximately $38,000 of the initial $54,000 payment was for the security deposit and was recorded on the balance sheet as a long-term asset, The remaining $16,000 went towards our first month of rent. The agreement has a termination date of November 29, 2015. The Company expects its annual lease costs to approximate $337,000 per year (approximately $1.02 million in the aggregate) until the termination of this agreement in November 2015.

Other

Pursuant to a Clinical Research Service Agreement, executed in April 2005, the Company is obligated to pay Pharm — Olam International for service fees related to our Phase I clinical trial. As of October 31, 2012, the Company has an outstanding balance of $223,620 on this agreement.

Moore Employment Agreement and Option Agreements. We are party to an employment agreement with Mr. Moore, dated as of August 21, 2007 (memorializing an oral agreement dated December 15, 2006), that provides that he will serve as our Chairman of the Board and Chief Executive Officer for an initial term of two years. For so long as Mr. Moore is employed by us, Mr. Moore is also entitled to nominate one additional person to serve on our board of directors. Following the initial term of employment, the agreement was renewed for a one year term, and is automatically renewable for additional successive one year terms, subject to our right and Mr. Moore’s right not to renew the agreement upon at least 90 days’ written notice prior to the expiration of any one year term.

Under the terms of the agreement, Mr. Moore was entitled to receive a base salary (currently $350,000 per year). This amount is subject to annual review for increases by our board of directors in its sole discretion. The agreement also provides that Mr. Moore is entitled to receive family health insurance at no cost to him. Mr. Moore’s employment agreement does not provide for the payment of a bonus.

We have also agreed to grant Mr. Moore 12,000 shares of our common stock if the price of common stock (adjusted for any splits) is equal to or greater than $50.00 for 40 consecutive business days. Pursuant to the terms of his employment agreement, all options will be awarded and vested upon a merger of the company which is a change of control or a sale of the company while Mr. Moore is employed. In addition, if Mr. Moore’s employment is terminated by us, Mr. Moore is entitled to receive severance payments equal to one year’s salary at the then current compensation level.

Mr. Moore has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 12 months thereafter under certain circumstances. In addition, Mr. Moore is subject to a non-solicitation provision for 12 months after termination of his employment.

Rothman Employment Agreement and Option Agreements. We previously entered into an employment agreement with Dr. Rothman, Ph.D., dated as of March 7, 2005, that provided that he would serve as our Vice President of Clinical Development for an initial term of one year. While the employment agreement has expired and has not been formally renewed in accordance with the agreement, Dr. Rothman remains employed by us and is currently our Executive V.P. of Clinical and Scientific Operations. Dr. Rothman’s current salary is $305,000, consisting of $275,000 in cash and $30,000, payable in our common stock.

Dr. Rothman has agreed to refrain from engaging in certain activities that are competitive with us and our business during his employment and for a period of 18 months thereafter under certain circumstances. In addition, Dr. Rothman is subject to a non-solicitation provision for 18 months after termination of his employment.

INCOME TAXES:

12 Months Ended

Oct. 31, 2012

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

13. INCOME TAXES:

The income tax provision (benefit) consists of the following:

	October 31, 2012		October 31, 2011
Federal
Current	$	—	$	—
Deferred		(9,974,596)		(1,292,094)
State and Local
Current		(346,787)		(379,472)
Deferred		(1,826,038)		(81,597)
Change in valuation allowance		11,800,634		1,373,691
Income tax provision (benefit)	$	(346,787)	$	(379,472)

The Company has U.S. federal net operating loss carryovers (NOLs) of approximately $55,127,000 and $32,485,000 at October 31, 2012 and 2011, respectively, available to offset taxable income through 2032. If not used, these NOLs may be subject to limitation under Internal Revenue Code Section 382 should there be a greater than 50% ownership change as determined under the regulations. The Company also has New Jersey State Net Operating Loss carry overs of $26,880,000 and $12,593,000, as of October 31, 2012 and October 31, 2011, respectively, available to offset future taxable income through 2032.

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
	October 31, 2012		October 31, 2011
Deferred Tax Assets
Net operating loss carryovers	$	21,162,237	$	12,994,244
Stock-based compensation		1,907,607		1,474,016
Other deferred tax assets		957,982		48,470
Total deferred tax assets	$	24,027,826	$	14,516,730
Valuation allowance		(22,414,639)		(10,614,005)
Deferred tax asset, net of valuation allowance	$	1,613,187	$	3,902,725
Deferred Tax Liabilities
Valuation of warrants		—		(3,241,085)
Other deferred tax liabilities		(1,613,187)		(661,640)
Total deferred tax liabilities	$	(1,613,187)	$	(3,902,725)
Net deferred tax asset (liability)	$	—	$	—

The expected tax expense (benefit) based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Year ended October 31, 2012			Year ended October 31, 2011
US Federal statutory rate		(34.00)	%		(34.00)	%
State income tax, net of federal benefit		(5.9)
Fair value of common stock warrant liability		(15.0)
Deferred tax adjustment		(39.3)
Change in valuation allowance		97.8			16.9
Other permanent differences		(6.5)			12.6	%
Income tax provision (benefit)		(2.9)	%		(4.5)	%

Sale of Net Operating Losses (NOLs)

The Company may be eligible, from time to time, to receive cash from the sale of our Net Operating Losses under the State of New Jersey NOL Transfer Program. In February 2011, the Company received a net cash amount of $379,742 from the sale of our state net operating losses (“NOLs”) through the year ending October 31, 2009. In January 2012, the Company received a net cash amount of $346,787 from the sale of our state NOLs for the periods through October 31, 2010. In December 2012, the Company received notification that it will receive a net cash amount of approximately $725,000 from the sale of our state NOLs and R&D tax credits for the periods ended October 31, 2010 and 2011. These proceeds were received in January 2013.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on this assessment, management has established a full valuation allowance against all of the deferred tax assets for each period because it is more likely than not that all of the deferred tax assets will not be realized. The change in valuation allowance for the years ended October 31, 2012 and 2011 is $11,800,634 and $1,373,691, respectively.

SHAREHOLDERS' EQUITY

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

12. SHAREHOLDERS’ EQUITY

Equity Enhancement Program

On October 26, 2012, the Company entered into a Common Stock Purchase Agreement, which it refers to as the Hanover Purchase Agreement, with Hanover, which requires Hanover to purchase up to $10.0 million of shares of its common stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of common stock will be the higher of (i) the minimum price, which the Company refers to as the Floor Price, set forth in its notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the common stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period.

In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, the Company issued Hanover 28,000 Commitment Fee Shares in November 2012. The Company recognized non-cash expense of approximately $157,000 related to the issuance of the Commitment Fee Shares in the nine months ended July 31, 2013. The Company has also agreed to issue Hanover additional Maintenance Fee Shares of its common stock in the event that no shares of common stock have been purchased or sold pursuant to the Hanover Purchase Agreement during any calendar quarter during the 24 month term per the terms of the Hanover Purchase Agreement.

The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that the Company breaches any of its representations and warranties under the Hanover Purchase Agreement.

In connection with the Hanover Purchase Agreement, on October 26, 2012, the Company entered into a registration rights agreement, which it refers to as the Hanover Registration Rights Agreement, with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, the Company filed with the SEC a registration statement for the purpose of registering the resale of the common stock issued to Hanover.

During the three months ended July 31, 2013, the Company sold 3,200 shares of its common stock for proceeds totaling $23,940. During the nine months ended July 31, 2013, the Company sold 348,724 shares of its common stock for proceeds totaling $2,934,624.

Ironridge Settlement

On December 20, 2012, the Superior Court of the State of California for the County of Los Angeles Central District entered an Order for Approval of Stipulation for Settlement of Claims, which the Company refers to as the Order, in the matter titled Ironridge Global IV, Ltd. vs. Advaxis, Inc. The Order, together with the Stipulation for Settlement of Claims, which the Company refers to as the Stipulation, dated December 19, 2012, between the Company and Ironridge Global IV, Ltd., which it refers to as Ironridge, provides for full and final settlement of Ironridge’s $692,761 claim against the Company in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which the Company refers to as the Claim. Pursuant to the terms of the Order and the Stipulation, the Company was obligated to issue 267,117 shares of its common stock to settle the $692,761 owed. On December 21, 2012, the Company issued and delivered to Ironridge 360,000 shares of its common stock, par value $0.001 per share. Accordingly, Ironridge returned 92,883 shares of its common stock on January 30, 2013.

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances.

Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 324,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $31.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding. In addition, the Company redeemed two hundred twenty-six (226) shares of Series B Preferred Stock held by the Investor for an aggregate redemption price of $3,141,004 consisting of (i) cash in an amount of $76,622 and (ii) cancellation of certain promissory notes issued by an affiliate of the Investor to the Company in the aggregate amount of $3,051,000 and accrued interest of approximately $13,382. This resulted in a net promissory note receivable of $9,998,210 as of October 31, 2011. The Company also recorded $50,402, $149,562 and $485,812 in accrued interest on the promissory notes through the three and nine months ended July 31, 2013 and the twelve months ended October 31, 2012, respectively. The value of the Promissory Note and Interest Receivable was $10,633,584 and $10,484,022 as of July 31, 2013 and October 31, 2012, respectively. The promissory bears interest at 2% per annum which is credited directly to capital.

On April 4, 2011, the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment, Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

In order to satisfy certain conditions set forth in the Preferred Stock Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Preferred Stock Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “Additional Warrant”) to purchase up to an additional 204,480 shares of the Company’s common stock, at an initial exercise price of $18.75 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “Warrant Shares”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Preferred Stock Purchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “Promissory Note”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled.

As of July 31, 2013, the Series B preferred stock had a liquidation preference of $10,277,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,877,570. At October 31, 2012 the Series B preferred stock had a liquidation preference of $9,722,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,322,570. During the three and nine months ended July 31, 2013 and 2012 and the period from March 1, 2002 (date of inception) to July 31, 2013, the Company accrued dividends of $185,000, $555,000 and $2,877,570, respectively.

On April 4, 2011, the Company and the Holder also entered into an Amended and Restated Security Agreement to ensure that any Promissory Note issued upon exercise of the Additional Warrant will be entitled to the benefits of the security and collateral provisions of the Security Agreement dated as of July 19, 2010.

During the nine months ended July 31, 2013 and 2012, the Company did not sell any preferred shares to Optimus.

As of both July 31, 2013 and October 31, 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000.

14. SHAREHOLDERS’ EQUITY:

Equity Enhancement Program

On October 26, 2012, we entered into a Common Stock Purchase Agreement, with Hanover Holdings I, LLC, a New York limited liability company,, requires Hanover to purchase up to $10.0 million of shares of our common stock over the 24-month term following the effectiveness of the resale registration statement. The purchase price for such shares of common stock will be the higher of (i) the minimum price, (Floor Price), set forth in our notice electing to effect such issuance, and (ii) 90% of the arithmetic average of the five lowest closing sale prices of the common stock during the applicable ten trading day pricing period (or, if less, the arithmetic average of all trading days with closing sale prices in excess of the Floor Price), subject to adjustment.. Each trading day with a closing sale price less than the Floor Price is excluded from the calculation of the purchase price and automatically reduces the number of trading days in the applicable pricing period.

In consideration for Hanover’s execution and delivery of the Hanover Purchase Agreement, in connection with the execution and delivery of the Hanover Purchase Agreement, we have issued Hanover 28,000 Commitment Fee Shares. We have also agreed to issue Hanover additional Maintenance Fee Shares of our common stock in the event that no shares of common stock have been purchased or sold pursuant to the Agreement during any calendar quarter during the 24 month term. The number of Maintenance Fee Shares to be delivered to Hanover, from time to time, with respect to any calendar quarter, will be equal to approximately $15,000 worth of shares of common stock at a 10% discount to market.

The Hanover Purchase Agreement provides for indemnification of Hanover and its affiliates in the event that Hanover certain events related to a breach by us of any of our representations and warranties under the Hanover Purchase Agreement.

In connection with the Hanover Purchase Agreement, on October 26, 2012, we entered into a registration rights agreement with Hanover, and granted to Hanover certain registration rights related to the Commitment Fee Shares, the Maintenance Fee Shares, and the shares issuable under the Hanover Purchase Agreement. Under the Hanover Registration Rights Agreement, we agreed to prepare and file with the SEC one or more registration statements for the purpose of registering the resale of the common stock issued to Hanover. the Securities. We agreed to file the initial registration statement with the SEC within 12 calendar days of the Hanover Purchase Agreement and to use our commercially reasonable efforts to cause such registration statement to be declared effective within 90 calendar days of the Hanover Purchase Agreement (120 calendar days if the registration statement is reviewed by the SEC).

Series B Preferred Stock Financing

On July 19, 2010, the Company entered into a Series B Preferred Stock Purchase Agreement with Optimus (the “Series B Purchase Agreement”), pursuant to which Optimus agreed to purchase, upon the terms and subject to the conditions set forth therein and described below, up to $7.5 million of the Company’s newly authorized, non-convertible, redeemable Series B preferred stock (“Series B Preferred Stock”) at a price of $10,000 per share. Under the terms of the Series B Purchase Agreement, subject to the Company’s ability to maintain an effective registration statement for the Warrant Shares (as defined below), the Company may from time to time until July 19, 2013, present Optimus with a notice to purchase a specified amount of Series B Preferred Stock. Subject to satisfaction of certain closing conditions, Optimus is obligated to purchase such shares of Series B Preferred Stock on the 10^th trading day after the date of the notice. The Company will determine, in its sole discretion, the timing and amount of Series B Preferred Stock to be purchased by Optimus, and may sell such shares in multiple tranches. Optimus will not be obligated to purchase the Series B Preferred Stock upon the Company’s notice (i) in the event the average closing sale price of the Company’s common stock during the nine trading days following delivery of such notice falls below 75% of the closing sale price of the Company’s common stock on the trading day prior to the date such notice is delivered to Optimus, or (ii) to the extent such purchase would result in the Company and its affiliates beneficially owning more than 9.99% of the Company’s outstanding common stock. The Series B Preferred Stock is only redeemable at the option of the Company as set forth in the Company’s Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock and not otherwise subject to redemption or repurchase by the Company in any circumstances.

Pursuant to the Series B Purchase Agreement, on July 19, 2010, the Company issued to an affiliate of Optimus a three-year warrant to purchase up to 324,000 shares of the Company’s common stock (the “Warrant Shares”), at an initial exercise price of $31.25 per share, subject to adjustment as described below. The warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Series B Purchase Agreement. On each tranche notice date, that portion of the warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the warrant may be paid (at the option of the affiliate of Optimus) in cash or by its issuance of a four-year, full-recourse promissory note, bearing interest at 2% per annum, and secured by a specified portfolio of assets. However, such promissory note is not due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Series B Preferred Stock issued or outstanding. At various times through October 31, 2011, Optimus exercised 616,159 warrants, at prices ranging from $18.75 to $25.00, into shares of common stock and paid for such exercises with promissory notes totaling $13,049,210. In addition, the Company redeemed two hundred twenty-six (226) shares of Series B Preferred Stock held by the Investor for an aggregate redemption price of $3,141,004 consisting of (i) cash in an amount of $76,622 and (ii) cancellation of certain promissory notes issued by an affiliate of the Investor to the Company in the aggregate amount of $3,051,000 and accrued interest of approximately $13,382. This resulted in a net promissory note receivable of $9,998,210 as of October 31, 2011. The Company also recorded $485,812 and $285,300 in accrued interest on the promissory notes through October 31, 2012 and 2011, respectively. The value of the Promissory Note and Interest Receivable was $10,484,022 and $10,283,510 at October 31, 2012 and 2011, respectively. The promissory bears interest at 2 % per annum which is credited directly to capital.

On April 4, 2011, the Company and Optimus entered into an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010 between the Company and Optimus. Under the amendment Optimus remains obligated, from time to time until July 19, 2013, to purchase up to an additional 284 shares of non-convertible, redeemable Series B Preferred Stock, $0.001 par value per share (the “Series B Preferred Stock”) at a purchase price of $10,000 per share upon notice from the Company to the Investor, subject to the satisfaction of certain conditions set forth in the Purchase Agreement.

In order to satisfy certain conditions set forth in the Purchase Agreement that would allow the Company to require the Investor to purchase the remaining shares of Series B Preferred Stock under the Purchase Agreement, the Amendment provides that, among other things, the Company will issue to the Holder a three-year warrant (the “Additional Warrant”) to purchase up to an additional 204,480 shares of the Company’s common stock, at an initial exercise price of $18.75 per share, subject to adjustment as described below. The Additional Warrant will become exercisable on the earlier of (i) the date on which a registration statement registering for resale the shares of the Company’s common stock issuable upon exercise of the Additional Warrant (the “Warrant Shares”) becomes effective and (ii) the first date on which such Warrant Shares are eligible for resale without limitation under Rule 144 (assuming a cashless exercise of the Additional Warrant). The Additional Warrant consists of and is exercisable in tranches, with a separate tranche being created upon each delivery of a tranche notice under the Purchase Agreement. On each tranche notice date, that portion of the Additional Warrant equal to 135% of the tranche amount will vest and become exercisable, and such vested portion may be exercised at any time during the exercise period on or after such tranche notice date. On and after the first tranche notice date and each subsequent tranche notice date, the exercise price of the Additional Warrant will be adjusted to the closing sale price of a share of the Company’s common stock on the applicable tranche notice date. The exercise price of the Additional Warrant may be paid (at the option of the Investor) in cash or by the Investor’s issuance of a four-year, full-recourse promissory note (each, a “Promissory Note”), bearing interest at 2% per annum, and secured by specified portfolio of assets. However, no Promissory Note will be due or payable at any time that (a) the Company is in default of any preferred stock purchase agreement for Series B Preferred Stock or any warrant issued pursuant thereto, any loan agreement or other material agreement or (b) there are any shares of the Company’s Series B Preferred Stock issued or outstanding. The Additional Warrant also provides for cashless exercise in certain circumstances. If a “Funding Default” (as such term is defined in the Additional Warrant) occurs and the Additional Warrant has not previously been exercised in full, the Company has the right to demand surrender of the Additional Warrant (or any remaining portion thereof) without compensation, and the Additional Warrant will automatically be cancelled.

Holders of Series B preferred stock will be entitled to receive dividends, which will accrue in shares of Series B preferred stock on an annual basis at a rate equal to 10% per annum from the issuance date. Accrued dividends will be payable upon redemption of the Series B preferred stock or upon the liquidation, dissolution or winding up of our company. In the event the company redeems all or a portion of any shares of the Series B Preferred Stock then held by Optimus, Optimus shall apply, and the Company may offset, the proceeds of any such redemption to pay down the accrued interest and outstanding principal of the Promissory Note from Optimus. At October 31, 2012 the Series B preferred stock had a liquidation preference of $9,722,570 comprised of $10,000 per share plus the total of the cumulative accrued dividends in the amount of $2,322,570. During the years ended October 31, 2012 and 2011 and the period from March 1, 2002 (date of inception) to October 31, 2012, the Company accrued dividends of $740,000, $1,538,686 and $2,322,570 respectively.

During the year ended October 31, 2011 the Company issued and sold 177 shares of non-convertible, redeemable Series B Preferred Stock to Optimus pursuant to the terms of a Preferred Stock Purchase. Prior to closing on the Preferred Stock purchase, the Company received $300,000 from Optimus in exchange for promissory notes (subsequently repaid at closing). The Company received gross proceeds of $1.47 million (net proceeds of $1.34 million) from this transaction.

In connection with these transactions, Optimus exercised 126,023 warrants at exercise prices ranging from $18.75 to $19.375. In addition, on April 4, 2011, under an amendment to the Preferred Stock Purchase Agreement dated July 19, 2010, the Company issued Optimus a three-year warrant to purchase 204,480 shares of the Company’s common stock at an initial exercise price of $18.75. As of both October 31, 2011 and 2012 these 204,480 warrants remained outstanding. During December 2011, the Company unreserved for issuance shares related to the 204,480 preferred stock warrants.

As of both October 31, 2011 and 2012, the Company continued to have 284 shares of its Series B Preferred Stock available for sale to Optimus at a gross purchase price of $10,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

FAIR VALUE

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

13. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities

•

Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2013:


July 31, 2013	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $5.625 – $21.25 from May 2013 through August 2017	$	—	$	$	736,059	$	736,059


July 31, 2013
Short-term Convertible Notes Payable at fair value
May 2012 Notes	$	—	$	$	83,333	$	83,333
Asher Notes – May and July 2013					507,830		507,830
Redwood Management LLC					388,751		388,751
JMJ Financial					995,166		995,166
Short-term convertible Notes Payable at fair value				$	1,975,080	$	1,975,080


October 31, 2012	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $6.625 – $21.25 from October 2012 through August 2017	$	—	$	$	434,136	$	434,136


October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	—	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012					362,791		362,791
Magna Exchange Note					333,086		333,086
Asher Note					150,687		150,687
French, Patton & Paterson Notes					208,664		208,664
Short-term convertible Notes and fair value of Embedded Derivative				$	1,643,541	$	1,643,541

Common stock warrant liability:


	July 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		—
Exercise of warrants		(795,411	)
Issuance of additional warrants due to anti-dilution provisions		30,887
Change in fair value		(394,420	)
Balance at July 31, 2013	$	736,059

Convertible notes at fair value:


	July 31, 2013 (Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of notes		1,238,277
Transfer-out		(1,808,454	)
Change in Fair Value of notes		901,716
Ending balance – July 31, 2013	$	1,975,080

15. FAIR VALUE

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii)knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

•

Level 1 — Quoted prices in active markets for identical assets or liabilities

•

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities

The following table provides the liabilities carried at fair value measured on a recurring basis as of October 31, 2012:

October 31, 2012	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $0.053 – $0.17 from October 2012 through August 2017	$	—	$	$	434,136	$	434,136
Embedded Derivative Liability							—

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	—	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664
Other Short-term Notes Payable – not measured at fair value (net of debt discount of $4,541 related to unamortized OID)							371,968
Short-term convertible Notes and FV of Embedded Derivative						$	2,015,509

October 31, 2011	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $0.15 – $0.1952 from February 2011 through November 2015	$	—	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012				$	946,046	$	946,046

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the twelve months ended October 31, 2012 and October 31, 2011.

Common stock warrant liability:

	October 31, 2012		October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071	$	13,006,194
Issuance of common stock warrants		—		600,407
Exercises and Exchanges of warrants		59,572		(1,295,884)
Change in fair value		(923,052)		(3,789,889)
Balance at January 31, 2012 and 2011	$	5,527,591	$	8,520,828
Issuance of common stock warrants		—		3,111,758
Exercises of warrants		—		(639,960)
Exchanges of warrants		(134,796)		—
Change in fair value		(2,302,707)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088	$	15,908,302
Issuance of common stock warrants		291,400		41,344
Reclassification of liabilities to equity		—
Debt for Equity Exchange: Bridge Notes		(4,750)		—
July Warrant Exchanges		(407,501)		—
Exercises and/or Exchanges of warrants		—		(1,186,959)
Change in fair value		(1,703,252)		(6,826,019)
Balance at July 31, 2012 and 2011		1,265,985		7,936,668
Issuance of common stock warrants		36,134		—
Reclassification of warrant liability to equity		—		(186,908)
Exchange of warrants		—		816,259
Issuance of additional warrants due to anti-dilution provisions		150		—
Change in fair value		(868,133)		(2,174,948)
Balance at October 31, 2012 and 2011		434,136		6,391,071

Embedded Derivative Liability

	October 31, 2012		October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046	$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568		3,505,605
Note Conversions and Payoffs		(836,468)		(683,977)
Debt for Equity Exchange		(115,046)		(190,449)
Change in fair value		(301,100)		(1,766,161)
Ending balance	$	—	$	946,046

	October 31, 2012
May 2012 Notes
Issuance of notes		687,000
Issuance of C/S warrants		(291,400)
Changes in fair value		192,713
	$	588,313

	October 31, 2012
Hanover PIPE Notes
Issuance of notes		265,000
Changes in fair value		97,791
	$	362,791

	October 31, 2012
Magna Exchange Note
Issuance of notes		400,075
Conversions to common stock		(100,000)
Changes in fair value		33,011
	$	333,086
Asher Note
Issuance of notes		103,500
Changes in fair value		47,187
	$	150,687
French, Patton & Paterson Notes
Issuance of notes		175,000
Issuance of warrants		(36,134)
Changes in fair value		69,798
	$	208,664

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

SUBSEQUENT EVENTS

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

14. SUBSEQUENT EVENTS

Subsequent events have been evaluated through the date that the financial statements were issued. All appropriate subsequent event disclosures, if any, have been made in the notes to the financial statements.

On August 1, 2013, pursuant to a private placement agreement, the Company issued 4,000 shares of common stock to a consultant, upon the execution of this agreement.

On August 8, 2013, the remaining May 2012 note-holder converted its remaining $83,333 in principal into 26,371 shares of the Company’s common stock at a conversion rate of $3.16. The May 2012 Notes matured on May 18, 2013. There are no remaining May 2012 Notes outstanding.

On August 12, 2013, the Company issued 3,600 shares of common stock for consulting services valued at $15,000.

On August 12, 2013, the Company issued 2,330 shares of its common stock to employees under the Employee Stock Purchase Plan (ESPP) for an aggregate purchase price of $7,027.

On August 14, 2013, the Company issued 15,723 shares of common stock for consulting services valued at $50,000.

JMJ Financial

On August 14, 2013, the Company borrowed an additional $100,000 under the JMJ April 2013 convertible promissory note. At this date, the Company has borrowed $625,000 under the JMJ April 2013 Note. JMJ Financial has no obligation to lend the Company the remaining $95,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note and may not prepay any portion of the note without JMJ Financial’s consent. On August 9, 2013 and September 5, 2013, JMJ Financial converted $67,515 and $39,600 in principal and interest, respectively on its April 2013 Note into 51,000 shares of common stock at conversion rates ranging from $1.89 to $2.20. After these conversions, approximately $525,000 in principal remained outstanding under the JMJ April 2013 Note.

Tonaquint

On August 14, 2013, in lieu of a cash installment payment on the outstanding Tonaquint Note, the Company issued 33,309 shares of common stock. Of the 33,309 shares issued to Tonaquint, 21,843 were issued to satisfy the second installment payment consisting of principal in the amount of $49,444 and interest of $5,810 for a total conversion amount of $55,254. This amount was converted at a conversion price of approximately $2.53. The remaining 11,466 shares were issued related to the installment payment, made by the Company in shares, in July 2013 pursuant to a true-up provision in the convertible promissory note agreement that allows Tonaquint to receive additional shares if the conversion price, used at the time of the installment payment, decreases in a stated period of time following said payment.

On August 15, 2013, the Company issued 10,500 shares of its common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $2.81 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. The Company received total net proceeds of $29,516 in connection with this draw down.

On August 20, 2013, in a private placement pursuant to a note purchase agreement, the Company issued an accredited investor a secured convertible promissory note in the aggregate principal amount of $108,000, for a purchase price of $100,000. This note bears interest at a rate of 20% per annum and is convertible into shares of the Company’s common stock at a conversion price equal to the lower of $3.00 or 80% of the volume weighted average price for the five days preceding conversion, with a floor price of $2.50. To secure prompt payment under the note, the Company granted the holder a continuing security interest in all net proceeds it receives up to the aggregate amount of $108,000 plus accrued interest from the sale of its NOLs or research and development tax credits through the New Jersey Economic Development Program. This note matures on February 21, 2014, nine months after its issuance, and may not be converted prior to maturity although the Company may prepay this note at any time. In addition, the Company is required to repay this note within three business days of closing any financing greater than $2,000,000.

Resignation of Thomas A. Moore and Appointment of Dan O’Connor as Chief Executive Officer

At a meeting of the Company’s Board of Directors held on August 14, 2013, Thomas A. Moore indicated his intent to resign as Chairman of the Board of Directors and President and Chief Executive Officer (“CEO”) effective August 19, 2013 in line with the previously contemplated succession plan. Thomas A. Moore continues to serve on the Board of Directors and is acting as a consultant to the Company pursuant to the terms of a consulting agreement dated August 19, 2013, the terms of which are described below. In light of Mr. Moore’s notification to the Board of his intent to resign as President and CEO and the Board’s succession plan, the Board appointed Daniel J. O’Connor (formerly Executive Vice President), to the position of President and CEO, effective August 19, 2013. Mr. O’Connor’s appointment as President and CEO is the outcome of the succession planning initiatives over the past year by Mr. Moore and the Board of Directors. The Board of Directors also fixed the number of Board members at seven and appointed Mr. O’Connor as a Director to fill the newly created vacancy in accordance with the the Company’s Bylaws, all effective August 19, 2013. Mr. O’Connor will hold office as a Director until the next annual meeting of stockholders of the Company subject to his earlier resignation or removal. Mr. O’Connor has not currently been appointed to any standing committee of the Board of Directors.

Dr. James Patton, Chairman of the Audit Committee, was elected to serve as Non-executive Chairman of the Board effective August 19, 2013.

Thomas A. Moore Consulting and Severance Agreements

On August 19, 2013, the Company entered into a consulting agreement with Mr. Moore, which took effect as of such date. Under the consulting agreement, Mr. Moore will assist the development of the Company’s veterinary program and perform the duties assigned by the CEO, the Chairman of the Board and/or Board of Directors related to strategic planning and business development, or any other matter so delegated. Mr. Moore is required to be able to commit at least 20 hours per week to his consulting duties under the agreement. The consulting agreement provides for an initial term of one year, after which it terminates unless the Company notifies Mr. Moore of its intent to renew prior to the expiration of the initial term, following which it will be renewed upon such terms and conditions as they may mutually agree. If the Company elects to continue beyond the initial term, either Mr. Moore or the Company may terminate, at any time for any reason with or without cause upon 90 days written notice.

Pursuant to the terms of the consulting agreement, Mr. Moore is entitled to: (i) annualized compensation of $350,000 (payable monthly, with the first payment due September 20, 2013), with 12% per annum interest accruing on payments not made in accordance with the agreed terms, (ii) reimbursement for any COBRA costs, (iii) a one-time $100,000 payment if the Company closes a financing greater than $5,000,000 during the initial term of the agreement (which one-time payment may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000), which amounts are to be in repayment of loans extended by Mr. Moore to the Company, (iv) be treated as non-employee Director for purposes of attendance fees under the Company’s Director compensation program (but not for purposes of the annual retainer), (v) receive a one-time grant of 30,000 options under the Incentive Plan on or around November 1, 2013, and be considered in “Continuous Service” for purposes of his outstanding option awards under the Incentive Plan (as such term is defined in the Incentive Plan) and (v) reimbursement of reasonable documented travel expenses as contemplated by the consulting agreement.

Termination Agreement

On August 19, 2013, the Company entered into an agreement with a financial advisor to terminate a July 2012 engagement agreement between the parties, pursuant to which the advisor asserted claims for unpaid fees related to the introduction of investors to the Company and services provided. As consideration for terminating the agreement the Company agreed to pay the advisor approximately $589,000 in monthly installment payments in either cash or shares of the Company’s common stock, and a 3-year warrant to purchase 30,154 shares of the Company’s common stock at an exercise price of $4.90 per share. Additionally, the Company agreed to pay the advisor $150,000 upon the completion of a contemplated public offering of securities.

Yenson Co. Ltd.

On August 28, 2013, the Company entered into a Securities Purchase Agreement with Yenson Co. Ltd (“Investor”). Investor purchased $100,000 of the Company’s common stock at a purchase price of approximately $2.21 per share, resulting in 45,353 shares of its common stock being issued. In addition, the investor received 50% warrant coverage, resulting in the issuance of a warrant to purchase 22,161 shares of the Company’s common stock, at an exercise price of $2.76 per warrant. The warrant expires 3 years from the date of the agreement.

JMJ Financial

On September 4, 2013, the Company entered into a securities purchase agreement with JMJ Financial pursuant to which it issued JMJ Financial, in a private placement, an $800,000 convertible promissory note and 19,231 restricted shares of its common stock as a $50,000 origination fee for the note. The securities agreement provides that the Company will “true up” JMJ Financial by issuing additional shares of its common stock if JMJ Financial does not receive at least $50,000 of net proceeds from the sale of such shares of common stock when, and if, it disposes of such shares.

The face amount of the note reflects an aggregate principal amount of $800,000 for total consideration of $720,000 (or a 10% original issue discount). However, the Company has currently only borrowed $500,000 from JMJ Financial under this convertible promissory note, all of which JMJ Financial paid in cash. JMJ Financial has no obligation to lend the remaining $220,000 of available principal amount under the note and may never do so. The Company has no obligation to pay JMJ Financial any amounts on the unfunded portion of the note and may not prepay any portion of the note without JMJ Financial’s consent.

The convertible promissory note matures September 4, 2014 and, in addition to the 10% original issue discount, provides for payment of a one time interest charge of 5% on funded amounts. The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financial’s option into shares of the Company’s common stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion. However, at no time will JMJ Financial be entitled to convert any portion of the note to the extent that after such conversion, JMJ Financial (together with its affiliates) would beneficially own more than 4.99% of the Company’s outstanding shares common stock as of such date. The Company agreed to reserve at least 2,000,000 shares of its common stock for conversion of the note. The note also provides for penalties and rescission rights if the Company does not deliver shares of its common stock upon conversion with the require timeframes.

The convertible promissory note includes customary event of default provisions, and provides for a default rate of the lesser of 18% or the maximum permitted by law. Upon the occurrence of an event of default, the lender may require the Company to pay in cash the “Mandatory Default Amount,” which is defined in the note to mean the greater of (i) the outstanding principal amount of the note plus all interest, liquidated damages and other amounts owing under the note, divided by the conversion price on the date payment of such amount is demanded or paid in full, whichever is lower, multipled by the volume-weighted-average price, or VWAP, on the date payment of such amount is demanded or paid in full, whichever has a higher VWAP, or (ii) 150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.

If the Company completes a public offering of $5,000,000 or more, JMJ Financial has the right, at its election, to require it to repay the note, in whole or in part, in amount equal to 125% of the sum of the funded principal amount being repaid plus all accrued and unpaid interest liquidated damages, fees, and other amounts due on such principal amount.

On September 9, 2013, the Company issued 21,000 shares of its common stock to JMJ Financial upon conversion of $39,690 of principal and interest of a convertible promissory note issued to JMJ Financial in April 2013.

On September 11, September 12 and September 25, 2013, the Company issued Tonaquint an aggregate 55,387, 46,816 and 49,157 shares of its common stock upon conversion of an aggregate $334,736 of notes issued to Tonaquint in December 2012.

On September 17, 2013, the Company issued 25,582 shares of its common stock to an accredited investor as an installment payment under an engagement letter termination agreement and also issued the accredited investor a 2-year warrant to acquire 30,154 shares of its common stock at $4.90 per share pursuant to such agreement, and on September 27, 2013, the Company issued 158,385 shares of its common stock as payment in full of its remaining obligation under the settlement agreement.

On September 18, 2013, the Company issued 20,438 shares of its common stock to JMJ Financial upon conversion of $38,628 of principal and interest a convertible promissory note issued to JMJ Financial in April 2013.

On September 26, 2013, the Company agreed to issue 33,750 shares of its common stock to an accredited investor in connection with the settlement of a dispute under a prior agreement.

On September 27, 2013, the Company agreed to issue 125,000 shares of its common stock to Redwood Management, LLC, upon conversion of $277,778 of a convertible promissory note issued in a June 2013 in a bridge financing.

16. SUBSEQUENT EVENTS

Asher Note

On November 12, 2012, in a private placement pursuant to a note purchase agreement, we issued Asher Enterprises, Inc, which we refer to as Asher, a convertible promissory note in the aggregate principal amount of $153,500 for a purchase price of $150,000, which we refer to as the November Asher Note. The November Asher Note bears interest at a rate of 8% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of the November Asher Note. The November Asher Note is convertible into shares of our common stock at a conversion price equal to 65% of the arithmetic average of the four lowest closing trading prices for the common stock during the 20 trading day period ending on the latest complete trading day prior to the applicable conversion date. The November Asher Note matures on August 14, 2013, nine months from its issuance date. The November Asher Note may be converted by Asher, at its option, in whole or in part. The September Asher Note includes a limitation on conversion, which provides that at no time will Asher be entitled to convert any portion of the September Asher Note to the extent that after such conversion Asher (together with its affiliates) would beneficially own more than 4.99% of the outstanding shares of the common stock as of such date.

Private Placements of Convertible Notes to Hanover

On December 6, 2012, in a private placement pursuant to a note purchase agreement, we issued Hanover a convertible promissory note in the aggregate principal amount of $100,000 for a purchase price of $100,000, which we refer to as the Hanover December 2012 Note. The Hanover December 2012 Note bears interest at a rate of 12% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of such Hanover December 2012 Note. The Hanover December 2012 Note is convertible into shares of our common stock at a conversion price of $3.75 per share. On December 5, Hanover exchanged the Initial Hanover PIPE Notes for convertible notes in the form of the Hanover December 2012 Note in all material respects (other than date of issuance, exchange date, the maturity date of May 19, 2012 solely with respect to the Exchanged Hanover PIPE Note issued in exchange for the Hanover September 2012 PIPE Note and the maturity date of June 19, 2013 solely with respect to the Exchanged Hanover PIPE Note issued in exchange for the Hanover October 2012 PIPE Note) that also are convertible into shares of our common stock at a conversion price of $3.75 per share, which we refer to as the Exchanged Hanover PIPE Notes. Each of the Hanover December 2012 Note and the Exchanged Hanover PIPE Notes are subject to limitations on conversion if after giving effect to such conversion Hanover would beneficially own more than 4.99% of our common stock.

Other Hanover Related Transactions

During November and December, 2012, pursuant to the terms of various Assignment Agreements, we delivered convertible notes to Magna in an aggregate principal amount of $340,522, convertible into shares of common stock, which we refer to as the Magna Exchange Notes. The Magna Exchange Notes bear interest at a rate of 6% per annum, which interest accrues, but does not become payable until maturity or acceleration of the principal of the Second Magna Exchange Note. Prior to the date of this filing, all Magna Exchange Notes (including the $400K Magna note in Footnote 6) have been converted in full into 202,521 shares of our common stock in accordance with its terms and no longer remains outstanding.

Ironridge Settlement

On December 20, 2012, the Superior Court of the State of California for the County of Los Angeles — Central District entered an Order for Approval of Stipulation for Settlement of Claims, which we refer to as the Order, in the matter titled Ironridge Global IV, Ltd. v. Advaxis, Inc. The Order, together with the Stipulation for Settlement of Claims, which we refer to as the Stipulation, dated December 19, 2012, between us and Ironridge Global IV, Ltd., which we refer to as Ironridge, provides for the full and final settlement of Ironridge’s $692,761 claim against us in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which we refer to as the Claim. Pursuant to the terms of the Order and the Stipulation, we are obligated to issue 267,117 shares of our common stock to settle the $692,761 owed. On December 21, 2012, we issued and delivered to Ironridge 360,000 shares of our common stock, par value $0.001 per share. Accordingly, Ironridge will return 92,882 shares of our common stock.

JMJ Note

On December 26, 2012, in a private placement pursuant to a note purchase agreement, we issued JMJ Financial a convertible promissory note for a purchase price of $100,000, which we refer to as the December 2012 Note. If the December 2012 Note is repaid on or before January 31, 2013, we will pay JMJ Financial a principal amount of $125,000. If the December 2012 Note is rolled into a future financing, we will have to pay JMJ Financial a principal amount of $115,000. At the holder’s election, principal and interest can be converted at a conversion price equal to 70% of the lowest closing trading price for our common stock during the 25 trading day period ending on the latest complete trading day prior to the applicable conversion date.

Sale of stock under the Equity Enhancement Program

Under the Hanover Purchase Agreement, the Company may require Hanover Holdings to purchase up to $10.0 million of our common stock over a 24 month period (See Footnote 13 — Shareholders’ Equity).

On December 31, 2012, we issued 55,924 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $3.325 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We received total net proceeds of $185,975 in connection with this draw down.

On January 17, 2013, we issued 35,200 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $4.675 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We received total net proceeds of $164,656.80 in connection with this draw down.

On February 12, 2013, we issued 64,000 shares of our common stock to Hanover Holdings in connection with the settlement of a draw down pursuant to the Hanover Purchase Agreement, at a price of approximately $8.04 per share. The per share price for such shares was established under the terms of the Hanover Purchase Agreement. We receive total net proceeds of $515,520 in connection with this draw down.

Tonaquint Note

On December 13, 2012, we entered into an agreement, which we refer to as the Tonaquint Purchase Agreement, with Tonaquint, Inc., which we refer to as Tonaquint, whereby we issued Tonaquint a secured convertible promissory note for the initial principal sum of $890,000, which we refer to as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can be converted at a fixed price of $20.00 per share but is subject to reduction in the event that we issue shares below the conversion price of $20.00.

On the closing date, Tonaquint (i) funded us with $490,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 2. Mortgage Note 1 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 8 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.

We have agreed to make installment payments on the Tonaquint Note beginning 6 months after closing in cash or in stock. If we choose to make installment payments in stock, then such stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date. Tonaquint has the right to receive additional shares if the market price of our common stock is lower than the price per share of our common stock on the installment date.

REVERSE STOCK SPLIT

12 Months Ended

Oct. 31, 2012

Equity [Abstract]

Reverse Stock Split [Text Block]

17. REVERSE STOCK SPLIT

At the Annual Meeting of Stockholders held on June 14, 2013, the Company’s stockholders approved the filing of a Certificate of Amendment to effect a reverse stock split of its issued and outstanding common stock, and the filing of a Certificate of Amendment to decrease the total number of its authorized shares of common stock. On July 11, 2013, the Company’s Board of Directors authorized a reverse stock split at a ratio of 1-for-125 and approved the implementation of the authorized share capital decrease after the effectiveness of the reverse stock split. Accordingly, the Company amended its Amended and Restated Certificate of Incorporation by the filing of two Certificates of Amendment with the Delaware Secretary of State as follows: (a) on July 11, 2013, to effect a 1-for-125 reverse stock split of our common stock, par value $0.001 per share, to take effect on July 12, 2013 at 4:30 p.m. EDT, and (b) on July 12, 2013, to decrease the total number of authorized shares of common stock on a post-reverse stock split basis, so that the total number of shares that the Company has the authority to issue is 30,000,000 shares, of which 25,000,000 shares are common stock and 5,000,000 shares are “blank check” preferred stock. The reverse stock split was effective at approximately 4:30 p.m. EDT on July 12, 2013, and the share capital decrease took effect thereafter upon filing with the Delaware Secretary of State. All references in this Report to number of shares, price per share and weighted average number of shares outstanding of Common Stock prior to this reverse stock split and share capital decrease have been adjusted to reflect the reverse stock split and share capital decrease on a retroactive basis, unless otherwise noted.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Accounting Policies [Abstract]

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash

Concentration Risk, Credit Risk, Policy [Policy Text Block]

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits.

Property, Plant and Equipment, Policy [Policy Text Block]

Net Loss per Share


	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

Net Loss Per Share

	As of October 31,
	2012		2011
Warrants		802,580		1,102,734
Stock Options		358,459		218,539
Convertible Debt (using the if-converted method)		271,354		493,283
Total		1,432,393		1,814,556

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock Based Compensation

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of financial instruments

Derivatives, Embedded Derivatives [Policy Text Block]

Derivative Financial instruments

Debt Discount and Amortization Of Debt Discount [Policy Text Block]

Debt discount and amortization of debt discount

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment.” This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s financial position and results of operations.

Income Tax, Policy [Policy Text Block]

Income Taxes

ASC Topic 740-10-30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740-10-40 provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented. The Company files tax returns in U.S. federal and state jurisdictions, including New Jersey, and are subject to audit by tax authorities beginning with the year ended October 31, 2009.

Reclassification, Policy [Policy Text Block]

Reclassification

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share.

	As of July 31,
	2013		2012
Warrants		899,494		917,910
Stock Options		467,923		358,459
Convertible Debt (using the if-converted method)		478,695		92,759
Total		1,846,112		1,369,128

The table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share. For 2012 and 2011, approximately 440,000 warrants and 345,200 warrants, respectively (excluding approximately 205,000 warrants, held by an affiliate of Optimus) include anti-dilutive provisions to adjust the number and price of the warrants based on certain types of equity transactions.

	As of October 31,
	2012		2011
Warrants		802,580		1,102,734
Stock Options		358,459		218,539
Convertible Debt (using the if-converted method)		271,354		493,283
Total		1,432,393		1,814,556

SHARE-BASED COMPENSATION EXPENSE (Tables)

12 Months Ended

Oct. 31, 2012

Share Based Compensation Disclosure [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

the effect on the Company’s net loss would have been as follows for the period March 1, 2002 (date of inception) to October 31, 2012:

	March 1, 2002 (date of inception) to October 31, 2012
Net Loss as reported	$	(47,557,543)
Add: Stock based option expense included in recorded net loss		89,217
Deduct stock option compensation expense determined under fair value based method		(328,176)
Adjusted Net Loss	$	(47,796,502)

PROPERTY AND EQUIPMENT (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consists of the following:


	July 31, 2013 (Unaudited)			October 31, 2012
Laboratory equipment	$	284,516		$	287,516
Accumulated depreciation		(223,074	)		(209,448	)
Net Property and Equipment	$	61,442		$	78,068

Property and equipment consists of the following:

	October 31, 2012		October 31, 2011
Laboratory Equipment	$	287,518	$	195,672
Accumulated Depreciation		(209,450)		(195,672)
Net Property and Equipment	$	78,068	$	—

INTANGIBLE ASSETS (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]


	July 31, 2013 (Unaudited)			October 31, 2012
License	$	651,992		$	651,992
Patents		2,626,365			2,422,409
Total intangibles		3,278,357			3,074,401
Accumulated amortization		(778,566	)		(660,646	)
Intangible Assets	$	2,499,791		$	2,413,755

	October 31, 2012		October 31, 2011
License	$	651,992	$	651,992
Patents		2,422,409		2,117,505
Total intangibles		3,074,401		2,769,497
Accumulated Amortization		(660,646)		(512,645)
Intangible Assets	$	2,413,755	$	2,256,852

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for the next five years is as follows:


Year ended October 31,
2013, remainder	$	35,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

Estimated amortization expense for the next five years is as follows:

Year ended October 31,
2013		140,000
2014		140,000
2015		140,000
2016		140,000
2017		140,000

ACCRUED EXPENSES: (Tables)

12 Months Ended

Oct. 31, 2012

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]

The following table represents the major components of accrued expenses:

	October 31, 2012		October 31, 2011
Salaries and other compensation	$	774,001	$	531,040
Clinical Trial		56,468		2,358,248
Vendors		77,512		—
Consultants		32,200		32,200
Financing costs		174,970		—
Legal		214,902		46,346
Interest Payable		28,859		—
Other		8,500		8,500
	$	1,367,412	$	2,976,334

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Convertible Notes Payable [Abstract]

Schedule of Debt [Table Text Block]


	July 31, 2013 (Unaudited)		October 31, 2012
October 2011 Note Financing	$	—	$	58,824
December 2011 Note Financing		—		131,928
May 2012 Note Financing		83,333		588,313
Bridge Notes		62,882		185,758
JMJ Financial		995,166		73,590
Hanover Holdings Note		—		362,791
Magna		—		333,086
Chris French		—		25,950
Asher		507,830		150,687
Yvonne Paterson		—		103,804
James Patton		—		78,909
Redwood Management LLC		388,751		—
Total Convertible Notes		2,037,962		2,093,640
Unamortized discount – Original Issue Discount (OID)		—		(4,541	)
Current Portion of Convertible Notes	$	2,037,962	$	2,089,099

Convertible Notes payable consist of the following:

	October 31, 2012		October 31, 2011
May 2011 Note Financing	$	—	$	3,392,158
October 2011 Note Financing		58,824		1,341,738
December 2011 Note Financing		131,928		—
May 2012 Note Financing		588,313		—
Bridge Notes		185,758		711,701
JMJ Financial		73,590		570,802
Hanover Holdings Note		362,791		—
Magna		333,086		—
Chris French		25,950		—
Asher		150,687		—
Yvonne Paterson		103,804		—
James Patton		78,909		—
Total Convertible Notes		2,093,640		6,016,399
Unamortized discount		(4,541)		(1,300,345)
Derivative Liability		—		946,046
		2,089,099		5,662,100
Current Portion of Convertible Notes		2,089,099		5,091,298
Long-term Convertible Notes less current portion	$	—	$	570,802

COMMON STOCK WARRANT LIABILITY (Tables)

9 Months Ended

Jul. 31, 2013

Warrant Liability [Abstract]

Schedule Of Warrant Liability Disclosure [Table Text Block]


Type	Exercise Price			Amount		Expiration Date		Type of Financing
Exchange Warrants – Nonexercisable	$	18.75			278,329		October 2014		July 2012 Exchanges
Common Stock Purchase Warrant	$	18.75			28,632		May 2015		May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			11,628		October 2014 - October 2015		Oct 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			17,706		May 2015 - January 2016		December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			13,333		May 2017		May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	15.11 - 21.25			214,416		December 2013 - April 2015		Bridge Notes
Common Stock Purchase Warrant	$	4.375			1,333		December 2015		Stock Purchase Agreement
Common Stock Purchase Warrant	$	18.75			376		N/A		Vendor & Other
Common Stock Purchase Warrant	$	10.625 - 18.75			29,883		May 2014 - May 2017		Placement Agent - Convertible Debt Financing
Common Stock Purchase Warrant		5.625 - 10.625			13,095		October 2015 - August 2017		August - September 2012 Convertible Promissory Notes
Common Stock Purchase Warrant		357			86,283		December 2014		Tonaquint Promissory Note
		Subtotal:			695,014
Common Stock Purchase Warrant		TBD	⁽¹⁾		204,480		April 2014		Preferred Stock Agreement (4/04/2011)
		Grand Total			899,494

(1)


Type	Exercise Price			Amount		Expiration Date		Type of Financing
Exchange Warrants – Nonexercisable	$	18.75			278,329		October 2014		July 2012 Warrant Exchanges
Common Stock Purchase Warrant	$	18.75			28,632		May 2015		May 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			11,628		October 2014 - October 2015		October 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			17,706		January 2015 - January 2016		December 2011 Convertible Debt Financing
Common Stock Purchase Warrant	$	18.75			22,222		May 2017		May 2012 Convertible Debt Financing
Common Stock Purchase Warrant	$	14.95 - 21.25			198,036		January 2013 - April 2015		Bridge Notes
Common Stock Purchase Warrant	$	18.75			376		N/A		Vendor & Other
Common Stock Purchase Warrant	$	18.75			29,883		May 2014 - May 2017		Placement Agent - Convertible Debt Financing
Common Stock Purchase Warrant		6.625 - 18.75			11,288		October 2015 - August 2017		August - September 2012 Convertible Promissory Notes
		Subtotal:			598,100
Common Stock Purchase Warrant		TBD	⁽¹⁾		204,480		April 2014		Preferred Stock Agreement (4/04/2011)
		Grand Total			802,580

Schedule Of Fair Value Warrant Liability [Table Text Block]

In fair valuing the warrant liability, at July 31, 2013 and October 31, 2012, the Company used the following inputs in its Black-Scholes Model (BSM Model):


	(Unaudited) July 31, 2013			October 31, 2012
Exercise Price:	$	4.375 – 21.25		$	6.625 – 21.25
Stock Price		3.50			5.625
Expected Term:		153 – 1588 days			81 – 1736 days
Expected Volatility		93.73% – 153.00	%		66.51% – 146.78	%
Risk Free Rate:		.08% – .0995	%		0.09 – .056	%

DERIVATIVES (Tables)

12 Months Ended

Oct. 31, 2012

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments [Table Text Block]

The table below lists the Company’s derivative instruments as of October 31, 2012 and 2011:

Description	Principal		Original Issue Discount		Warrant Liability		Embedded Derivative Liability
Total Valuation at October 31, 2010	$	777,154	$	21,937	$	13,006,194	$	81,028
Issuance of November 2010 Bridge Notes		931,579		96,579		391,076		150,156
Exchange of November 2010 Bridge Notes		17,175		17,175		86,963		9,389
Issuance of January 2011 Bridge Notes		452,941		57,941		173,808		41,024
Note Payoffs		(187,582)
Issuance of Warrants						35,523
Accreted Interest				(73,363)
Exercise of Warrants						(1,382,847)
Change in FV						(3,789,889)		(51,972)
Total Valuation at January 31, 2011		1,991,267		120,269		8,520,828		229,625
Issuance of Q2 2011 Bridge Notes		473,392		43,392		121,238		71,336
Issuance of Long-term Convertible Promissory Notes		626,400						—
Note Payoffs		(159,675)						(5,904)
Issuance of Warrants						2,990,520
Accreted Interest				(74,422)
Exercise of Warrants						(639,960)
Change in FV						4,915,676		763,523
Total Valuation at April 30, 2011	$	2,931,384	$	89,239	$	15,908,302	$	1,058,580
Issuance of Q3 2011 Bridge Notes		11,765		1,765		4,968		5,051
Issuance of May 2011 Notes		7,077,936		1,553,254		—		2,719,345
Note Payoffs		(26,316)						(8,860)
Additional warrants issued to Bridge Note holder						36,376
Exchange of Bridge Notes		8,033		8,033				2,656
Conversion of Bridge Notes		(1,164,947)						(381,209)
Conversion of May 2011 Notes		(671,500)						(166,980)
Exchanges/Exercises of October 2007 Warrants						(1,186,959)
Accreted Interest				(340,050)
Change in FV						(6,826,019)		(2,141,984)
Total Valuation at July 31, 2011	$	8,166,355		1,312,241		7,936,668		1,086,599
Issuance of October 2011 Notes		2,326,471		459,396		—		396,818
Note Payoffs		(155,806)
Issuance of Long-term Convertible Promissory Notes		86,400
Conversion of Bridge Notes		(221,788)						(10,530)
Conversion of May 2011 Notes		(1,225,561)						(110,494)
Reclassification of Warrant liability to Equity						(186,908)
Exchange of Warrants						816,259
Accreted Interest				(471,290)
Change in FV						(2,174,948)		(416,347)
Total Valuation at October 31, 2011	$	8,976,071		1,300,347		6,391,071		946,046
Issuance of December 2011 Notes		1,232,353		258,178		—		306,568
Conversion of Bridge Notes		(169,000)						—
Conversion of May 2011 Notes		(1,924,060)						(341,342)
Conversion of October 2011 Notes		(1,227,500)						(329,433)
Partial Note Repayments		(52,941)
Conversion of Long-term Convertible Promissory Notes		(540,000)
Exchange of Warrants						59,572
Accreted Interest				(532,559)
Change in FV						(923,052)		159,657
Total Valuation at January 31, 2012	$	6,294,923	$	1,025,966	$	5,527,591	$	741,496
Exchange of Bridge Notes		52,941				—
Conversion of May 2011 Notes		(38,000)						(5,016)
Conversion of December 2011 Notes		(827,500)						(160,677)
Exchange of Warrants						(134,796)
Accreted Interest				(569,419)
Change in FV						(2,302,707)		(438,054)
Total Valuation at April 30, 2012	$	5,482,364	$	456,547	$	3,090,088	$	137,749
Issuance of May 2012 Notes		953,333				291,400
Debt for Equity Exchange: May and October 2011, December 2011 Notes		(4,473,673)		(200,632)				(115,046)
Debt for Equity Exchange: Bridge Notes		(50,000)				(4,750)
July 2012 Exchange of Warrants						(407,501)
JMJ Settlement Agreement		540,000
JMJ Note Conversions		(712,800)
Accreted Interest				(229,392)
Change in FV						(1,703,252)		(20,567)
Total Valuation at July 31, 2012	$	1,739,224		26,523		1,265,985		2,136
Issuance of Patton Note		66,667				13,311
Issuance of French Note		25,000				4,565
Issuance of Paterson Note		100,000				18,258
Issuance of Hanover September Note		132,500
Issuance of Asher Note		103,500
Issuance of Hanover October Note		132,500
Issuance of JMJ Note		100,000
Assignment of Notes to Magna		(384,264)
New Magna Note (result of above assignment)		400,075
Magna Conversions		(100,000)
Accreted Interest				(21,984)
Additional warrants issued due to investors due to anti-dilution provision						150
Change in FV						(868,133)		(2,136)
Total Valuation at October 31, 2012	$	2,315,202		4,541		434,136		—

Schedule Of Derivative Instruments Warrants [Table Text Block]

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Exchange warrants-nonexercisable		18.7		278,329	October 2014	July 2012 Warrant Exchanges
Common Stock Purchase Warrant		18.7		28,632	May 2015	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.7		11,628	October 2014 - October 2015	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.7		17,706	January 2015 - January 2016	December 2011 Convertible DebtFinancing
Common Stock Purchase Warrant		18.7		22,222	May 2017	May 2012 Convertible Debt Financing
Common Stock Purchase Warrant		18.69 - 21.25		198,037	January 2013 - April 2015	Bridge Notes
Common Stock Purchase Warrant		18.7		376	N/A	Vendor & Other
Common Stock Purchase Warrant		18.7		29,883	May 2014 - May 2017	Placement Agent – Convertible DebtFinancing
Common Stock Purchase Warrant		6.625 -18.7		11,288	October 2015 - August 2017	August – September 2012 ConvertiblePromissory Notes
		Subtotal:		598,101
Common Stock Purchase Warrant		TBD⁽¹⁾		204,479	April 2014	Preferred Stock Agreement (4/04/2011)
		Grand Total		802,580

(1)

Type	Exercise Price		Amount		Expiration Date	Type of Financing
Common Stock Purchase Warrant		18.75		376,723	August – October 2012	2007 Securities Purchase Agreement
Common Stock Purchase Warrant		18.75		2,296	August 2012	August 2007 Notes
Common Stock Purchase Warrant		18.75		188,745	May 2014	May 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.75		62,039	October 2014	October 2011 Convertible Debt Financing
Common Stock Purchase Warrant		18.75 - 21.25		181,040	January 2013 – April 2015	Bridge Notes
Common Stock Purchase Warrant		18.75		61,396	August 2014	Executive Officer
Common Stock Purchase Warrant		18.75 - 24.40		3,576	February 2012	Vendor & Other
Common Stock Purchase Warrant		18.75		22,438	May 2014 - November 2015	Placement Agent - Convertible DebtFinancing
		Subtotal		898,253
Common Stock Purchase Warrant		TBD⁽¹⁾		204,479	April 2014	Optimus Preferred Stock Agreement(4/04/2011)
		Grand Total		1,102,732

(1)

Schedule Of Share Based Compensation Of Fair Value Of Options Using Black Scholes Option Pricing Model [Table Text Block]

The fair value of the warrant liability, as of October 31, 2012 was approximately $.4 million At October 31, 2011 the Company had approximately 808,333 of its total 1,102,733 outstanding warrants classified as liability warrants (common stock warrant liability). The fair value of the warrant liability, as of October 31, 2011, was approximately $6.39 million. In fair valuing the warrant liability, at October 31, 2012 and October 31, 2011, the Company used the following inputs in its BSM Model:

	10/31/2012		10/31/2011
Exercise Price:		6.625 - 21.257		18.75 - 21.25
Stock Price		5.625		17.625
Expected term:		81 - 1736 days		289 - 1219 days
Volatility %		66.51% - 146.78%		60.23% - 163.40%
Risk Free Rate:		.09% - .72%		.09 - .56%

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7476318&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

STOCK OPTIONS: (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of changes in the stock option plan for nine months ended July 31, 2013 is as follows:


	Number of Options			Weighted-Average Exercise Price
Outstanding at October 31, 2012:		358,459		$	20.00
Granted		134,600		$	9.375
Exercised		—			—
Expired		(25,136	)		18.75
Outstanding at July 31, 2013		467,923		$	17.50
Vested and Exercisable at July 31, 2013		290,300		$	17.50

	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life In Years		Aggregate Intrinsic Value
Outstanding as of October 31, 2010		211,739		20.00		7.4		415,967
Granted		6,800		15.00		9.2		15,200
Cancelled or Expired		—		—		—		—
Outstanding as of October 31, 2011		218,539		20.00		8.1		367,417
Granted		140,320		18.75		9.0		—
Cancelled or Expired		(400)		12.50		6.75		—
Outstanding as of October 31, 2012		358,459		20.00				—
Vested & Exercisable at October 31, 2012		234,225	$	20.00		5.75	$	—

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The expected dividend yield is zero as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

	Year Ended October 31, 2012		Year Ended October 31, 2011
Expected volatility	143.00	%		150.44	%
Expected Life	10.0 years			10.0 years
Dividend yield	0			0
Risk-free interest rate	2.10	%		3.50	%
Forfeiture Rate	4.4	%		4.4	%

INCOME TAXES : (Tables)

12 Months Ended

Oct. 31, 2012

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The income tax provision (benefit) consists of the following:

	October 31, 2012		October 31, 2011
Federal
Current	$	—	$	—
Deferred		(9,974,596)		(1,292,094)
State and Local
Current		(346,787)		(379,472)
Deferred		(1,826,038)		(81,597)
Change in valuation allowance		11,800,634		1,373,691
Income tax provision (benefit)	$	(346,787)	$	(379,472)

Summary of Operating Loss Carryforwards [Table Text Block]

The Company’s deferred tax assets (liabilities) consisted of the effects of temporary differences attributable to the following:

	Years Ended
	October 31, 2012		October 31, 2011
Deferred Tax Assets
Net operating loss carryovers	$	21,162,237	$	12,994,244
Stock-based compensation		1,907,607		1,474,016
Other deferred tax assets		957,982		48,470
Total deferred tax assets	$	24,027,826	$	14,516,730
Valuation allowance		(22,414,639)		(10,614,005)
Deferred tax asset, net of valuation allowance	$	1,613,187	$	3,902,725
Deferred Tax Liabilities
Valuation of warrants		—		(3,241,085)
Other deferred tax liabilities		(1,613,187)		(661,640)
Total deferred tax liabilities	$	(1,613,187)	$	(3,902,725)
Net deferred tax asset (liability)	$	—	$	—

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

The expected tax expense (benefit) based on the statutory rate is reconciled with actual tax expense benefit as follows:

	Year ended October 31, 2012			Year ended October 31, 2011
US Federal statutory rate		(34.00)	%		(34.00)	%
State income tax, net of federal benefit		(5.9)
Fair value of common stock warrant liability		(15.0)
Deferred tax adjustment		(39.3)
Change in valuation allowance		97.8			16.9
Other permanent differences		(6.5)			12.6	%
Income tax provision (benefit)		(2.9)	%		(4.5)	%

FAIR VALUE (Tables)

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Fair Value [Line Items]

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	October 31, 2012
May 2012 Notes
Issuance of notes		687,000
Issuance of C/S warrants		(291,400)
Changes in fair value		192,713
	$	588,313

	October 31, 2012
Hanover PIPE Notes
Issuance of notes		265,000
Changes in fair value		97,791
	$	362,791

	October 31, 2012
Magna Exchange Note
Issuance of notes		400,075
Conversions to common stock		(100,000)
Changes in fair value		33,011
	$	333,086
Asher Note
Issuance of notes		103,500
Changes in fair value		47,187
	$	150,687
French, Patton & Paterson Notes
Issuance of notes		175,000
Issuance of warrants		(36,134)
Changes in fair value		69,798
	$	208,664

Embedded Derivative Liability [Member]

Fair Value [Line Items]

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Embedded Derivative Liability

	October 31, 2012		October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	946,046	$	81,028
Issuance of embedded derivatives associated with convertible notes		306,568		3,505,605
Note Conversions and Payoffs		(836,468)		(683,977)
Debt for Equity Exchange		(115,046)		(190,449)
Change in fair value		(301,100)		(1,766,161)
Ending balance	$	—	$	946,046

Common Stock Warrant Liability [Member]

Fair Value [Line Items]

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

The following table provides the liabilities carried at fair value measured on a recurring basis as of July 31, 2013:


July 31, 2013	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $5.625 – $21.25 from May 2013 through August 2017	$	—	$	$	736,059	$	736,059


July 31, 2013
Short-term Convertible Notes Payable at fair value
May 2012 Notes	$	—	$	$	83,333	$	83,333
Asher Notes – May and July 2013					507,830		507,830
Redwood Management LLC					388,751		388,751
JMJ Financial					995,166		995,166
Short-term convertible Notes Payable at fair value				$	1,975,080	$	1,975,080


October 31, 2012	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $6.625 – $21.25 from October 2012 through August 2017	$	—	$	$	434,136	$	434,136


October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	—	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012					362,791		362,791
Magna Exchange Note					333,086		333,086
Asher Note					150,687		150,687
French, Patton & Paterson Notes					208,664		208,664
Short-term convertible Notes and fair value of Embedded Derivative				$	1,643,541	$	1,643,541

The following table provides the liabilities carried at fair value measured on a recurring basis as of October 31, 2012:

October 31, 2012	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $0.053 – $0.17 from October 2012 through August 2017	$	—	$	$	434,136	$	434,136
Embedded Derivative Liability							—

October 31, 2012
Short term Convertible Notes Payable
May 2012 Notes	$	—	$	$	588,313	$	588,313
Hanover PIPE Notes – September & October 2012				$	362,791		362,791
Magna Exchange Note				$	333,086		333,086
Asher Note				$	150,687		150,687
French, Patton & Paterson Notes				$	208,664	$	208,664
Other Short-term Notes Payable – not measured at fair value (net of debt discount of $4,541 related to unamortized OID)							371,968
Short-term convertible Notes and FV of Embedded Derivative						$	2,015,509

October 31, 2011	Level 1		Level 2	Level 3		Total
Common stock warrant liability, warrants exercisable at $0.15 – $0.1952 from February 2011 through November 2015	$	—	$	$	6,391,071	$	6,391,071
Embedded derivative liability, convertible at $0.15 from August 2011 through May 2012				$	946,046	$	946,046

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Common stock warrant liability:


	July 31, 2013 (Unaudited)
Beginning balance: October 31, 2012	$	434,136
Issuance of common stock warrants		1,460,867
Reclassification of warrant liability to equity		—
Exercise of warrants		(795,411	)
Issuance of additional warrants due to anti-dilution provisions		30,887
Change in fair value		(394,420	)
Balance at July 31, 2013	$	736,059

The following table summarizes the changes in fair value of the Company's Level 3 financial instruments for the twelve months ended October 31, 2012 and October 31, 2011.

Common stock warrant liability:

	October 31, 2012		October 31, 2011
Beginning balance at October 31, 2011 and 2010	$	6,391,071	$	13,006,194
Issuance of common stock warrants		—		600,407
Exercises and Exchanges of warrants		59,572		(1,295,884)
Change in fair value		(923,052)		(3,789,889)
Balance at January 31, 2012 and 2011	$	5,527,591	$	8,520,828
Issuance of common stock warrants		—		3,111,758
Exercises of warrants		—		(639,960)
Exchanges of warrants		(134,796)		—
Change in fair value		(2,302,707)		4,915,676
Balance at April 30, 2012 and 2011	$	3,090,088	$	15,908,302
Issuance of common stock warrants		291,400		41,344
Reclassification of liabilities to equity		—
Debt for Equity Exchange: Bridge Notes		(4,750)		—
July Warrant Exchanges		(407,501)		—
Exercises and/or Exchanges of warrants		—		(1,186,959)
Change in fair value		(1,703,252)		(6,826,019)
Balance at July 31, 2012 and 2011		1,265,985		7,936,668
Issuance of common stock warrants		36,134		—
Reclassification of warrant liability to equity		—		(186,908)
Exchange of warrants		—		816,259
Issuance of additional warrants due to anti-dilution provisions		150		—
Change in fair value		(868,133)		(2,174,948)
Balance at October 31, 2012 and 2011		434,136		6,391,071

Convertible Note [Member]

Fair Value [Line Items]

Fair Value, Instruments Classified In Shareholders' Equity Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Convertible notes at fair value:


	July 31, 2013 (Unaudited)
Beginning balance – October 31, 2012		1,643,541
Issuance of notes		1,238,277
Transfer-out		(1,808,454	)
Change in Fair Value of notes		901,716
Ending balance – July 31, 2013	$	1,975,080

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Textual) - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	Jun. 14, 2013	Oct. 31, 2012	Jul. 31, 2013	Oct. 31, 2010	Jul. 12, 2013	Mar. 10, 2013	Oct. 31, 2011
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued		$ 950,000	$ 800,000	$ (7,693,230)
Stockholders Equity, Reverse Stock Split	1-for-125		1-for-125
Common Stock, Par Or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001			$ 0.001	$ 0.001
Common Stock, Shares Authorized	25,000,000	25,000,000	25,000,000				25,000,000
Preferred Stock, Shares Authorized	5,000,000	5,000,000	5,000,000				5,000,000
Sale Of Warrant Minimum Price Per Warrant			$ 15.11
Minimum [Member]
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Sale Of Stock, Price Per Share			$ 3.16
Post Reverse Stock Split [Member]
Schedule Of Nature Of Operations And Basis Of Presentation [Line Items]
Common Stock, Par Or Stated Value Per Share					$ 0.001
Capital Units, Authorized					30,000,000
Common Stock, Shares Authorized					25,000,000
Preferred Stock, Shares Authorized					5,000,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	9 Months Ended		12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	1,846,112	1,369,128	1,432,393	1,814,556
Warrant [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	899,494	917,910	802,580	1,102,734
Employee Stock Option [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	467,923	358,459	358,459	218,539
Convertible Debt Securities [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Total	478,695	92,759	271,354	493,283

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textuals) - USD ($)	9 Months Ended		12 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011
Total	1,846,112	1,369,128	1,432,393	1,814,556
Accumulated Amortization of Other Deferred Costs			$ 89,976	$ 11,152
Property, Plant and Equipment, Estimated Useful Lives			3 to 5 years
Warrant [Member]
Total			440,000	345,200
Optimus Warrant [Member]
Total			205,000

SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	3 Months Ended		9 Months Ended		10 Months Ended		12 Months Ended									128 Months Ended	137 Months Ended
SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2004	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2009	Oct. 31, 2008	Oct. 31, 2007	Oct. 31, 2006	Oct. 31, 2005	Dec. 31, 2003	Oct. 31, 2012	Jul. 31, 2013
Stock Compensation Expense Disclosure [Line Items]
Net Loss as reported	$ (1,595,185)	$ (3,104,569)	$ (12,580,037)	$ (10,079,628)	$ (538,076)	$ (166,936)	$ (12,069,687)	$ (8,115,740)	$ (10,812,200)	$ 929,244	$ (5,416,418)	$ (2,454,453)	$ (6,197,744)	$ (1,805,789)	$ (909,745)	$ (47,557,543)	$ (60,137,580)
Add: Stock based option expense included in recorded net loss																89,217
Deduct stock option compensation expense determined under fair value based method																(328,176)
Adjusted Net Loss																$ (47,796,502)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Property And Equipment [Line Items]
Laboratory equipment	$ 284,516	$ 287,516	$ 195,672
Accumulated depreciation	(223,074)	(209,448)	(195,672)
Net Property and Equipment	$ 61,442	$ 78,068	$ 0

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
Property And Equipment [Line Items]
Depreciation expense	$ 4,442	$ 4,592	$ 13,626	$ 9,184	$ 13,776	$ 28,406	$ 209,448	$ 223,074

INTANGIBLE ASSETS (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Finite-Lived Intangible Assets [Line Items]
License	$ 651,992	$ 651,992	$ 651,992
Patents	2,626,365	2,422,409	2,117,505
Total intangibles	3,278,357	3,074,401	2,769,497
Accumulated amortization	(778,566)	(660,646)	(512,645)
Intangible Assets	$ 2,499,791	$ 2,413,755	$ 2,256,852

INTANGIBLE ASSETS (Details 1)	Oct. 31, 2012 USD ($)
Amortization Expense Per Equivalent Unit of Production or Per Dollar of Gross Revenue [Line Items]
2013, remainder	$ 35,000
2014	140,000
2015	140,000
2016	140,000
2017	$ 140,000

INTANGIBLE ASSETS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
INTANGIBLE ASSETS (Details Textual) - USD ($)	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Deferred Tax Liabilities, Deferred Expense, Capitalized Patent Costs						$ 33,000
Amortization expense of intangibles	$ 40,109	$ 37,435	$ 117,920	$ 109,859	$ 148,002	$ 132,288	$ 742,642	$ 860,562
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations			2014		2014
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Patents Expirations			2023		2023

ACCRUED EXPENSES: (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Accrued Expenses [Line Items]
Salaries and other compensation		$ 774,001	$ 531,040
Clinical Trial		56,468	2,358,248
Vendors		77,512	0
Consultants		32,200	32,200
Financing costs		174,970	0
Legal		214,902	46,346
Interest Payable		28,859	0
Other		8,500	8,500
Accrued Liabilities, Current	$ 1,242,464	$ 1,367,412	$ 2,976,334

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details) - USD ($)	Jul. 31, 2013	Jan. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	$ 2,037,962		$ 2,093,640	$ 6,016,399
Unamortized discount - Original Issue Discount (OID)	0		(4,541)	(1,300,345)
Derivative Liability				946,046
Long-Term Debt				5,662,100
Current Portion of Convertible Notes	2,037,962		2,089,099	5,091,298
Long-term Convertible Notes less current portion				570,802
May 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes			0	3,392,158
October 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		58,824	1,341,738
Unamortized discount - Original Issue Discount (OID)			(984,733)	(2,705)
December 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		131,928	0
Unamortized discount - Original Issue Discount (OID)		$ (26,896)	(26,896)
May 2012 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	83,333		588,313	0
Bridge Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	62,882		185,758	711,701
Jmj Financial [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	995,166		73,590	570,802
Derivative Liability	995,166
Hanover Holdings Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		362,791	0
Magna [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		333,086	0
Unamortized discount - Original Issue Discount (OID)			(28,896)
Chris French [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		25,950	0
Asher [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	507,830		150,687	0
Yvonne Paterson [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		103,804	0
James Patton [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	0		78,909	$ 0
Redwood Management LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Total Convertible Notes	$ 388,751		$ 0

SHORT-TERM CONVERTIBLE NOTES & FAIR VALUE OF EMBEDDED DERIVATIVE (Details Textual) - USD ($)											1 Months Ended																			3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended							128 Months Ended	137 Months Ended
	Aug. 08, 2013	Jul. 12, 2013	Mar. 14, 2013	Dec. 06, 2012	Nov. 12, 2012	Sep. 11, 2012	Aug. 02, 2012	May 14, 2012	May 08, 2012	May 09, 2011	Sep. 30, 2013	Sep. 27, 2013	Jul. 31, 2013	Jun. 27, 2013	Jun. 21, 2013	May 31, 2013	Apr. 26, 2013	Dec. 28, 2012	Oct. 31, 2012	Oct. 19, 2012	Sep. 27, 2012	Sep. 19, 2012	Aug. 27, 2012	Jul. 21, 2012	Dec. 31, 2011	Dec. 29, 2011	Nov. 30, 2011	Oct. 28, 2011	Aug. 19, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2007	Oct. 31, 2006	Oct. 31, 2005	Dec. 31, 2003	Oct. 31, 2012	Jul. 31, 2013	Aug. 14, 2013	Mar. 10, 2013	Jan. 31, 2013	Dec. 31, 2012	Dec. 26, 2012	Oct. 25, 2012	Sep. 25, 2012	Aug. 31, 2012	Jul. 31, 2011
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price								$ 10.625																																							$ 3.75
Debt Instrument, Maturity Date																								Dec. 31, 2012
Debt Conversion, Converted Instrument, Amount																																						$ 1,000,000	$ 300,000	$ 613,158	$ 15,969
Debt Conversion, Converted Instrument, Shares Issued			170,624
Issuance of notes													$ 76,491						$ 158,824					$ 250,000						$ 76,491		$ 76,491			$ 158,824							$ 158,824	$ 76,491					$ 100,000
Warrants To Purchase Of Common Stock																																86,283
Long-term Debt, Gross																								$ 250,000																					$ 250,000					$ 100,000
Original Issue Discount, net of accreted interest													0						4,541											0		$ 0			4,541	$ 1,300,345						4,541	0
Long-term Debt																																				5,662,100
Debt Instrument, Interest Rate, Stated Percentage																								33.00%
Proceeds From Convertible Debt																																2,110,500	$ 500,000		3,282,463	8,351,423						17,859,400	19,969,900
Stock Issued During Period, Value, New Issues																																		$ 235,000		1,676,554	$ 6,828,293	$ 9,380,902
Interest Payable, Current																			28,859																28,859	0						28,859
Convertible Notes Payable													2,037,962						$ 2,093,640											2,037,962		2,037,962			2,093,640	6,016,399						2,093,640	2,037,962
Gains (Losses) On Extinguishment Of Debt																														1,723	$ (932,421)	349,009	$ (2,173,491)		$ (2,187,787)	$ (461,595)						$ (992,942)	(643,933)
Bridge Loan [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																			$ 18.75																$ 18.75							$ 18.75
Debt Conversion, Converted Instrument, Amount																																			$ 169,000
Debt Conversion, Converted Instrument, Shares Issued																																			9,013
Repayments of Debt																																			$ 53,000
Gains (Losses) On Extinguishment Of Debt																																			$ 27,000
Minimum [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																																												$ 1.89
Maximum [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price																																												$ 2.20
May 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current										$ 7,100,000
Debt Instrument Discount Percentage										15.00%
Debt Instrument, Payment Terms										Each investor paid $0.85 for each $1.00 of principal amount of May 2011
Debt Instrument, Convertible, Conversion Price										$ 18.75									$ 18.75																$ 18.75	$ 18.75						$ 18.75
Percentage Of Common Stock Issuable Upon Conversion										50.00%
Debt Instrument, Maturity Date										May 12, 2012
Investors Minimum Beneficially Ownership Percentage										4.99%
Change In Fair Value Of Embedded Conversion Option and Warrants										$ 4,905,842
Debt Conversion, Converted Instrument, Amount																																			$ 1,962,060	$ 1,897,000
Debt Conversion, Converted Instrument, Shares Issued																																			104,643	101,177
Other Noncash Expense																																			$ 318,000
Accretion of Discount																																			1,788,718	$ 3,117,123
Proceeds From Convertible Debt										$ 6,000,000
Convertible Notes Payable																			$ 0																$ 0	3,392,158						$ 0
Percentage Of Note Convertible Prior To Maturity										85.00%
May 2011 Note Financing [Member] \| Exchange Agreements [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																																			300,800
Issuance of notes																			3,200,000																$ 3,200,000							3,200,000
Warrants To Purchase Of Common Stock																																			28,800
Surrendering Of Warrants To Purchase Of Common Stock																																			179,200
October 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																			$ 58,824																$ 58,824							$ 58,824
Debt Instrument Discount Percentage																												15.00%
Debt Instrument, Payment Terms																												Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the October 2011 offering
Debt Instrument, Convertible, Conversion Price																			$ 18.75									$ 18.75							$ 18.75							$ 18.75
Percentage Of Common Stock Issuable Upon Conversion																												50.00%
Investors Minimum Beneficially Ownership Percentage																												4.99%
Change In Fair Value Of Embedded Conversion Option and Warrants																												$ 987,439
Debt Conversion, Converted Instrument, Amount																																$ 58,824
Debt Conversion, Converted Instrument, Shares Issued																																18,224			65,466
Other Noncash Expense																																$ 70,000			$ 296,000
Issuance of notes																			$ 1,200,000									400,000							1,200,000							$ 1,200,000
Long-term Debt, Gross																			54,824									59,000							54,824							54,824
Original Issue Discount, net of accreted interest																			984,733																984,733	2,705						984,733
Proceeds From Convertible Debt																												$ 50,000
Convertible Notes Payable													$ 0						58,824											$ 0		$ 0			$ 58,824	1,341,738						58,824	$ 0
Percentage Of Note Convertible Prior To Maturity																												85.00%
October 2011 Note Financing [Member] \| Investor [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																												$ 2,300,000
Proceeds From Convertible Debt																												$ 2,000,000
October 2011 Note Financing [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 3.16																	$ 3.16		$ 3.16											$ 3.16
October 2011 Note Financing [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													3.25																	3.25		3.25											3.25
October 2011 Note Financing [Member] \| Exchange Agreements [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																																			10,400
Other Noncash Expense																																			$ 530,000
Issuance of notes																			1,000,000																$ 1,000,000							1,000,000
Warrants To Purchase Of Common Stock																																			96,800
Surrendering Of Warrants To Purchase Of Common Stock																																			48,000
December 2011 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																			$ 131,928							$ 1,232,000									$ 131,928							$ 131,928
Debt Instrument Discount Percentage																										15.00%
Debt Instrument, Payment Terms																										Each investor paid $0.85 for each $1.00 of principal amount of Notes purchased at the closing of the December 2011 offering
Debt Instrument, Convertible, Conversion Price													$ 3.49						$ 18.75							$ 18.75				$ 3.49		$ 3.49			$ 18.75							$ 18.75	$ 3.49
Percentage Of Common Stock Issuable Upon Conversion													6.00%													50.00%				6.00%		6.00%											6.00%
Debt Instrument, Maturity Date																										Jan. 09, 2013
Investors Minimum Beneficially Ownership Percentage																										4.99%
Change In Fair Value Of Embedded Conversion Option and Warrants																										$ 586,376
Debt Conversion, Converted Instrument, Amount																																$ 170,589			$ 828,000
Debt Conversion, Converted Instrument, Shares Issued																																48,888			44,133
Other Noncash Expense																																$ 104,000			$ 205,000
Issuance of notes																			$ 158,824																158,824							$ 158,824
Original Issue Discount, net of accreted interest																			26,896																26,896							26,896				$ 26,896
Accretion of Discount																																			559,480
Proceeds From Convertible Debt																										$ 1,000,000
Convertible Notes Payable													$ 0						131,928											$ 0		$ 0			131,928	$ 0						131,928	$ 0
Percentage Of Note Convertible Prior To Maturity																										85.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																										26,629
December 2011 Note Financing [Member] \| Rodman Renshaw, LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Percentage Of Common Stock Issuable Upon Conversion																																				4.00%
December 2011 Note Financing [Member] \| Magna Group, LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Other Noncash Expense																																			$ 31,284
December 2011 Note Financing [Member] \| Minimum [Member] \| Rodman Renshaw, LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Placement Agent Fees Percentage																																			6.00%
December 2011 Note Financing [Member] \| Maximum [Member] \| Rodman Renshaw, LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Placement Agent Fees Percentage																																			7.00%
December 2011 Note Financing [Member] \| Exchange Agreements [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																																			20,000
Other Noncash Expense																																			$ 100,000
Issuance of notes																			215,000																$ 215,000							215,000
Warrants To Purchase Of Common Stock																																			10,400
Surrendering Of Warrants To Purchase Of Common Stock																																			23,200
May 2012 Note Financing [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current								$ 953,333
Debt Instrument Discount Percentage								25.00%
Debt Instrument, Convertible, Conversion Price								$ 18.75					$ 3.16																	$ 3.16		$ 3.16											$ 3.16
Percentage Of Common Stock Issuable Upon Conversion								50.00%
Debt Instrument, Maturity Date								May 18, 2013																								May 18, 2012
Debt Conversion, Converted Instrument, Amount																																$ 870,000
Debt Conversion, Converted Instrument, Shares Issued																																275,240
Other Noncash Expense								$ 133,634																								$ 25,200
Other Noncash Income																														$ 65,294					$ 178,913
Fair Value Of Interest and Additional Warrants Issued								$ 291,400
Exchange Agreement Warrants Exercise Price								$ 18.75
Debt Instrument, Fair Value Disclosure								$ 454,680
Interest and Debt Expense								291,400
Unrealized Gain On Note								266,332
Warrant Liability													$ 18,426						112,487											18,426		18,426			112,487							112,487	$ 18,426
Convertible Debt													83,000																	83,000		83,000											83,000
Proceeds From Convertible Debt								715,000
Convertible Notes Payable													$ 83,333						588,313											$ 83,333		$ 83,333			588,313	$ 0						588,313	$ 83,333
May 2012 Note Financing [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 3.16												$ 3.16																	$ 3.16		$ 3.16											$ 3.16
Debt Conversion, Converted Instrument, Amount	$ 83,333																															$ 83,333
Debt Conversion, Converted Instrument, Shares Issued	26,371
May 2012 Note Financing [Member] \| Rodman Renshaw, LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current								400,000
Issuance of notes								$ 2,844
Fair Value Of Warrants Issued								28,000
Proceeds From Convertible Debt								$ 715,000
Placement Agent Fees Percentage								7.00%
May 2012 Note Financing [Member] \| Warrant Liability [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Other Noncash Expense																																7,717
May 2012 Note Financing [Member] \| Exchange Agreements [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Other Noncash Expense																																			1,300,000
Senior Convertible Promissory Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																													6,149
Long-term Debt, Gross																																																				$ 88,824
Interest Payable, Current																																																				$ 26,471
December To April Maturity Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Long-term Debt, Gross																			1,886,851																1,886,851	479,000						1,886,851
Increase In Interest In Consideration For Conversion																																				$ 25,208
Additional Warrants In Consideration For Conversion																																				6,528
Fair Value Of Interest and Additional Warrants Issued																																				$ 87,000
August To October Maturity Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Long-term Debt, Gross																																				$ 318,000
Additional Warrants In Consideration For Conversion																																				5,804
Fair Value Of Interest and Additional Warrants Issued																																				$ 80,000
Repayments of Debt																																				$ 99,000
Junior Convertible Subordinated Convertible Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 170,589						$ 186,000											$ 170,589		$ 170,589			$ 186,000							$ 186,000	$ 170,589
Debt Instrument, Convertible, Conversion Price																																				$ 18.75
Percentage Of Common Stock Issuable Upon Conversion													6.00%																	6.00%		6.00%											6.00%
Debt Conversion, Converted Instrument, Amount																														$ 11,765		$ 11,765				$ 1,300,000
Debt Conversion, Converted Instrument, Shares Issued																																				69,221
Issuance of notes													$ 158,824																	158,824		158,824											$ 158,824
Long-term Debt, Gross													63,000																	63,000		63,000				$ 756,000							63,000
Original Issue Discount, net of accreted interest																																				45,000
Minimum Percentage Of Warrant Received Coverage																			23.00%																23.00%							23.00%
Maximum Percentage Of Warrant Received Coverage																			75.00%																75.00%							75.00%
Repayments of Debt																																				530,000
Fair Value Of Warrants Issued																																			27,000
Long-term Debt																																				711,701
Exchange Agreement Amount																			$ 300,000																$ 300,000							$ 300,000
Exchange Agreement Amount Debt Issued Value																			$ 352,941																$ 352,941							$ 352,941
Exchange Agreement Shares Issuable Upon Excercise Of Warrants																			18,823																18,823							18,823
Exchange Agreement Warrants Exercise Price																			$ 18.75																$ 18.75							$ 18.75
Loss On Note Retirement																			$ 247,000																$ 247,000							$ 247,000
Other Operating Income (Expense), Net																																			$ 22,000
Junior Convertible Subordinated Convertible Notes [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument Discount Percentage																			10.00%																10.00%							10.00%
Junior Convertible Subordinated Convertible Notes [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument Discount Percentage																			15.00%																15.00%							15.00%
Jmj Financial [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																		$ 100,000					$ 100,000													$ 570,802
Debt Instrument Discount Percentage																	10.00%																			8.00%
Debt Instrument, Convertible, Conversion Price																							$ 20.00
Percentage Of Common Stock Issuable Upon Conversion																							95.00%
Debt Instrument, Maturity Date																	Apr. 26, 2014
Debt Conversion, Converted Instrument, Amount																									$ 660,000		$ 500,000					$ 100,000			$ 660,000	$ 660,000
Debt Conversion, Converted Instrument, Shares Issued																																24,744			37,807	28,800
Other Noncash Expense									$ 805,000
Other Noncash Income																																$ 96,000			$ 250,000	$ 36,000
Issuance of notes									$ 32,000																																										$ 26,000
Long-term Debt, Gross																		115,000
Debt Instrument, Fair Value Disclosure													995,166					125,000					$ 73,590							995,166		$ 995,166											995,166
Debt Instrument, Convertible, Terms of Conversion Feature																	The convertible promissory note is convertible at any time, in whole or in part, at JMJ Financials option into shares of the Companys common stock at the lesser of $8.75 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion.
Common Stock, Capital Shares Reserved for Future Issuance									500,000								160,000
Percentage Of Funded Amount Granted To Participate In Public Offering																	125.00%
Amount Of Public Offering Require To Pay Note																	$ 10,000,000
Proceeds From Convertible Debt																	425,000	$ 100,000					$ 100,000
Debt Instrument, Interest Rate Terms																																18
Debt Instrument, Debt Default, Description of Notice of Default																																150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.
Convertible Notes Payable													995,166						$ 73,590											995,166		$ 995,166			$ 73,590	570,802						$ 73,590	995,166
Stock Issued During Period Mutual Release Of Claims																							32,615
Jmj Financial [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																	$ 800,000
Debt Instrument Discount Percentage																	10.00%
Debt Conversion Convertible Instrument Remaining Borrowed Amount														$ 195,000
Proceeds From Conversion Of Convertible Debt, Current																	$ 300,000
Debt Conversion, Converted Instrument, Amount																	125,000
Proceeds From Convertible Debt														$ 100,000			$ 720,000
Jmj Financial [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Stock Issued During Period, Value, New Issues											$ 5,000,000
Magna [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 58,824																	$ 58,824		$ 58,824											$ 58,824
Percentage Of Common Stock Issuable Upon Conversion													6.00%						73.00%											6.00%		6.00%			73.00%							73.00%	6.00%
Investors Minimum Beneficially Ownership Percentage																			4.99%																4.99%							4.99%
Debt Conversion, Converted Instrument, Amount																																$ 300,000			$ 100,000
Debt Conversion, Converted Instrument, Shares Issued																			20,176													80,992
Other Noncash Expense																			$ 33,011													$ 44,000			13,500
Issuance of notes																			740,599																740,599							$ 740,599							$ 400,076
Original Issue Discount, net of accreted interest																			28,896																28,896							28,896
Debt Instrument, Interest Rate, Stated Percentage													6.00%																	6.00%		6.00%											6.00%
Debt Instrument, Fair Value Disclosure																			333,086																333,086							333,086
Convertible Notes Payable													$ 0						$ 333,086											$ 0		$ 0			333,086	0						$ 333,086	$ 0
Value Of Additional Convertible Notes To Be Issued																																			$ 340,523
Magna [Member] \| Convertible Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Issuance of notes																																																	122,876
Magna [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 3.21						$ 4.453											$ 3.21		$ 3.21			$ 4.453							$ 4.453	$ 3.21
Magna [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													4.14						$ 5.15											4.14		4.14			$ 5.15							$ 5.15	4.14
Magna [Member] \| Exchange Agreements [Member] \| Convertible Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Issuance of notes																																																	$ 617,723
Asher [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current					$ 153,500	$ 103,500
Debt Instrument Discount Percentage						8.00%
Debt Instrument, Convertible, Conversion Price													$ 6.50																	$ 6.50		$ 6.50											$ 6.50
Percentage Of Common Stock Issuable Upon Conversion					65.00%	61.00%
Investors Minimum Beneficially Ownership Percentage					4.99%	4.99%
Debt Conversion, Converted Instrument, Amount																																$ 103,500
Debt Conversion, Converted Instrument, Shares Issued																																16,439
Other Noncash Expense																																			$ 47,187
Issuance of notes					$ 153,500
Debt Instrument, Interest Rate, Stated Percentage					8.00%	8.00%
Proceeds From Convertible Debt					$ 150,000	$ 100,000
Percentage Of Volume Arithmetic Average Price					65.00%	61.00%
Convertible Notes Payable													$ 507,830						$ 150,687											$ 507,830		$ 507,830			150,687	0						$ 150,687	$ 507,830
Hanover Holdings Notes [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																						$ 132,500
Debt Instrument, Convertible, Conversion Price													$ 3.75																	$ 3.75		$ 3.75											$ 3.75
Percentage Of Common Stock Issuable Upon Conversion																				65.00%
Debt Conversion, Converted Instrument, Amount																																$ 365,000
Debt Conversion, Converted Instrument, Shares Issued																																97,333
Other Noncash Expense																				$ 97,791
Original Issue Discount, net of accreted interest													$ 72,000																	$ 72,000		$ 72,000											$ 72,000
Proceeds From Convertible Debt																						$ 132,500
Hanover Holdings Notes [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current				$ 100,000																$ 132,500
Debt Instrument, Convertible, Conversion Price				$ 3.75
Percentage Of Common Stock Issuable Upon Conversion				4.99%																4.99%
Long-term Debt, Gross													122,092																	122,092		122,092											122,092
Debt Instrument, Interest Rate, Stated Percentage				12.00%
Accretion of Discount																														10,055		122,092
Proceeds From Convertible Debt				$ 100,000																$ 132,500
Second Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 153,500																	$ 153,500		153,500											$ 153,500
Debt Instrument, Maturity Date													Aug. 14, 2013
Debt Conversion, Converted Instrument, Shares Issued																														44,161
Other Noncash Income																																$ 63,980
Second Asher Note [Member] \| Minimum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 3.43																	$ 3.43		$ 3.43											$ 3.43
Second Asher Note [Member] \| Maximum [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 3.90																	$ 3.90		$ 3.90											$ 3.90
Chris French [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 25,000						25,000											$ 25,000		$ 25,000			25,000							25,000	$ 25,000
Debt Instrument, Convertible, Conversion Price													$ 5.625																	$ 5.625		$ 5.625											$ 5.625
Debt Instrument, Maturity Date																																Oct. 26, 2015
Investors Minimum Beneficially Ownership Percentage																					4.99%
Debt Conversion, Converted Instrument, Shares Issued																																4,527
Other Noncash Expense																																$ 21,000			5,515
Fair Value Of Warrants Issued																					4,565
Debt Instrument, Interest Rate, Stated Percentage																					12.00%
Number Of Shares Reserve For Issuance Up On Excise Of Warrants													2,263																	2,263		2,263											2,263
Interest Payable, Current													$ 633																	$ 633		$ 633											$ 633
Convertible Notes Payable													0						25,950											0		0			25,950	0						25,950	0
Yvonne Paterson [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current													$ 100,000																	$ 100,000		$ 100,000											$ 100,000
Debt Instrument, Convertible, Conversion Price													$ 5.625																	$ 5.625		$ 5.625											$ 5.625
Investors Minimum Beneficially Ownership Percentage																					4.99%
Debt Conversion, Converted Instrument, Shares Issued																																18,107
Other Noncash Expense																																$ 32,000			$ 22,062
Warrants To Purchase Of Common Stock																																9,054
Fair Value Of Warrants Issued																																			18,258
Debt Instrument, Interest Rate, Stated Percentage																																																		12.00%
Proceeds From Convertible Debt																																			$ 100,000
Interest Payable, Current													$ 2,532																	$ 2,532		$ 2,532											$ 2,532
Convertible Notes Payable													0						103,804											0		0			103,804	0						103,804	0
James Patton [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current							$ 66,667						$ 66,667																	$ 66,667		$ 66,667											$ 66,667
Debt Instrument Discount Percentage							25.00%
Debt Instrument, Payment Terms							0.75 for each $1.00
Debt Instrument, Convertible, Conversion Price							$ 3.16						$ 3.16																	$ 3.16		$ 3.16											$ 3.16
Percentage Of Common Stock Issuable Upon Conversion							50.00%
Investors Minimum Beneficially Ownership Percentage							4.99%
Debt Conversion, Converted Instrument, Shares Issued																														21,092
Other Noncash Expense																																$ 5,700			38,944
Other Noncash Income																														$ 8,400					$ 3,277
Fair Value Of Warrants Issued																																			13,311
Accretion of Discount																																			$ 5,200
Debt Instrument, Fair Value Disclosure													$ 2,304																	2,304		2,304											$ 2,304
Unrealized Gain On Note																														$ 94,000
Unrealized Loss On Note																																$ 3,590
Proceeds From Convertible Debt							$ 50,000
Number Of Shares Reserve For Issuance Up On Excise Of Warrants													1,778																	1,778		1,778											1,778
Interest Payable, Current													$ 3,355																	$ 3,355		$ 3,355											$ 3,355
Convertible Notes Payable													$ 0						78,909											$ 0		$ 0			78,909	$ 0						78,909	$ 0
Third Magna Exchange Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Convertible, Conversion Price													$ 3.25																	$ 3.25		$ 3.25											$ 3.25
Debt Conversion, Converted Instrument, Amount																														$ 111,111		$ 111,111
Debt Conversion, Converted Instrument, Shares Issued																														34,241		34,241
Other Noncash Expense																														$ 106,000		$ 106,000
Third Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Other Noncash Expense																																131,462
Debt Instrument, Fair Value Disclosure													$ 334,962																	334,962		334,962											$ 334,962
Third Asher Note [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current																$ 203,500
Debt Instrument, Maturity Date																Feb. 03, 2014
Investors Minimum Beneficially Ownership Percentage																4.99%
Debt Instrument, Interest Rate, Stated Percentage																8.00%
Proceeds From Convertible Debt																$ 200,000
Percentage Of Volume Arithmetic Average Price																65.00%
Fourth Asher Note [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current		$ 103,500
Investors Minimum Beneficially Ownership Percentage		4.99%
Other Noncash Expense																																69,368
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Fair Value Disclosure		$ 172,868
Proceeds From Convertible Debt		$ 100,000
Percentage Of Volume Arithmetic Average Price		65.00%
Fourth Asher Note [Member] \| Private Placement [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Instrument, Maturity Date		Apr. 16, 2014
Redwood Management LLC [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Convertible Notes Payable, Current															$ 277,777
Debt Instrument Discount Percentage															10.00%
Debt Instrument, Convertible, Conversion Price															$ 6.25
Debt Instrument, Maturity Date															Dec. 30, 2013
Investors Minimum Beneficially Ownership Percentage															4.99%
Other Noncash Expense																																110,972
Debt Instrument, Interest Rate, Stated Percentage															5.00%
Debt Instrument, Fair Value Disclosure													388,751																	388,751		$ 388,751											388,751
Debt Instrument, Convertible, Terms of Conversion Feature																																The Company agreed to reserve at least 2.5 times the number of shares of its common stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwoods consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.
Proceeds From Convertible Debt															$ 250,000
Percentage Of Volume Weighted Average Price															70.00%
Convertible Notes Payable													$ 388,751						$ 0											$ 388,751		$ 388,751			$ 0							$ 0	$ 388,751
Redwood Management LLC [Member] \| Subsequent Event [Member]
Schedule Of Short term Convertible Notes Fair Value Of Embedded Derivative [Line Items]
Debt Conversion, Converted Instrument, Shares Issued												125,000

NOTES PAYABLE- FORMER OFFICER: (Details Textual) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended		128 Months Ended	137 Months Ended
	Jul. 31, 2013	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013	Mar. 10, 2013	Sep. 25, 2012	Jul. 21, 2012
Schedule Of Notes Payable officer [Line Items]
Long-term Debt, Gross							$ 250,000	$ 100,000	$ 250,000
Common Stock, Value, Issued	$ 4,898	$ 4,898	$ 3,158	$ 2,001	$ 3,158	$ 4,898
Moore Notes [Member]
Schedule Of Notes Payable officer [Line Items]
Debt Instrument, Interest Rate During Period		12.00%
Repayments of Debt		$ 85,700	35,000
Long-term Debt, Gross	428,000	428,000	477,000	408,000	477,000	428,000
Interest Expense, Debt	7,198	24,841	$ 2,969,520	$ 78,077	$ 300,022	324,862
Notes Payable, Current	11,200	11,200				11,200
Common Stock, Value, Issued	$ 6,000,000	$ 6,000,000				$ 6,000,000
Debt Instrument, Description		In August 2013, Mr. Moore resigned as Chairman of the Board of Directors and as Chief Executive Officer and entered into a consulting agreement with the Company, which provided for a $100,000 payment towards the Moore Notes in the event the Company closes a financing greater than $5,000,00 during the initial term of the consulting agreement (which amount may be increased to $429,076.59 at the Company’s discretion if the financing exceeds $15,000,000).

NOTES PAYABLE-OTHER: (Details Textual) - USD ($)		1 Months Ended
NOTES PAYABLE-OTHER: (Details Textual) - USD ($)	Mar. 10, 2013	Jul. 21, 2012	Jul. 31, 2013	Jun. 14, 2013	Dec. 31, 2012	Dec. 26, 2012	Oct. 31, 2012	Sep. 25, 2012	May 14, 2012	Oct. 31, 2011
Schedule Of Notes Payable other [Line Items]
Interest Related To Promissory Note	$ 37,000	$ 37,000
Long-term Debt, Gross	$ 250,000	$ 250,000						$ 100,000
Debt Instrument, Interest Rate, Stated Percentage		33.00%
Debt Instrument, Maturity Date		Dec. 31, 2012
Issuance of notes		$ 250,000	$ 76,491			$ 100,000	$ 158,824
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001	$ 0.001			$ 0.001			$ 0.001
Debt Instrument, Convertible, Conversion Price					$ 3.75				$ 10.625

LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)		3 Months Ended	9 Months Ended
LONG-TERM CONVERTIBLE NOTE (Details Textual) - USD ($)	Mar. 14, 2013	Jul. 31, 2013	Jul. 31, 2013	Mar. 19, 2013	Mar. 13, 2013	Dec. 31, 2012	Dec. 13, 2012	Oct. 31, 2012	Jul. 31, 2012	Jul. 21, 2012	May 14, 2012	Oct. 31, 2011	Oct. 31, 2010	Feb. 28, 2002
Schedule Of Long term Convertible Note [Line Items]
Convertible Notes Payable		$ 2,037,962	$ 2,037,962					$ 2,093,640				$ 6,016,399
Debt Instrument, Interest Rate, Stated Percentage										33.00%
Debt Instrument, Convertible, Conversion Price						$ 3.75					$ 10.625
Cash		40	40					232	$ 5,288			1,096,538	$ 108,381	$ 0
Share Percentage Of Notes Payable To Be Purchased Upon Warrant Issued							75.00%
Long-term Convertible Note (less unamortized debt discount of $66,148)		1,104,680	$ 1,104,680				$ 890,000	$ 0				$ 570,802
Debt Instrument, Maturity Period							5 years
Debt Conversion, Converted Instrument, Shares Issued	170,624
Warrants To Purchase Of Common Stock			86,283
Tonaquint Note [Member]
Schedule Of Long term Convertible Note [Line Items]
Convertible Notes Payable		$ 49,444	$ 49,444				$ 890,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Convertible, Conversion Price		$ 3.57	$ 3.57				$ 20.00
Description On Stock Issued For Installment Payment Of Note			stock will be issued at a price per share equal to 80% of the average of the 5 lowest daily closing bid prices for the common stock during the 20 consecutive trading days prior to the installment date (which is adjusted to 70% if the average of the 3 lowest volume weighted average prices during such 20-day period is less than $1.25 per share)
Long-term Convertible Note (less unamortized debt discount of $66,148)		$ 1,104,680	$ 1,104,680
Debt Conversion, Converted Instrument, Shares Issued		27,583
Secured Long-term Debt, Noncurrent				$ 202,657	$ 202,493
Debt Instrument, Payment Terms			Beginning in June 2013, the Company began making monthly installment payments on the Tonaquint Note as required by the terms of the note, which contemplates 18 installment payments equal to approximately $50,000.
Debt Instrument, Increase, Accrued Interest		$ 49,000
Other Noncash Expense		$ 264,124
Tonaquint Note [Member] \| Second Mortgage [Member]
Schedule Of Long term Convertible Note [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							5.00%
Cash							$ 400,000
Secured Long-term Debt, Noncurrent							$ 200,000

COMMON STOCK WARRANT LIABILITY (Details) - $ / shares

9 Months Ended

12 Months Ended

Jul. 31, 2013

Oct. 31, 2012

Oct. 31, 2011

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

899,494

802,580

61,396

Expiration Date

August 2014

July 2012 Warrant Exchanges [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

278,329

Expiration Date

October 2014

May 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

28,632

Expiration Date

May 2015

October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

11,628

December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

17,706

May 2012 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

22,222

Expiration Date

May 2017

Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

198,037

181,040

Vendor and Other [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Class of Warrant or Right, Outstanding

376

3,576

Expiration Date

N/A

February 2012

Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

$ 18.75

Class of Warrant or Right, Outstanding

29,883

22,438

August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

11,288

Preferred Stock Agreement [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

204,479

Expiration Date

April 2014

Maximum [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 21.25

$ 24.40

Maximum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2015

Maximum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

January 2016

Maximum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 21.25

Expiration Date

April 2015

Maximum [Member] | Vendor and Other [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 24.40

Maximum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

May 2017

November 2015

Maximum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.7

Expiration Date

August 2017

Minimum [Member]

Class of Warrant or Right [Line Items]

Exercise Price

5.625

$ 6.625

$ 18.75

Minimum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2014

Minimum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

January 2015

Minimum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.69

$ 18.75

Expiration Date

January 2013

Minimum [Member] | Vendor and Other [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Minimum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

May 2014

Minimum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 6.625

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | July 2012 Warrant Exchanges [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

278,329

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | May 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

28,632

Expiration Date

May 2015

Common Stock Purchase Warrant [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

11,628

Common Stock Purchase Warrant [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

17,706

Common Stock Purchase Warrant [Member] | May 2012 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

13,333

22,222

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

214,416

198,036

Common Stock Purchase Warrant [Member] | Vendor and Other [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

376

Expiration Date

N/A

Common Stock Purchase Warrant [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Class of Warrant or Right, Outstanding

29,883

Common Stock Purchase Warrant [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

13,095

11,288

Common Stock Purchase Warrant [Member] | Preferred Stock Agreement [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

^[1]

204,480

Expiration Date

^[1]

April 2014

Common Stock Purchase Warrant [Member] | Subtotal [Member]

Class of Warrant or Right [Line Items]

Class of Warrant or Right, Outstanding

695,014

598,100

898,253

Common Stock Purchase Warrant [Member] | Tonaquint Promissory Note [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 357

Class of Warrant or Right, Outstanding

86,283

Expiration Date

December 2014

Common Stock Purchase Warrant [Member] | Stock Purchase Agreement [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 4.375

Class of Warrant or Right, Outstanding

1,333

Expiration Date

December 2015

Common Stock Purchase Warrant [Member] | Maximum [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

January 2016

Common Stock Purchase Warrant [Member] | Maximum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 21.25

Expiration Date

April 2015

Common Stock Purchase Warrant [Member] | Maximum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 18.75

Expiration Date

May 2017

Common Stock Purchase Warrant [Member] | Maximum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 10.625

$ 18.75

Expiration Date

August 2017

Common Stock Purchase Warrant [Member] | Minimum [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | Minimum [Member] | October 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

October 2014

Common Stock Purchase Warrant [Member] | Minimum [Member] | December 2011 Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Expiration Date

May 2015

January 2015

Common Stock Purchase Warrant [Member] | Minimum [Member] | Bridge Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 15.11

$ 14.95

Expiration Date

December 2013

January 2013

Common Stock Purchase Warrant [Member] | Minimum [Member] | Placement Agent Convertible Debt Financing [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 10.625

Expiration Date

May 2014

Common Stock Purchase Warrant [Member] | Minimum [Member] | August and September 2012 Convertible Promissory Notes [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 5.625

$ 6.625

Expiration Date

October 2015

[1]	During December 2011, the Company unreserved for issuance shares related to the preferred stock warrants. If exercisable, exercise price means an amount per warrant share equal to the closing sale price of a share of common stock on the applicable tranche notice date.

COMMON STOCK WARRANT LIABILITY (Details 1) - $ / shares	9 Months Ended	12 Months Ended
COMMON STOCK WARRANT LIABILITY (Details 1) - $ / shares	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Class of Warrant or Right [Line Items]
Stock Price	$ 3.50	$ 5.625	$ 17.625
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 4.375	$ 6.625	$ 18.75
Expected term:	153 days	81 days	289 days
Expected Volatility	93.73%	66.51%	60.23%
Risk Free Rate:	0.08%	0.09%	0.09%
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price:	$ 21.25	$ 21.25	$ 21.257
Expected term:	1588 days	1736 days	1219 days
Expected Volatility	153.00%	146.78%	163.40%
Risk Free Rate:	0.0995%	0.056%	0.56%

COMMON STOCK WARRANT LIABILITY (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,494		899,494		802,580	61,396	802,580	899,494
Derivative Liability, Fair Value, Gross Liability						$ 6,390,000
Exercises Of Warrants					21,960	57,866
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 18.75	$ 18.75	$ 18.75
Proceeds from exercise of warrants			$ 94,444	$ 411,765	$ 411,765	$ 1,085,001	$ 1,666,766	$ 1,761,210
Warrants Subject To Anti Dilution Provisions			804,000
Anti Dilution Provisions Additional Warrants Issuable					42,400
Anti Dilution Provisions Additional Warrants Exercise Price					$ 18.6875
Fair Value Adjustment of Warrants	$ 0.7				$ 0.4
Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.625		$ 5.625		$ 6.625	$ 18.75	$ 6.625	$ 5.625
Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 21.25		$ 21.25		$ 21.25	$ 24.40	$ 21.25	$ 21.25
Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	499,000		499,000					499,000
Exercise of warrants			$ 278,000
Derivative Liability, Fair Value, Gross Liability	$ 736,000		736,000		$ 434,000		$ 434,000	$ 736,000
Non Cash Warrant Expenses			$ 1,100,000
Non Cash Warrant Income				$ 4,900,000
Warrants Subject To Anti Dilution Provisions			124,000
Derivative, Gain (Loss) on Derivative, Net, Total	$ 1,800,000	$ 1,700,000
Warrant Liability [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,000		899,000					899,000
Derivative Liability, Fair Value, Gross Liability					$ 682,000		$ 682,000
Warrant Equity [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	122,000		122,000		121,000		121,000	122,000
Exercise of warrants			$ 278,329
Warrants With Anti Dilution Provisions [Member]
Class of Warrant or Right [Line Items]
Reduction In Warrant Outstanding Subject To Anti Dilution Provision			$ 124,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 15.11		$ 15.11		$ 18.70		$ 18.70	$ 15.11
Warrants Subject To Anti Dilution Provisions			124,000
Anti Dilution Provisions Additional Warrants Issuable	10,000
Anti Dilution Provisions Additional Warrants Exercise Price			$ 25.00		$ 12.50
Warrants With Anti Dilution Provisions [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	621,165		621,165					621,165
Warrants With Anti Dilution Provisions [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One			40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two			50.00%
Warrants With Anti Dilution Provisions [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Probability Of Exercise Of Additional Warrants At Exercise Price One			50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two			60.00%
Warrant [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Outstanding	899,000		899,000		803,000		803,000	899,000
Derivative Liability, Fair Value, Gross Liability	$ 777,000		$ 777,000					$ 777,000
Warrant [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.375		$ 4.375		$ 6.625		$ 6.625	$ 4.375
Warrant [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	21.25		$ 21.25		$ 21.25		$ 21.25	21.25
Exercise Of Warrants [Member]
Class of Warrant or Right [Line Items]
Exercises Of Warrants			8,889	21,961
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 10.625	$ 18.75	$ 10.625	$ 18.75				$ 10.625
Proceeds from exercise of warrants			$ 94,444	$ 412,000

DERIVATIVES (Details) - USD ($)	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2010
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount	$ 2,315,202	$ 1,739,224	$ 5,482,364	$ 6,294,923	$ 8,976,071	$ 8,166,355	$ 2,931,384	$ 1,991,267	$ 777,154
Derivative Issuance Discount	4,541	26,523	456,547	1,025,966	1,300,347	1,312,241	89,239	120,269	21,937
Derivative Liability, Notional Amount	434,136	1,265,985	3,090,088	5,527,591	6,391,071	7,936,668	15,908,302	8,520,828	13,006,194
Embedded Derivative Liability	$ 0	2,136	137,749	741,496	946,046	1,086,599	1,058,580	229,625	81,028
Note Payoffs [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount						(155,806)	(26,316)	(159,675)	(187,582)
Embedded Derivative Liability							(8,860)	(5,904)
Exercise Of Warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount								(639,960)	(1,382,847)
Issuance of November 2010 Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount									931,579
Derivative Issuance Discount									96,579
Derivative Liability, Notional Amount									391,076
Embedded Derivative Liability									150,156
Exchange of November 2010 Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount									17,175
Derivative Issuance Discount									17,175
Derivative Liability, Notional Amount									86,963
Embedded Derivative Liability									9,389
Issuance of January 2011 Bridge Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount									452,941
Derivative Issuance Discount									57,941
Derivative Liability, Notional Amount									173,808
Embedded Derivative Liability									41,024
Issuance Of Warrant [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount								2,990,520	35,523
Accreted Interest [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Issuance Discount		(21,984)	(229,392)	(569,419)	(532,559)	(471,290)	(340,050)	(74,422)	(73,363)
Change in fair value [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		(868,133)	(1,703,252)	(2,302,707)	(923,052)	(2,174,948)	(6,826,019)	4,915,676	(3,789,889)
Embedded Derivative Liability		(2,136)	(20,567)	(438,054)	159,657	(416,347)	(2,141,984)	763,523	$ (51,972)
Issuance of Q2 2011 Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount								473,392
Derivative Issuance Discount								43,392
Derivative Liability, Notional Amount								121,238
Embedded Derivative Liability								71,336
Issuance of Q3 2011 Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount							11,765
Derivative Issuance Discount							1,765
Derivative Liability, Notional Amount							4,968
Embedded Derivative Liability							5,051
Issuance Of Long Term Convertible Promissory Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount						86,400		626,400
Embedded Derivative Liability								$ 0
Issuance of May 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount							7,077,936
Derivative Issuance Discount							1,553,254
Derivative Liability, Notional Amount							0
Embedded Derivative Liability							2,719,345
Additional warrants issued to Bridge Note Holder [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount							36,376
Exchange Of Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount				52,941			8,033
Derivative Issuance Discount							8,033
Derivative Liability, Notional Amount				0
Embedded Derivative Liability							2,656
Bridge Note Conversions [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount					(169,000)	(221,788)	(1,164,947)
Embedded Derivative Liability					0	(10,530)	(381,209)
Conversion of May 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount				(38,000)	(1,924,060)	(1,225,561)	(671,500)
Embedded Derivative Liability				(5,016)	(341,342)	(110,494)	(166,980)
ExchangesExercises of October 2007 Warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount							$ (1,186,959)
Issuance of October 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount						2,326,471
Derivative Issuance Discount						459,396
Derivative Liability, Notional Amount						0
Embedded Derivative Liability						396,818
Reclassification of Warrant liability to Equity [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount						(186,908)
Issuance of December 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount					1,232,353
Derivative Issuance Discount					258,178
Derivative Liability, Notional Amount					0
Embedded Derivative Liability					306,568
Conversion of October 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount					(1,227,500)
Embedded Derivative Liability					(329,433)
Partial Note Repayments [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount					(52,941)
Conversion of Long-term Convertible Promissory Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount					(540,000)
Exchange of Warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount				(134,796)	$ 59,572	$ 816,259
Conversion of December 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount				(827,500)
Embedded Derivative Liability				$ (160,677)
Issuance of May 2012 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount			953,333
Derivative Liability, Notional Amount			291,400
Debt for Equity Exchange May and October 2011, December 2011 Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount			(4,473,673)
Derivative Issuance Discount			(200,632)
Embedded Derivative Liability			(115,046)
Debt for Equity Exchange Bridge Notes [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount			(50,000)
Derivative Liability, Notional Amount			(4,750)
July 2012 Exchange of Warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount			(407,501)
JMJ Settlement Agreement [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount			540,000
JMJ Note Conversions [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount			$ (712,800)
Issuance of Patton Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		66,667
Derivative Liability, Notional Amount		13,311
Issuance of French Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		25,000
Derivative Liability, Notional Amount		4,565
Issuance of Paterson Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		100,000
Derivative Liability, Notional Amount		18,258
Issuance of Hanover September Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		132,500
Issuance of Asher Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		103,500
Issuance of Hanover October Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		132,500
Issuance of JMJ Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		100,000
Assignment of Notes to Magna [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		(384,264)
New Magna Note [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		400,075
Magna Conversions [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Notional Amount		(100,000)
Additional warrants issued due to investors due to anti-dilution provision [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Liability, Notional Amount		$ 150

DERIVATIVES (Details 2) - $ / shares	9 Months Ended	12 Months Ended
DERIVATIVES (Details 2) - $ / shares	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stock Price	$ 3.50	$ 5.625	$ 17.625
Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Exercise Price:	$ 21.25	$ 21.25	$ 21.257
Expected term:	1588 days	1736 days	1219 days
Volatility %	153.00%	146.78%	163.40%
Risk Free Rate:	0.0995%	0.056%	0.56%
Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Exercise Price:	$ 4.375	$ 6.625	$ 18.75
Expected term:	153 days	81 days	289 days
Volatility %	93.73%	66.51%	60.23%
Risk Free Rate:	0.08%	0.09%	0.09%

DERIVATIVES (Details Textual) - USD ($)			1 Months Ended	9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
DERIVATIVES (Details Textual) - USD ($)	Jul. 05, 2012	Jun. 08, 2012	Oct. 31, 2011	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013	Jun. 14, 2013	Mar. 10, 2013	Dec. 31, 2012
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount			61,396	899,494		802,580	61,396	802,580	899,494
Class Of Warrant Exercise Price Of Warrants			$ 18.75			$ 18.75	$ 18.75	$ 18.75
Servicing Liability at Fair Value, Other Changes in Fair Value							$ 9.8
Exercises Of Warrants						21,960	57,866
Proceeds From Warrant Exercises				$ 94,444	$ 411,765	$ 411,765	$ 1,085,001	$ 1,666,766	$ 1,761,210
Stock Issued During Period Value Exchange Of Warrants						$ 223,596	1,533,965
Anti Dilution Provisions Additional Warrants Exercise Price						$ 18.6875
Anti Dilution Provisions Additional Warrants Issuable						42,400
Derivative Liability, Fair Value, Gross Liability			$ 6,390,000				$ 6,390,000
Common Stock, Par Or Stated Value Per Share			$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Exercise Price One [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Anti Dilution Provisions Additional Warrants Exercise Price						18.6875
Exercise Price Two [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Anti Dilution Provisions Additional Warrants Exercise Price						12.50
Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants			24.40	21.25		21.25	24.40	21.25	21.25
Maximum [Member] \| Common Stock [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants						21.25		21.25
Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants			$ 18.75	$ 5.625		6.625	$ 18.75	6.625	$ 5.625
Minimum [Member] \| Common Stock [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants						$ 6.625		$ 6.625
Warrant [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount			294,400			120,800	294,400	120,800
Warrant [Member] \| Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants			$ 0.1952			$ 0.17	$ 0.1952	$ 0.17
Warrant [Member] \| Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants			$ 0.15			$ 0.053	$ 0.15	$ 0.053
Warrat Liability [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount			1,102,733			681,780	1,102,733	681,780
Class Of Warrant Exercise Price Of Warrants						$ 403,451		$ 403,451
Reduction In Warrant Outstanding Subject To Anti Dilution Provision			$ 104,800			$ 13.1
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 6,391,000			434,000	$ 6,391,000	$ 434,000
Servicing Liability at Fair Value, Other Changes in Fair Value						$ 7,800,000	$ 6,400,000
2011 Warrant Exchange [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Warrants Purchased During Period						38,330
Non Cash Warrant Expenses						$ 25,000
Stock Issued During Period Value Exchange Of Warrants						12,776
Other Noncash Income						$ 54,000
Common Stock, Par Or Stated Value Per Share						$ 0.001		$ 0.001
2011 Warrant Exchange [Member] \| Common Stock [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Warrants Purchased During Period							51,107
Non Cash Warrant Expenses							$ 89,000
July 2012 Warrant Exchanges [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Exchanges Of Warrants	$ 278,329
Warrants Purchased During Period	189,812	88,516
Other Noncash Income	$ 408,000
Debt Instrument, Convertible, Type of Equity Security		6,400
2007 warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Exchanges Of Warrants						$ 3,200
Reduction In Warrant Outstanding Subject To Anti Dilution Provision						$ 126,956
Warrants With Anti Dilution Provisions [Member] \| Common Stock [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount						524,251		524,251
Warrants With Anti Dilution Provisions [Member] \| Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants			$ 21.25			$ 18.75	$ 21.25	$ 18.75
Probability Of Exercise Of Additional Warrants At Exercise Price One						50.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two						60.00%
Warrants With Anti Dilution Provisions [Member] \| Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Class Of Warrant Exercise Price Of Warrants						$ 4.45		$ 4.45				$ 6.625
Probability Of Exercise Of Additional Warrants At Exercise Price One						40.00%
Probability Of Exercise Of Additional Warrants At Exercise Price Two						50.00%
Embedded Derivative Liability [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount			1,102,733				1,102,733
Exchanges Of Warrants						$ 400,000	$ 1.9
Reduction In Warrant Outstanding Subject To Anti Dilution Provision							395,200
Warrants Not Settleable in Cash, Fair Value Disclosure			$ 808,333			681,780	808,333	$ 681,780
Servicing Liability at Fair Value, Other Changes in Fair Value						6,000,000
Derivative Liability, Fair Value, Gross Liability			6,400,000				6,400,000
Embedded Derivative, Fair Value of Embedded Derivative, Net, Total			$ 946,000				$ 946,000
Exercise Of Warrants [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Proceeds From Warrant Exercises						$ 412,000

STOCK OPTIONS: (Details) - USD ($)	9 Months Ended	12 Months Ended
STOCK OPTIONS: (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Schedule Of Stock Options [Line Items]
Outstanding Number of Options Beginning Balnce	358,459	218,539	211,739
Granted Number of Options	134,600	140,320	6,800
Exercised Number of Options	0
Expired Number of Options	(25,136)	(400)	0
Outstanding Number of Options Ending Balance	467,923	358,459	218,539
Vested and Exercisable Number of Options Ending Balance	290,300	234,225
Outstanding Weighted-Average Exercise Price Beginning Balance	$ 20.00	$ 20.00	$ 20.00
Granted Weighted-Average Exercise Price	9.375	18.75	15.00
Exercised Weighted-Average Exercise Price	0
Expired Weighted Average Exercise Price	18.75	12.50	0
Outstanding Weighted-Average Exercise Price Ending Balance	17.50	20.00	$ 20.00
Vested and Exercisable Weighted-Average Exercise Price Ending Balance	$ 17.50	$ 20.00
Outstanding Weighted Average Remaining Contractual Life In Years		8 years 1 month 6 days	7 years 4 months 24 days
Granted Weighted Average Remaining Contractual Life In Years		9 years	9 years 2 months 12 days
Cancelled or Expired Weighted Average Remaining Contractual Life In Years		6 years 9 months	0 years
Outstanding Weighted Average Remaining Contractual Life In Years			8 years 1 month 6 days
Vested & Exercisable Weighted Average Remaining Contractual Life In Years	1 year 5 months 1 day	5 years 9 months
Outstanding Aggregate Intrinsic Value	$ 0	$ 367,417	$ 415,967
Granted Aggregate Intrinsic Value		0	15,200
Cancelled or Expired Aggregate Intrinsic Value		0	0
Outstanding Aggregate Intrinsic Value		0	$ 367,417
Vested and Exercisable Aggregate Intrinsic Value		$ 0

STOCK OPTIONS : (Details 1)	12 Months Ended
STOCK OPTIONS : (Details 1)	Oct. 31, 2012	Oct. 31, 2011
Schedule Of Stock Options [Line Items]
Expected volatility	143.00%	150.44%
Expected Life	10 years	10 years
Dividend yield	0.00%	0.00%
Risk-free interest rate	2.10%	3.50%
Forfeiture Rate	4.40%	4.40%

STOCK OPTIONS: (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		128 Months Ended	137 Months Ended
STOCK OPTIONS: (Details Textual) - USD ($)	Aug. 22, 2011	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2012	Jul. 31, 2013	Jun. 14, 2013	Aug. 13, 2012	Sep. 27, 2011	Oct. 31, 2010
Schedule Of Stock Options [Line Items]
Vested & Exercisable Weighted Average Remaining Contractual Life In Years				1 year 5 months 1 day		5 years 9 months
Common stock, shares authorized		25,000,000		25,000,000		25,000,000	25,000,000	25,000,000	25,000,000	25,000,000
Granted Weighted-Average Exercise Price				$ 9.375		$ 18.75	$ 15.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		467,923		467,923		358,459	218,539	358,459	467,923				211,739
Non-cash charges to consultants and employees for options and stock				$ 3,103,122	$ 877,251	$ 1,146,843	$ 795,226	$ 4,980,046	$ 8,083,168
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value				1,657,500	2,539,792	2,539,792	103,125
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options		$ 1,472,000		1,472,000		2,047,000		2,047,000	1,472,000
Income Tax Effects Allocated Directly to Equity, Employee Stock Options						18,300
Employee Stock Ownership Plan (ESOP), Compensation Expense		320,000	$ 290,000	2,600,000	878,000
Share-Based Compensation				$ 3,103,122	877,251	1,146,843	795,226	$ 4,980,046	$ 8,083,168
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value				$ 0
General and Administrative Expense [Member]
Schedule Of Stock Options [Line Items]
Non-cash charges to consultants and employees for options and stock		222,000	162,000	$ 1,600,000	480,000	610,000	379,000
Share-Based Compensation		222,000	162,000	1,600,000	480,000	610,000	379,000
Research and Development Expense [Member]
Schedule Of Stock Options [Line Items]
Non-cash charges to consultants and employees for options and stock		98,000	128,000	1,000,000	398,000	480,000	272,000
Share-Based Compensation		$ 98,000	$ 128,000	$ 1,000,000	398,000	$ 480,000	272,000
Employees and Consultants [Member]
Schedule Of Stock Options [Line Items]
Options granted to consultants and professionals (in shares)				271,560		140,320
Granted Weighted-Average Exercise Price						$ 18.75
Employees and Consultants [Member] \| Minimum [Member]
Schedule Of Stock Options [Line Items]
Granted Weighted-Average Exercise Price				$ 9.375
Employees and Consultants [Member] \| Maximum [Member]
Schedule Of Stock Options [Line Items]
Granted Weighted-Average Exercise Price				$ 18.75
Equity Option [Member]
Schedule Of Stock Options [Line Items]
Vested & Exercisable Weighted Average Remaining Contractual Life In Years						2 years
Non-cash charges to consultants and employees for options and stock							651,000
Share-Based Compensation							$ 651,000
Common Stock [Member]
Schedule Of Stock Options [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans						1,656
Two Thousand and Four Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		19,052		19,052		19,052		19,052	19,052
Two Thousand and Five Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		42,952		42,952		43,552		43,552	42,952
Two Thousand and Nine Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		142,735		142,735		155,535		155,535	142,735
Two Thousand and Eleven Omnibus Incentive Plan [Member]
Schedule Of Stock Options [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance												160,000
Common stock, shares authorized											520,000
Two Thousand and Eleven Omnibus Incentive Plan [Member] \| Common Stock [Member]
Schedule Of Stock Options [Line Items]
Common stock, shares authorized											360,000
Two Thousand and Eleven Employee Stock Purchase Plan [Member]
Schedule Of Stock Options [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	85.00%
Common Stock, Capital Shares Reserved for Future Issuance	40,000
Proceeds from Stock Plans				$ 5,290	1,657
Income Tax Effects Allocated Directly to Equity, Employee Stock Options				$ 22,575	$ 18,300
Stock Issued During Period, Shares, Employee Stock Purchase Plans						1,656
Stock Option Plan [Member]
Schedule Of Stock Options [Line Items]
Non-cash charges to consultants and employees for options and stock						$ 10,900,000
Share-Based Compensation						$ 10,900,000

COMMITMENTS AND CONTINGENCIES (Details Textual)							1 Months Ended					3 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Textual)	Mar. 13, 2013 USD ($)	Mar. 06, 2013 USD ($)	Jun. 13, 2012 USD ($) $ / shares shares	Apr. 04, 2011 USD ($)	May 10, 2010 USD ($) $ / shares shares	Mar. 07, 2005 USD ($)	Mar. 22, 2013 USD ($) $ / shares shares	Dec. 20, 2012 shares	Jul. 24, 2012 USD ($) shares	Apr. 30, 2011 USD ($) ft²	Jul. 31, 2009 USD ($)	Jul. 31, 2013 USD ($) $ / shares shares	Jul. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2002 USD ($) shares	Oct. 31, 2012 USD ($) $ / shares shares	Oct. 31, 2011 USD ($) $ / shares shares	Oct. 31, 2010 USD ($)	Oct. 31, 2007 USD ($) shares	Apr. 30, 2011 a
Commitments And Contingencies [Line Items]
Stock issued														$ 235,000		$ 1,676,554	$ 6,828,293	$ 9,380,902
Stock Price \| $ / shares												$ 3.50	$ 3.50		$ 5.625	$ 17.625
Payments for Leasing Costs				$ 16,000
Granted Weighted-Average Exercise Price \| $ / shares													$ 9.375		$ 18.75	$ 15.00
Common stock, shares issued \| shares												4,898,248	4,898,248		3,158,433	2,001,377
Non Cash Income												$ 148,000	$ 148,000		$ 223,620
Accounts payable												223,620	223,620
Settlement Claim												75,000	75,000
Proceeds From Net Operating Losses													725,000
Area of Land										10,000									10.000
Common Stock [Member]
Commitments And Contingencies [Line Items]
Stock issued														$ 1				$ 474
Stock Issued (in shares) \| shares								267,117						320				473,826
Brio Claim [Member]
Commitments And Contingencies [Line Items]
Stock Price \| $ / shares							$ 25.00
Loss Contingency Damages Sought Shares \| shares							21,742
Loss Contingency, Damages Sought, Value							$ 500,000
Brio Claim [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Other Noncash Expense													232,000
Mr Moore [Member]
Commitments And Contingencies [Line Items]
Stock issued															12,000
Increase Decrease In Officer Compensation															$ 350,000
Granted Weighted-Average Exercise Price \| $ / shares															$ 50.00
Dr Rothman [Member]
Commitments And Contingencies [Line Items]
Base Officers Compensation						$ 305,000
Officer Compensation Payable In Cash						275,000
Officer Compensation Payable In Stock						$ 30,000
Separation Agreement [Member]
Commitments And Contingencies [Line Items]
General Release Agreement		$ 275,000
Office and Laboratory Lease [Member]
Commitments And Contingencies [Line Items]
Payments for Leasing Costs										$ 21,000
Cost of Utilities										7,200
Cost Of Utilities Per R E										$ 10,700
Lease Expiration Date										Nov. 29, 2015
Expected Lease Operating Expenses										$ 38,000			337,000
Operating Leases, Rent Expense										54,000			1,020,000
Estimated Utility Cost	$ 450,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt	200,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months	100,000
Operating Leases, Future Minimum Payments, Due in Two Years	100,000
Reduced Monthly Lease Payment Under Sublease Agreement	$ 20,000
Pennsylvania [Member]
Commitments And Contingencies [Line Items]
Option Exercise Fee Payable					$ 35,000
Stock issued					$ 70,000
Stock Issued (in shares) \| shares					3,111
Stock Price \| $ / shares					$ 22.50
Historical Patent Costs					$ 462,000
Licenses Revenue															$ 517,000
Licensing Agreement Expenses													460,000
Total Projected Agreement Cost											$ 12,200,000
Numoda [Member]
Commitments And Contingencies [Line Items]
Stock issued					$ 350,000
Stock Issued (in shares) \| shares			120,000		28,000				192,467
Due from Affiliates												7,650,000	7,650,000		7,400,000
Non Cash Income									$ 618,000
Total Projected Agreement Cost											$ 12,200,000
Other Noncash Income			$ 869,000
Purchase Price Per Share \| $ / shares			$ 18.75
Cancellation Of Accounts Receivables			$ 2,250,000
Accounts payable												$ 1,400,000	$ 1,400,000		$ 858,000
Settlement Claim									1,800,000
Numoda Socius Stock Issuance [Member]
Commitments And Contingencies [Line Items]
Common stock, shares issued \| shares												197,449	197,449
Other Noncash Income												$ 0	$ 615,000
Clinical Trail Services Settlement Claim									2,888,860
Settlement Claim									1,800,000
Settlement Claim Towards Transaction Related Costs									$ 1,000,000
Office Laboratory Lease [Member]
Commitments And Contingencies [Line Items]
Cost of Utilities										7,200
Cost Of Utilities Per R E										$ 10,700
Lease Expiration Date										Nov. 29, 2015
Expected Lease Operating Expenses										$ 38,000			337,000
Operating Leases, Rent Expense										$ 54,000			$ 1,020,000

INCOME TAXES: (Details) - USD ($)	12 Months Ended
INCOME TAXES: (Details) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Federal
Current	$ 0	$ 0
Deferred	(9,974,596)	(1,292,094)
State and Local
Current	(346,787)	(379,472)
Deferred	(1,826,038)	(81,597)
Change in valuation allowance	11,800,634	1,373,691
Income tax provision (benefit)	$ (346,787)	$ (379,472)

INCOME TAXES: (Details 1) - USD ($)	Oct. 31, 2012	Oct. 31, 2011
Deferred Tax Assets
Net operating loss carryovers	$ 21,162,237	$ 12,994,244
Stock-based compensation	1,907,607	1,474,016
Other deferred tax assets	957,982	48,470
Total deferred tax assets	24,027,826	14,516,730
Valuation allowance	(22,414,639)	(10,614,005)
Deferred tax asset, net of valuation allowance	1,613,187	3,902,725
Deferred Tax Liabilities
Valuation of warrants	0	(3,241,085)
Other deferred tax liabilities	(1,613,187)	(661,640)
Total deferred tax liabilities	(1,613,187)	(3,902,725)
Net deferred tax asset (liability)	$ 0	$ 0

INCOME TAXES: (Details 2)	12 Months Ended
INCOME TAXES: (Details 2)	Oct. 31, 2012	Oct. 31, 2011
Income Tax Disclosure [Line Items]
US Federal statutory rate	(34.00%)	(34.00%)
State income tax, net of federal benefit	(5.90%)
Fair value of common stock warrant liability	(15.00%)
Deferred Tax Adjustment	(39.30%)
Change in valuation allowance	97.80%	16.90%
Other permanent differences	(6.50%)	12.60%
Income tax provision (benefit)	(2.90%)	(4.50%)

INCOME TAXES (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
INCOME TAXES (Details Textual) - USD ($)	Dec. 31, 2012	Jan. 31, 2012	Feb. 28, 2011	Oct. 31, 2012	Oct. 31, 2011
Income Tax Disclosure [Line Items]
Net Cash Received Amount On Net Operating Losses		$ 346,787	$ 379,742
Sale Of Net Operating Losses	$ 725,000
Valuation Allowance, Deferred Tax Asset, Change in Amount				$ 11,800,634	$ 1,373,691
Deferred Tax Assets, Operating Loss Carryforwards, Domestic				55,127,000	32,485,000
Deferred Tax Assets, Operating Loss Carryforwards, State and Local				$ 26,880,000	$ 12,593,000

SHAREHOLDERS' EQUITY (Details Textual) - USD ($)		1 Months Ended						3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended			128 Months Ended	137 Months Ended
SHAREHOLDERS' EQUITY (Details Textual) - USD ($)	Apr. 04, 2011	Jan. 30, 2013	Dec. 21, 2012	Dec. 20, 2012	Nov. 30, 2012	Oct. 31, 2011	Jul. 19, 2010	Jul. 31, 2013	Jul. 31, 2012	Jul. 31, 2013	Jul. 31, 2012	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2007	Oct. 31, 2012	Jul. 31, 2013	Jun. 14, 2013	Mar. 10, 2013	Oct. 26, 2012	Jul. 21, 2012
Shareholders Equity [Line Items]
Preferred stock, shares authorized						5,000,000		5,000,000		5,000,000			5,000,000	5,000,000		5,000,000	5,000,000	5,000,000
Debt Instrument, Interest Rate, Stated Percentage																					33.00%
Exercise Price Of Options							$ 25.00
Warrants Exercised During Period														616,159
Common stock, par value (in dollars per share)						$ 0.001		$ 0.001		$ 0.001			$ 0.001	$ 0.001		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 18.75							$ 18.75	$ 18.75		$ 18.75
Preferred Stock, Amount of Preferred Dividends in Arrears								$ 185,000	$ 185,000	$ 555,000	$ 555,000		$ 740,000	$ 1,538,686		$ 2,322,570	$ 2,877,570
Notes Payable						$ 13,049,210								13,049,210
Preferred Stock redeemed														(90,003)
Promissory Note Receivable						10,283,510		$ 10,633,584		10,633,584			10,484,022	10,283,510		10,484,022	10,633,584
Note receivable in connection with exercise of warrants										0	0		0	2,389,500		9,998,210	9,998,210
Net proceeds of issuance of common stock										$ 3,011,872	$ 0			0		$ 11,988,230	$ 15,000,102
Preferred Stock, Dividend Rate, Percentage										10.00%
Promissory Note [Member]
Shareholders Equity [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							2.00%	2.00%		2.00%							2.00%
Accrued Interest On Promissory Note								$ 50,402		$ 149,562			$ 485,812
Promissory Note Receivable						285,300								$ 285,300
Note receivable in connection with exercise of warrants						$ 9,998,210
Optimus
Shareholders Equity [Line Items]
Warrants Exercised During Period													126,023
Minimum [Member]
Shareholders Equity [Line Items]
Sale of Stock, Price Per Share								$ 3.16		$ 3.16							$ 3.16
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 18.75		5.625		5.625			$ 6.625	$ 18.75		$ 6.625	5.625
Minimum [Member] \| Optimus
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						18.75							18.75	18.75		18.75
Maximum [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						24.40		$ 21.25		$ 21.25			21.25	24.40		21.25	21.25
Maximum [Member] \| Optimus
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						25.00							19.375	25.00		19.375
Warrant [Member] \| Minimum [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						0.15							0.053	0.15		0.053
Warrant [Member] \| Maximum [Member]
Shareholders Equity [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.1952							$ 0.17	$ 0.1952		$ 0.17
Common Stock [Member]
Shareholders Equity [Line Items]
Outstanding Stock Percentage													10.00%			10.00%
Maintenance Costs													$ 15,000
Stock Issued During Period, Shares, New Issues				267,117								320			473,826
Legal Settlement Liability				$ 692,761
Hanover Purchase Agreement [Member]
Shareholders Equity [Line Items]
Closing Sale Price Percentage																				90.00%
Purchase Of Shares																				10,000,000
Stock Issued During Period, Shares, New Issues								3,200		348,724
Other Noncash Expense					$ 28,000					$ 157,000
Net proceeds of issuance of common stock								$ 23,940		$ 2,934,624
Ironridge Settlement [Member]
Shareholders Equity [Line Items]
Stock Issued During Period, Shares, New Issues			360,000
Common Stock Shares Returned		92,883
Common stock, par value (in dollars per share)			$ 0.001
Attorney Fees				$ 692,761
Series B Preferred Stock [Member]
Shareholders Equity [Line Items]
Sale of Stock, Price Per Share	$ 10,000						$ 10,000	$ 10,000		$ 10,000			$ 10,000			$ 10,000	$ 10,000
Preferred stock, shares authorized							7,500,000
Closing Sale Price Percentage							75.00%
Outstanding Stock Percentage							9.99%
Preferred Stock Shares Available For Sale	284							284		284			284			284	284
Proceeds from Issuance of Debt														$ 1,470,000
Proceeds from Debt, Net of Issuance Costs														$ 1,340,000
Stock Issued During Period, Shares, New Issues														177
Repayments of Debt														$ 300,000
Class Of Options Or Right Number Of Securities Called By Options Or Rights							324,000
Exercise Price Of Options							$ 31.25
Percentage Of Warrant Vest and Exercisable							135.00%
Common stock, par value (in dollars per share)	$ 0.001
Liquidation preference						$ 9,722,570		$ 10,277,570		$ 10,277,570			$ 9,722,570	$ 9,722,570		$ 9,722,570	$ 10,277,570
Preferred Stock, Liquidation Preference Per Share								$ 10,000		$ 10,000			$ 10,000			$ 10,000	$ 10,000
Preferred Stock, Amount of Preferred Dividends in Arrears										$ 2,877,570			$ 2,322,570
Preferred Stock redeemed (in shares)							226
Preferred Stock redeemed							$ 3,141,004
Stock Redeemed Or Called During Period Value Paid In Cash							76,622
Stock Redeemed Or Called During Period Value Paid In Extinguishment Of Interest Debt Outstanding							13,382
Stock Redeemed Or Called During Period Value Paid In Extinguishment Of Debt Outstanding							$ 3,051,000
Series B Preferred Stock [Member] \| Optimus
Shareholders Equity [Line Items]
Liquidation preference													$ 9,722,570			$ 9,722,570
Series B Preferred Stock [Member] \| Warrant [Member]
Shareholders Equity [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Additional Warrant In Percentage	135.00%
Stock Issued During Period, Shares, New Issues	204,480
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 18.75

FAIR VALUE (Details) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	$ 736,059	$ 434,136	$ 6,391,071
Embedded Derivative Liability			946,046
May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		588,313
Embedded Derivative Liability	83,333	588,313
Asher Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		150,687
Embedded Derivative Liability	507,830	150,687
French, Patton & Paterson Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		208,664
Embedded Derivative Liability		208,664
Jmj Financial [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	995,166
Other Short Term Notes Payable [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		371,968
Short Term Convertible Notes and Fair Value Of Embedded Derivative [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		2,015,509
Embedded Derivative Liability	1,975,080	1,643,541
Hanover PIPE Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		362,791
Embedded Derivative Liability		362,791
Magna Exchange Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		333,086
Embedded Derivative Liability		333,086
Redwood Management LLC [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	388,751
Common Stock Warrant Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		434,136	6,391,071
Embedded Derivative Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability		0	946,046
Fair Value, Inputs, Level 1 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	0	0
Fair Value, Inputs, Level 1 [Member] \| May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		0
Embedded Derivative Liability	0	0
Fair Value, Inputs, Level 1 [Member] \| Common Stock Warrant Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable	736,059	434,136
Fair Value, Inputs, Level 3 [Member] \| May 2012 Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		588,313
Embedded Derivative Liability	83,333	588,313
Fair Value, Inputs, Level 3 [Member] \| Asher Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		150,687
Embedded Derivative Liability	507,830	150,687
Fair Value, Inputs, Level 3 [Member] \| French, Patton & Paterson Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		208,664
Embedded Derivative Liability		208,664
Fair Value, Inputs, Level 3 [Member] \| Jmj Financial [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	995,166
Fair Value, Inputs, Level 3 [Member] \| Short Term Convertible Notes and Fair Value Of Embedded Derivative [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	1,975,080	1,643,541
Fair Value, Inputs, Level 3 [Member] \| Hanover PIPE Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		362,791
Embedded Derivative Liability		362,791
Fair Value, Inputs, Level 3 [Member] \| Magna Exchange Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		333,086
Embedded Derivative Liability		333,086
Fair Value, Inputs, Level 3 [Member] \| Redwood Management LLC [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability	$ 388,751
Fair Value, Inputs, Level 3 [Member] \| Common Stock Warrant Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Common stock warrant liability, warrants exercisable		$ 434,136	6,391,071
Fair Value, Inputs, Level 3 [Member] \| Embedded Derivative Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Embedded Derivative Liability			$ 946,046

FAIR VALUE (Details 1) - USD ($)	3 Months Ended								9 Months Ended	12 Months Ended
FAIR VALUE (Details 1) - USD ($)	Oct. 31, 2012	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Embedded Derivative Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance				$ 946,046				$ 81,028	$ 0	$ 946,046	$ 81,028
Debt for Equity Exchange: Bridge Notes										(115,046)	(190,449)
Issuance of additional warrants due to anti-dilution provisions										306,568	3,505,605
Note Conversions and Payoffs										(836,468)	(683,977)
Change in fair value										(301,100)	(1,766,161)
Ending balance	$ 0				$ 946,046					0	946,046
Common Stock Warrant Liability [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	1,265,985	$ 3,090,088	$ 5,527,591	6,391,071	7,936,668	$ 15,908,302	$ 8,520,828	13,006,194	434,136	6,391,071	13,006,194
Issuance of common stock warrants	36,134	291,400	0	0	0	41,344	3,111,758	600,407	1,460,867
Exercises and Exchanges of warrants		0		59,572		(1,186,959)		(1,295,884)
Reclassification of warrant liability to equity	0	0			(186,908)				0
Debt for Equity Exchange: Bridge Notes		(4,750)				0
Exercise of warrants			0				(639,960)		(795,411)
Exchanges of warrants	0	(407,501)	(134,796)		816,259	0	0
Issuance of additional warrants due to anti-dilution provisions	150				0				30,887
Change in fair value	(868,133)	(1,703,252)	(2,302,707)	(923,052)	(2,174,948)	(6,826,019)	4,915,676	(3,789,889)	(394,420)
Ending balance	$ 434,136	$ 1,265,985	$ 3,090,088	$ 5,527,591	$ 6,391,071	$ 7,936,668	$ 15,908,302	$ 8,520,828	$ 736,059	$ 434,136	$ 6,391,071

FAIR VALUE (Details 2) - Convertible Notes [Member]	9 Months Ended
FAIR VALUE (Details 2) - Convertible Notes [Member]	Jul. 31, 2013 USD ($)
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 1,643,541
Issuance of notes	1,238,277
Transfer-out	(1,808,454)
Change in Fair Value of notes	901,716
Ending balance	$ 1,975,080

FAIR VALUE (Details 3) - USD ($)	12 Months Ended
FAIR VALUE (Details 3) - USD ($)	Oct. 31, 2012	Jul. 31, 2013	Dec. 26, 2012	Jul. 21, 2012	Oct. 31, 2011
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	$ 158,824	$ 76,491	$ 100,000	$ 250,000
Common Stock Warrant Liability	434,136	$ 736,059			$ 6,391,071
Hanover Pipe Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	265,000
Changes in fair value	97,791
Common Stock Warrant Liability	362,791
Asher Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	103,500
Changes in fair value	47,187
Common Stock Warrant Liability	150,687
Magna Exchange Note [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	400,075
Conversions to common stock	(100,000)
Changes in fair value	33,011
Common Stock Warrant Liability	333,086
Patton Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	175,000
Issuance of C/S warrants	(36,134)
Changes in fair value	69,798
Common Stock Warrant Liability	208,664
May Notes [Member]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes	687,000
Issuance of C/S warrants	(291,400)
Changes in fair value	192,713
Common Stock Warrant Liability	$ 588,313

FAIR VALUE (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
FAIR VALUE (Details Textual) - USD ($)	Jul. 31, 2013	Oct. 31, 2012	Oct. 31, 2011
Fair Value [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 18.75	$ 18.75
Expiration Date			August 2014
Exercise Price		$ 18.75	$ 18.75
Original Issue Discount, net of accreted interest	$ 0	$ 4,541	$ 1,300,345
Minimum [Member]
Fair Value [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.625	$ 6.625	$ 18.75
Exercise Price	5.625	6.625	18.75
Maximum [Member]
Fair Value [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	21.25	21.25	24.40
Exercise Price	$ 21.25	$ 21.25	$ 24.40
Warrant [Member]
Fair Value [Line Items]
Expiration Date	May 2013 through August 2017	October 2012 through August 2017	August 2011 through May 2012
Warrant [Member] \| Minimum [Member]
Fair Value [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.053	$ 0.15
Exercise Price		0.053	0.15
Warrant [Member] \| Maximum [Member]
Fair Value [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.17	0.1952
Exercise Price		$ 0.17	$ 0.1952
Common Stock Warrant Liability [Member]
Fair Value [Line Items]
Expiration Date			February 2011 through November 2015

SUBSEQUENT EVENTS (Details Textual) - USD ($)														1 Months Ended															9 Months Ended		10 Months Ended	12 Months Ended									128 Months Ended	137 Months Ended
SUBSEQUENT EVENTS (Details Textual) - USD ($)	Sep. 12, 2013	Sep. 11, 2013	Sep. 09, 2013	Sep. 04, 2013	Aug. 15, 2013	Aug. 14, 2013	Aug. 12, 2013	Aug. 08, 2013	Mar. 14, 2013	Feb. 12, 2013	Nov. 12, 2012	Sep. 11, 2012	May 14, 2012	Sep. 27, 2013	Sep. 26, 2013	Sep. 25, 2013	Sep. 18, 2013	Sep. 17, 2013	Aug. 28, 2013	Aug. 20, 2013	Aug. 19, 2013	Jul. 31, 2013	Jun. 21, 2013	Jan. 17, 2013	Dec. 31, 2012	Dec. 26, 2012	Dec. 20, 2012	Jul. 21, 2012	Jul. 31, 2013	Jul. 31, 2012	Dec. 31, 2002	Oct. 31, 2012	Oct. 31, 2011	Oct. 31, 2010	Oct. 31, 2009	Oct. 31, 2008	Oct. 31, 2007	Oct. 31, 2006	Oct. 31, 2005	Dec. 31, 2003	Oct. 31, 2012	Jul. 31, 2013	Sep. 05, 2013	Aug. 09, 2013	Jun. 14, 2013	Mar. 10, 2013	Dec. 21, 2012	Dec. 13, 2012	Dec. 06, 2012	Sep. 25, 2012
Subsequent Event [Line Items]
Conversion of debenture to Common Stock																																					$ 1,000,000	$ 300,000	$ 613,158	$ 15,969
Debt Instrument, Convertible, Conversion Price													$ 10.625												$ 3.75
Stock Issued During Period, Value, Issued for Services																																		$ 115,500	$ 18,180	$ 86,001	73,800	$ 54,858
Stock Issued During Period, Value, Employee Stock Purchase Plan																																$ 18,301
Debt Instrument, Face Amount																						$ 76,491				$ 100,000		$ 250,000	$ 76,491			$ 158,824									$ 158,824	$ 76,491
Stock Price																						$ 3.50							$ 3.50			$ 5.625	$ 17.625								$ 5.625	$ 3.50
Net Proceeds Of Issuance Of Common Stock																													$ 3,011,872	$ 0			$ 0								$ 11,988,230	$ 15,000,102
Debt Instrument, Interest Rate, Stated Percentage																												33.00%
Long-term Debt, Gross																												$ 250,000																		$ 250,000				$ 100,000
Proceeds From Convertible Debt																													2,110,500	500,000		$ 3,282,463	8,351,423								17,859,400	19,969,900
Proceeds From Notes Payable																													0	$ 2,388,963		250,000	0								250,000	250,000
Stock Issued During Period, Value, New Issues																															$ 235,000		1,676,554	$ 6,828,293			$ 9,380,902
Convertible Notes Payable																						$ 2,037,962							$ 2,037,962			$ 2,093,640	$ 6,016,399								$ 2,093,640	$ 2,037,962
Debt Conversion, Converted Instrument, Shares Issued									170,624
Debt Instrument, Maturity Date																												Dec. 31, 2012
Class Of Warrant Exercise Price Of Warrants																																$ 18.75	$ 18.75								$ 18.75
Common Stock, Shares Authorized																						25,000,000							25,000,000			25,000,000	25,000,000								25,000,000	25,000,000			25,000,000
Common Stock, Par Or Stated Value Per Share																						$ 0.001							$ 0.001			$ 0.001	$ 0.001								$ 0.001	$ 0.001			$ 0.001	$ 0.001
Tonaquint Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price																									$ 20.00																							$ 20.00
Convertible Notes Payable, Current																									$ 890,000
Debt Instrument, Interest Rate, Stated Percentage																									8.00%
Subsequent Event, Description																									On December 13, 2012, we entered into an agreement, which we refer to as the Tonaquint Purchase Agreement, with Tonaquint, Inc., which we refer to as Tonaquint, whereby we issued Tonaquint a secured convertible promissory note for the initial principal sum of $890,000, which we refer to as the Tonaquint Note. The Tonaquint Note bears interest at a rate of 8% and is due 26 months after its issue date. The Tonaquint Note can be converted at a fixed price of $20.00 per share but is subject to reduction in the event that we issue shares below the conversion price of $20.00.
Debt Conversion, Description																									On the closing date, Tonaquint (i) funded us with $490,000 in cash, (ii) issued a secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 1, and (iii) issued an additional secured mortgage note in the principal amount of $200,000, which we refer to as Mortgage Note 2. Mortgage Note 1 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 8 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions. Mortgage Note 2 bears interest at a rate of 5% and is due on the earlier of (i) 60 days following the maturity date under the Tonaquint Note, and (ii) the later of (A) 10 months after the closing date under the Tonaquint Purchase Agreement and (B) satisfaction of certain payment conditions.
Mr Moore [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues																																$ 12,000
Asher [Member]
Subsequent Event [Line Items]
Conversion of debenture to Common Stock																													$ 103,500
Debt Instrument, Convertible, Conversion Price																						$ 6.50							$ 6.50													$ 6.50
Debt Instrument, Face Amount											$ 153,500
Convertible Notes Payable, Current											153,500	$ 103,500
Debt Instrument Purchase Price											$ 150,000
Debt Instrument, Interest Rate, Stated Percentage											8.00%	8.00%
Proceeds From Convertible Debt											$ 150,000	$ 100,000
Convertible Notes Payable																						$ 507,830							$ 507,830			150,687	$ 0								$ 150,687	$ 507,830
Debt Conversion, Converted Instrument, Shares Issued																													16,439
Debt Instrument Discount Percentage												8.00%
Investors Minimum Beneficially Ownership Percentage											4.99%	4.99%
Percentage Of Common Stock Issuable Upon Conversion											65.00%	61.00%
Outstanding Shares In Percentage											4.99%
Sale Of Stock Under Equity Enhancement Program [Member]
Subsequent Event [Line Items]
Stock Price																								$ 4.675	$ 3.325
Debt Instrument Purchase Price																									$ 10,000,000
Sale Of Stock Under Equity Enhancement Program [Member] \| Hanover Purchase Agreement [Member]
Subsequent Event [Line Items]
Development Stage Entities, Stock Issued, Shares, Issued for Cash										64,000														35,200	55,924
Stock Price										$ 8.04
Net Proceeds Of Issuance Of Common Stock										$ 515,520														$ 164,656.80	$ 185,975
May 2012 Note Financing [Member]
Subsequent Event [Line Items]
Conversion of debenture to Common Stock																													$ 870,000
Debt Instrument, Convertible, Conversion Price													$ 18.75									$ 3.16							$ 3.16													$ 3.16
Convertible Debt																						$ 83,000							$ 83,000													$ 83,000
Convertible Notes Payable, Current													$ 953,333
Proceeds From Convertible Debt													$ 715,000
Convertible Notes Payable																						83,333							$ 83,333			588,313	$ 0								588,313	83,333
Debt Conversion, Converted Instrument, Shares Issued																													275,240
Debt Instrument Discount Percentage													25.00%
Debt Instrument, Maturity Date													May 18, 2013																May 18, 2012
Percentage Of Common Stock Issuable Upon Conversion													50.00%
Termination Agreement [Member]
Subsequent Event [Line Items]
Advisory Fees For Services In Termination Of Agreement																					$ 589,000
Class Of Warrant Term Of Warrants																					3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																					30,154
Class Of Warrant Exercise Price Of Warrants																					$ 4.90
Additional Advisory Fees For Services In Termination Of Agreement																					$ 150,000
Private Placements of Convertible Notes to Hanover [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price																																																	$ 3.75
Debt Instrument, Face Amount																																																	$ 100,000
Debt Instrument Purchase Price																																																	$ 100,000
Debt Instrument, Interest Rate, Stated Percentage																																																	12.00%
Outstanding Shares In Percentage																																																	4.99%
Other Hanover Related Transactions [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount																									$ 340,522
Debt Instrument, Interest Rate, Stated Percentage																									6.00%
Common Stock, Conversion Features																									Prior to the date of this filing, all Magna Exchange Notes (including the $400K Magna note in Footnote 6) have been converted in full into 202,521 shares of our common stock in accordance with its terms and no longer remains outstanding.
Ironridge Settlement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues																											267,117
Stock Issued During Period, Value, New Issues																											$ 692,761
Return Of Common Stock Shares																																															92,882
Common Stock, Shares Authorized																																															360,000
Common Stock, Par Or Stated Value Per Share																																															$ 0.001
Subsequent Event, Description																											The Order, together with the Stipulation for Settlement of Claims, which we refer to as the Stipulation, dated December 19, 2012, between us and Ironridge Global IV, Ltd., which we refer to as Ironridge, provides for the full and final settlement of Ironridges $692,761 claim against us in connection with past due invoices relating to attorney fees, which Ironridge purchased pursuant to a Receivable Purchase Agreement, dated December 14, 2012, which we refer to as the Claim.
JMJ Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount																										125,000
Long-term Debt, Gross																										$ 115,000
Closing Price Of Common Stock In Percentage																										70.00%
Redwood Management LLC [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price																							$ 6.25
Convertible Notes Payable, Current																							$ 277,777
Debt Instrument, Interest Rate, Stated Percentage																							5.00%
Proceeds From Convertible Debt																							$ 250,000
Percentage Of Volume Weighted Average Price																							70.00%
Convertible Notes Payable																						$ 388,751							$ 388,751			$ 0									$ 0	$ 388,751
Debt Instrument Discount Percentage																							10.00%
Debt Instrument, Maturity Date																							Dec. 30, 2013
Debt Instrument, Convertible, Terms Of Conversion Feature																													The Company agreed to reserve at least 2.5 times the number of shares of its common stock actually issuable upon full conversion of the Redwood Note, and not to take certain actions without Redwoods consent and granted Redwood the right, at its election, to participate in future financings subject to certain limited exceptions. So long as the Company is not in default, and provided it has given 20 days prior written notice, it may prepay the Redwood Note in full at any time at a premium of 110% of the amount owed (which multiple increases 4 months after the issuance date). In addition, if the Company completes a financing of $7,000,000 or more, Redwood has the right, at its election, to require the Company to repay the Redwood Note in full on the closing date of such financing on the same payment terms as noted in the preceding sentence. The Redwood Note includes customary event of default provisions, and provide for a default rate of 14%.
Investors Minimum Beneficially Ownership Percentage																							4.99%
Minimum [Member]
Subsequent Event [Line Items]
Class Of Warrant Exercise Price Of Warrants																						$ 5.625							$ 5.625			$ 6.625	$ 18.75								$ 6.625	$ 5.625
Maximum [Member]
Subsequent Event [Line Items]
Class Of Warrant Exercise Price Of Warrants																						$ 21.25							$ 21.25			$ 21.25	$ 24.40								$ 21.25	21.25
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues						51,000
Stock Issued During Period, Shares, Issued for Services						15,723	3,600
Stock Issued During Period, Value, Issued for Services						$ 50,000	$ 15,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans							2,330
Stock Issued During Period, Value, Employee Stock Purchase Plan							$ 7,027
Subsequent Event [Member] \| Jmj Financial [Member]
Subsequent Event [Line Items]
Convertible Debt																																											$ 39,600	$ 67,515
Debt Instrument, Face Amount				$ 800,000
Net Proceeds Of Issuance Of Common Stock				50,000
Debt Instrument Purchase Price				$ 720,000
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Long-term Debt, Gross						525,000
Proceeds From Convertible Debt						100,000
Proceeds From Notes Payable						625,000
Remaining Available Principal Amount To Lend						95,000
Stock Issued During Period, Value, New Issues				$ 5,000,000
Debt Conversion, Converted Instrument, Shares Issued			21,000														20,438
Debt Instrument Discount Percentage				10.00%
Debt Conversion Convertible Instrument Borrowed Amount				$ 500,000
Debt Conversion Convertible Instrument Remaining Borrowed Amount				$ 220,000
Debt Instrument, Maturity Date				Sep. 04, 2014
Debt Instrument, Convertible, Terms Of Conversion Feature				convertible promissory note is convertible at any time, in whole or in part, at JMJ Financials option into shares of the Companys common stock at the lesser of $2.65 or 70% of the average of the lowest two closing prices in the 20-day pricing period preceding a conversion.
Investors Minimum Beneficially Ownership Percentage				4.99%
Conversion of Stock, Shares Issued				2,000,000
Debt Instrument, Interest Rate Terms				18%
Debt Instrument, Debt Default, Description of Notice of Default				150% of the outstanding principal amount of the note plus 100% of all interest, liquidated damages and other amounts owing under the note.
Debt Conversion, Original Debt, Amount			$ 39,690
Subsequent Event [Member] \| Tonaquint Note [Member]
Subsequent Event [Line Items]
Conversion of debenture to Common Stock						$ 55,254
Stock Issued During Period, Shares, New Issues						33,309																11,466
Debt Instrument, Convertible, Conversion Price						$ 2.53														$ 3.00
Debt Instrument, Face Amount						$ 49,444
Interest Payable						$ 5,810
Debt Instrument Convertible Conversion Floor Price																				$ 2.50
Convertible Notes Payable, Current																				$ 108,000
Debt Instrument Purchase Price																				$ 100,000
Debt Instrument, Interest Rate, Stated Percentage																				20.00%
Repayments Of Debt																				$ 2,000,000
Proceeds From Convertible Debt																				$ 108,000
Stock Issued To Satisfy Second Installment Payment						21,843
Percentage Of Volume Weighted Average Price																				80.00%
Debt Conversion, Converted Instrument, Shares Issued	46,816	55,387														49,157
Debt Conversion, Original Debt, Amount	$ 334,736	$ 334,736														$ 334,736
Subsequent Event [Member] \| Mr Moore [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																					12.00%
Stock Options Granted Under Incentive Plan																					30,000
Annualized Compensation Monthly For Consulting Agreement																					$ 350,000
Description Of Payment For Consulting Agreement																					a one-time $100,000 payment if the Company closes a financing greater than $5,000,000 during the initial term of the agreement (which one-time payment may be increased to $429,076.59 at the Companys discretion if the financing exceeds $15,000,000)
Subsequent Event [Member] \| Yenson Co. Ltd. [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues																			45,353
Issuance Of Warrants To Purchase Common Stock																			22,161
Warrants Expiration Term																			3 years
Stock Issued During Period, Value, New Issues																			$ 100,000
Stock Issued During Period Price Per Share																			$ 2.21
Percentage Of Warrant Coverage																			50.00%
Issuance Of Warrants To Purchase Common Stock Exercise Price																			$ 2.76
Subsequent Event [Member] \| Accredited Investor [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price																		$ 4.9
Debt Conversion, Converted Instrument, Shares Issued														158,385	33,750			25,582
Subsequent Event [Member] \| Sale Of Stock Under Equity Enhancement Program [Member] \| Hanover Purchase Agreement [Member]
Subsequent Event [Line Items]
Stock Price					$ 2.81
Net Proceeds Of Issuance Of Common Stock					$ 29,516
Subsequent Event [Member] \| Sale Of Stock Under Equity Enhancement Program [Member] \| Tonaquint Note [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans					10,500
Subsequent Event [Member] \| May 2012 Note Financing [Member]
Subsequent Event [Line Items]
Conversion of debenture to Common Stock								$ 83,333																					$ 83,333
Debt Instrument, Convertible, Conversion Price								$ 3.16														$ 3.16							$ 3.16													$ 3.16
Debt Conversion, Converted Instrument, Shares Issued								26,371
Subsequent Event [Member] \| Private Placement Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services																													4,000
Subsequent Event [Member] \| Redwood Management LLC [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued														125,000
Debt Conversion, Original Debt, Amount														$ 277,778			$ 38,628
Subsequent Event [Member] \| Two Year Warrant [Member] \| Accredited Investor [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																		30,154
Subsequent Event [Member] \| Private Placement [Member] \| Jmj Financial [Member]
Subsequent Event [Line Items]
Debt Instrument Origination Fee				$ 50,000
Convertible Notes Payable				$ 800,000
Debt Conversion, Converted Instrument, Shares Issued				19,231
Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price						$ 1.89
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price						$ 2.20

REVERSE STOCK SPLIT (Details Textual) - $ / shares		9 Months Ended
REVERSE STOCK SPLIT (Details Textual) - $ / shares	Jun. 14, 2013	Jul. 31, 2013	Mar. 10, 2013	Oct. 31, 2012	Oct. 31, 2011
Class of Stock [Line Items]
Common Stock, Par Or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000		5,000,000	5,000,000
Common Stock, Shares Authorized	25,000,000	25,000,000		25,000,000	25,000,000
Shares Authorized For Issuance	30,000,000
Stockholders Equity, Reverse Stock Split	1-for-125	1-for-125

Label	Element	Value
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	$ 10,493
Preferred Stock [Member]
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	235,000
Retroactive Restatement To Reflect Value ReCapitalization	adxs_RetroactiveRestatementToReflectValueRecapitalization	$ (235,000)
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,418
Retroactive Restatement To Reflect Shares ReCapitalization	adxs_RetroactiveRestatementToReflectSharesRecapitalization	(3,481)
Retained Earnings [Member]
Net Loss As Reported	us-gaap_NetIncomeLoss	$ (166,936)
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	(1)
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Consultants	adxs_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsConsultants	10,493
Retroactive Restatement To Reflect Value ReCapitalization	adxs_RetroactiveRestatementToReflectValueRecapitalization	234,876
Common Stock [Member]
Retroactive Restatement To Reflect Value ReCapitalization	adxs_RetroactiveRestatementToReflectValueRecapitalization	$ 124
Retroactive Restatement To Reflect Shares ReCapitalization	adxs_RetroactiveRestatementToReflectSharesRecapitalization	124,461